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1. INTRODUCTION 
Although medicinal plants belong to the most ancient tools of medicine, with several species having 
confirmed use for millennia, the first scientific data on their active constituents and mechanisms of 
action are not much older than 200 years. The discovery of secondary plant metabolites started in the 
19th century, whereas the majority of pharmacological data was achieved in the 20th century. 
Compared to the huge number of plant taxa used in traditional medicine worldwide, the number of 
plants with confirmed efficacy, safety, elucidated mechanism of action and active constituents is 
infinitesimal. Plants of the European folk medicine have been studied relatively thoroughly, however, 
in case of several herbal drugs fundamental phytochemical and pharmacological data are missing.  
The aim of the present work was to provide phytochemical and pharmacological data on some 
medicinal plants to support their rational use. The use of flowers of Roman chamomile (Chamaemelum 
nobile) for the symptomatic treatment of mild spasmodic gastrointestinal complaints including 
bloating has been acknowledged by the European Medicines Agency recommended the extract [1]. 
This indication is based on the long-standing use of this plant for the listed purposes in folk medicine, 
[2] however, no experimental data are available on its spasmolytic activity. Our goal was to 
experimentally analyse the spasmolytic effect of the plant, its essential oil and to determine the active 
components responsible for this effect. In case of Matricaria chamomilla, several metabolites 
responsible for the diverse biological activities have been identified, however, the systematic data on 
their amounts in different geographical regions are missing. Our goal was to study the phytochemical 
variation of samples collected in Iran, in my homeland. 
In Iran, folk medicine is still a living tradition. Iranian flora is very diverse, comprising more 
than 8,000 vascular plant taxa, 2,597 of which are endemic or subendemic species [3]. Several species 
are used for therapeutic purposes without any scientific data on their active constituents. As part of 
my work, we examined the secondary metabolites of two native, previously slightly studied Iranian 
plants, Eremurus persicus and Ducrosia anethifolia. E. persicus is one of the 50 species of the genus 
[4], applied in Iranian folk medicine to treat skin diseases [5–11], as antidiabetic [11,12], and to treat 
gastrointestinal disorders and rheumatism [13]. From the six species of the Ducrosia genus, D. 
anethifolia is the most widely used in Iran. In folk medicine this plant is used in case of insomnia and 
anxiety [14], irregularities of menstruation, and for its carminative effect [15]. Since based on 
chemotaxonomic considerations we assumed that the latter species contains furocoumarins, our goal 
was to study the pharmacological effects of these compounds.  
Crocus sativus is the most important aromatic plant of Iran, with increasing importance as an 
aromatic plant. The stigma of C. sativus (saffron) has been used for the treatment of depression and 
anxiety in folk medicine. Its efficacy has been confirmed in several clinical trials as well. However, the 
price of the raw material is a major obstacle that prevents its widespread use as medicinal drug. Other 
plant parts, including tepal and stamen are considered as by-products of saffron production and are 
not utilized industrially. Recent studies refer to antidepressant activities of these plant parts [16–19]. 
Although there major components of tepal and stamen have already been reported [20–25], there are 
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no systematic data on the variations and ranges of these compounds. Such data are indispensable if 
saffron by-products will be considered as medicinally valuable industrial raw materials.  
 
2. AIMS OF THE STUDY 
The Iranian flora comprises a wide range of plants that have been widely applied in folk medicine. 
Although some of these have been previously subjected to phytochemical and pharmacological 
analysis, many medicinal plants are still un-investigated. The plants applied in the European folk 
medicine have generally been investigated more in detail, however, the active components and 
mechanisms of action of many plants of great importance are still undiscovered. The goals of our study 
were to: 
▪ study the phytochemical composition and certain bioactivities of some Iranian and European 
medicinal plants 
▪ review the literature on the studied plants, especially in case of the less studied Iranian 
medicinal plants 
▪ isolate and identify of secondary metabolites of Ducrosia anethifolia and study their 
antiproliferative/cytotoxic effect 
▪ isolate and identify of secondary metabolites of Eremurus persicus,  
▪ study the chemodiversity of Crocus sativus stamens and tepals 
▪ study the spasmolytic activity of Chamaemelum nobile and discover the mechanism of activity 
and its active components 
▪ study the chemodiversity of Matricaria chamomila essential oils of Iranian origin 
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3. LITERATURE OVERVIEW 
3.1. CHAMAEMELUM NOBILE (L.) ALL. 
Chamaemelum nobile (L.) All. (Roman chamomile) is a perennial herb native to South-Western Europe, 
and it is grown as a medicinal plant throughout Europe and Africa. In the European Pharmacopoeia, 
the dry flowers of the double-flowered variety are official [26]. 
The application of the plant in traditional herbal medicinal products has been accepted by the 
European Medicines Agency. The crushed herbal material (as tea) and a liquid extract of the plant 
(extraction solvent: ethanol 70% v/v) can be used for the symptomatic treatment of mild, spasmodic 
gastrointestinal complaints including bloating and flatulence [27]. 
 Taxonomy of C. nobile 
The Chamaemelum genus belongs to the Compositae (syn. Asteraceae) family, subfamily of 
Asteroideae, tribe of Anthemideae, order of Asterales, Asterids class, subclass of Asteridae, 
Spermatophyta subdivision, Magnoliopsida division [28]. 
 Phytochemistry of C. nobile 
The aliphatic esters of the EO (essential oil) [29], sesquiterpene lactones [30] and flavonoids [31–33] 
are the most characteristic phytoconstituents of C. nobile. The polysaccharide content of the dried 
flower was also found to be significant [34].  
 Folk medicinal use of C. nobile 
Chamaemelum nobile has been applied as a medicinal plant from the middle ages. The beginning of 
cultivation of the species was in England in the 16th century [35]. The double variety of the flower has 
certainly been known since the 18th century [36]. The plant is called “nobile” (Latin, noble) to 
distinguish its outstanding therapeutic efficacy compared to Matricaria recutita L. (German 
chamomile) [35]. 
In the different regions of Europe, C. nobile has been used for several ailments, including 
dysmenorrhoea, flatulence, nausea and vomiting, dyspepsia, anorexia, and specifically in case of 
flatulent dyspepsia and gastrointestinal pain associated with mental stress [37–41]. The use of C. 
nobile as tea was also described in the Mediterranean region to improve appetite and to prevent 
indigestion after meal [42–44]. Many of the abovementioned traditional applications of C. nobile 
might be related to its supposed smooth muscle-relaxant effect.  
 Bioactivities of C. nobile 
Most of the studies on C. nobile were performed with its EO. Antimicrobial effects of C. nobile EO 
against different bacterial and fungal strains [45–48] and the antifungal activity of the aqueous extract  
[49] have been reported. 
The heat shock protein modulating effects and anti-inflammatory capacity of the flavonoids 
apigenin and quercetin (the main flavonoids of the species), along with the anti-inflammatory 
activities of α-bisabolol, guaiazulene, and chamazulene as the major EO contents have been reported 
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in preclinical studies [50–53]. In vivo antiphlogistic effect of the polysaccharides of C. nobile was also 
described [34]. 
It is worth noting that no in vitro and in vivo studies have been carried out to evaluate the 
smooth muscle relaxant effect of the plant, although the use of C. nobile extract for gastrointestinal 
disorders seems to be related to this bioactivity. 
Nevertheless, an in vitro study was conducted to assess the vasorelaxant effect of an aqueous 
extract of C. nobile and the results showed an effect through the NO-cGMP pathway or possibly 
through a combination of Ca2+-channel inhibition plus NO-modulation and phosphodiesterase 
inhibition [54]. A significant hypotensive effect (in vivo) of C. nobile aqueous extract after the oral 
administration was reported on spontaneously hypertensive rats [55], which was supposed to be 
associated to the flavonoid content of the plant [56]. 
Only the effects after external application [57] and aromatherapeutic use [58] of C. nobile have 
been studied clinically. 
Since apigenin and luteolin exert remarkable smooth muscle relaxant activities on guinea pig 
ileum [59], and these flavonoids are the main constituents of C. nobile, the recommended smooth 
muscle-relaxant activity of the plant may be attributed to its flavonoid content.  
3.2. MATRICARIA CHAMOMILLA L. 
Matricaria chamomilla L. (syn. Chamomilla recutita L. Rauschert, German chamomile), is one of the 
renowned medicinal plants with long-standing folk medicinal use throughout Europe. The name 
chamomile derives from a Greek word meaning "ground apple" due to its aroma being similar to some 
apple varieties. The name of Matricaria originates from the Latin (matrix means uterus), because of 
the use of chamomile by women for gynaecological disorders and abnormalities of the menstrual cycle 
[60]. 
 Taxonomy of M. chamomilla 
The Matricaria genus belongs to the Asteraceae family, subfamily of Asteroideae, suborder of 
Asteridae, order of Asterales, Magnoliopsida class, Asteridae subclass, Spermatophyta subdivision, 
and division of Magnoliophyta [61] 
 Phytochemistry of M. chamomilla 
Sesquiterpenes are reported as the most dominant constituent of M. chamomilla EO. α-Bisabolol 
oxide A (7.9–62.1%) [62–65], α-bisabolol (56.9%) [66], β-farnesene (52.73%) [67], (E)-β-farnesene 
(42.59%) [68], α-bisabolol oxide B (25.56%) [65], β-cubebene (27.8%) [69], chamazulene (27.8–31.2%) 
[70], trans-β-farnesene [71,72], and spathulenol (12.50%) [73] were reported as the major EO 
compounds. 
Non-volatile secondary metabolites of M. chamomilla have also been explored. The major 
phytochemicals consist of polyphenols, especially the flavonoids apigenin, luteolin, patuletin, 
quercetin and their glucosides [74–76]; among them apigenin is reported as one of the most bioactive 
phenolics [75–77]. 
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 Folk medicinal use of M. chamomilla 
The flower of M. chamomilla is consumed around the world as herbal tea in an amount of over 1 
million cups daily [78,79]. While M. chamomilla is mainly used internally to facilitate digestion and as 
antispasmodic, it is also used externally to treat minor wounds. In traditional medicine, its use extends 
from the relief of various pains to the facilitation of menstruation [80]. M. chamomilla EO has been 
frequently applied in Iranian folk medicine as an anti-inflammatory, antispasmodic, anti-peptic ulcer, 
antibacterial and antifungal agent [81,82]. 
 Bioactivities of M. chamomilla 
In preclinical studies several biological activities have been reported for M. chamomilla, for instance 
anti-inflammatory, analgesic, and antispasmodic effects [83–86]. The wound healing effect of 
different extract gastrointestinal effects of the extracts and pure constituents have been confirmed in 
animal experiments. The aqueous extracts of flowers and the EO exerted central nervous system 
effects, including sleep-inducing, anxiolytic, and sedative activities [87]. Many of the former studies 
focused on the pharmacological effects of the EO and its constituents (α-bisabolol, bisabolol oxides, 
chamazulene) [88]. Moreover, antibacterial activities of various extracts and EO of M. chamomilla 
indicated a significant potential [60]. 
The following indications are partly based on the results of clinical studies: treatment of minor 
gastro-intestinal, relief of common cold symptoms, remedy of minor ulcers and inflammations of the 
mouth and throat, and healing of minor superficial wounds and small boils (furuncles) [87]. 
3.3. DUCROSIA ANETHIFOLIA (DC.) BOISS. 
D. anethifolia is one of the three wildly growing species of the genus in several areas of Iran, 
Afghanistan, Syria, Pakistan, Iraq, Lebanon, and some other Arab states and countries alongside of the 
Persian Gulf [89–91]. 
 Taxonomy of D. anethifolia 
The Ducrosia genus belongs to the Apiaceae Lindl. (Umbelliferae Juss.) family, sub-family Apioideae, 
order of Apiales, superorder of Rosidae, subclass of Dicotyledonae, Magnoliopsida class, Tracheophyta 
division [92]. The genus Ducrosia (Apiaceae) consists of six species: Ducrosia ismaelis Asch., D. 
flabellifolia Boiss., D. assadii Alava., D. areysiana (Deflers) Pimenov & Kljuykov, D. inaccessa 
(C.C.Towns.) Pimenov & Kljuykov and D. anethifolia (DC.) Boiss. 
 Phytochemistry of D. anethifolia 
3.3.2.1. Coumarin derivatives as the major phytochemicals of Ducrosia spp. 
Coumarins belong of benzopyrones (1,2-benzopyrones or 2H-1-benzopyran-2-ones). These 
compounds form an important class of oxygen-containing heterocycles extensively distributed in the 
nature [93]. 
The first natural coumarin was isolated in 1820 from the seeds of Dipteryx odorata (syn. 
Coumarouna odorata) (Fabaceae) [94]. The name of coumarin originates from the Portuguese term 
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“coumarou” used for the seeds of this plant [95]. It is assumed that these secondary metabolites have 
a protective role against predators and herbivores [96,97]. 
3.3.2.2. Chemotaxonomy of coumarins 
Coumarins have been isolated from hundreds of plants species distributed in more than 40 different 
families with diversity of 1300 types. Families with occurrence numbers of > 100 are identified as 
Apiaceae (Umbelliferae), Rutaceae, Asteraceae (Compositae), Fabaceae (Leguminosae), Oleaceae, 
Moraceae, and Thymelaeaceae, respectively [98]. Natural coumarins can be classified as simple 
coumarins, furocoumarins (linear and angular), dihydro-furocoumarins, pyranocoumarins (linear and 
angular), phenyl-coumarins, and bis-coumarins [93]. Apiaceae is the major and most diverse source of 
coumarins, containing five different types of coumarin derivatives including simple coumarins, linear 
and angular furocoumarins, linear and angular pyranocoumarins [98,99]. 
3.3.2.3. Furocoumarins 
Furocoumarins contain a furan ring fused with a coumarin nucleus. Depending on the attachment of 
furan group to the coumarin skeleton, they are structurally divided into linear and angular groups 
[100]. They are thought to be synthesized as phytoalexins [101]. 
Furocoumarins have been identified in several plant families, including Meliaceae, Rosaceae, 
Pittosporaceae and Asteraceae. The plants that with the highest furocoumarin contents are mostly 
members of the Fabaceae, Moraceae, Apiaceae and Rutaceae families [102]. 
Psoralen, bergapten, xanthotoxin, and imperatorin belong to the most widely distributed 
linear furocoumarins, whereas angelicin is the simplest angular compound. In combination with UV 
radiation in a dose- and time-dependent manner, linear furocoumarins have phototoxic and photo-
genotoxic effects [103]. Furthermore, other class of furocoumarins have also been described. 
Marmesin and coloumbianin are examples of dehydro-linear and angular furocoumarins, respectively. 
Consumption of furocoumarin-rich foods combined with UV exposure (320‒400 nm) has been 
correlated with phototoxic skin reactions, while long-term oral exposure to high doses of certain pure 
furocoumarins in PUVA (psoralen + UVA treatment for eczema, psoriasis, etc.) therapy may lead to 
higher occurrence of some types of skin tumors. Clinical evidence supports that intake of excessive 
amounts of furocoumarins might cause kidney and liver toxicity [104]. The most common phototoxic 
furocoumarins are psoralen, bergapten, angelicin, bergaptol, xanthotoxin, sphondin, and pimpinellin 
[105]. 
3.3.2.4. Chemistry of D. anethifolia 
The phytochemical profile of D. anethifolia has only been partly explored. Furocoumarins and 
terpenoids are characteristic components of the Ducrosia genus. From the seeds of D. anethifolia, two 
new terpenoids, the monoterpene ducrosin A and the sesquiterpene ducrosin B were isolated along 
with stigmasterol and the furocoumarins heraclenin and heraclenol [106]. Psoralen, 5-
methoxypsoralen, 8-methoxypsoralen, imperatorin, isooxypeucedanin, pabulenol, pangelin, 
oxypeucedanin methanolate, oxypeucedanin hydrate, 3-O-glucopyranosyl-β-sitosterol and 8-O-
debenzoylpaeoniflorin were also isolated from the extract of D. anethifolia [14,107]. GC analysis of 
the fatty acids showed high percentages of elaidic acid and oleic acid [106], beside 58.8% petroselinic 
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acid in the seed oil of D. anethifolia [108]. Apart from D. anethifolia, furocoumarins (psoralen, 
isopsoralen) have been reported only from D. ismaelis from this genus [109]. 
In the literature, most of papers deal with the composition of the EO. As major constituents, 
α-pinene (11.6% [110], 70.3% [111], 59.2% [112]); n-decanal (1.4‒45% [113], 45.06% [114], 70% [115], 
57% [116], 25.6–30.3% [117], 18.8% [118]), dodecanal (28.8% [119]), and cis-chrysanthenyl acetate 
(72.28%) [120,121] have been reported. 
 Folk medicinal use of the Ducrosia genus and D. anethifolia 
Ducrosia species belong to rare plants, hence their medicinal use is not widespread. D. flabellifolia 
Boiss. is traditionally used for its pain relieving and sedative properties in Jordan [122]. D. assadi has 
been consumed as a flavouring in food, and as antispasmodic, soporific, anti-inflammatory, antiseptic 
and carminative agent in the Iranian folk medicine [123,124]. 
In Iranian folk medicine, the whole herb of D. anethifolia (especially its aerial part) has been 
consumed as an analgesic and in case of insomnia and anxiety [14]. The aerial part, including the seed 
was described as carminative and useful for irregularities of menstruation [15]. Moreover, the herb is 
added to a variety of Persian foods for flavouring and spice [89,125]. 
 
 Bioactivities of the Ducrosia genus and D. anethifolia 
The ethanolic extract of D. flabellifolia exerted antiproliferative activity against MCF-7 and HEp-2 cell 
lines [126]. The EO of D. flabellifolia showed antimicrobial activity against Candida albicans and 
Staphylococcus aureus [122]. The EOs obtained from D. assadi was characterized by moderate 
antioxidant capacity in vitro [123]. 
The extracts of aerial parts of D. anethifolia have been assessed for its bioactivities in vitro and 
in vivo. Moderate anti-radical scavenging [111,127] and antibacterial effects [116,128] have been 
reported. The furocoumarin pangelin isolated from D. anethifolia showed effect against a panel of fast 
growing mycobacteria [107]. The EO of the seeds and the methanol extract of D. anethifolia showed 
a weak antibacterial effect against 14 Gram positive and negative bacteria [121,129].  
The EO of D. anethifolia demonstrated significant to moderate cytotoxic activity on three 
human cancer cell lines (K562, LS180 and MCF-7), while EO of D. flabellifolia possessed less remarkable 
effect [119]. The sesquiterpene ducrosin B isolated from D. anethifolia also exerted remarkable in vitro 
cytotoxicity against the human colon HCT-116 and ovary SKOV-3 cancer cell lines [106]. 
The crude extract of D. anethifolia and the isolated furocoumarins demonstrated in vivo 
antidiabetic activities [14]. The following activities of the EO have been described in in vivo 
experiments: anxiolytic [115,130,131], sedative [115], analgesic and anti-inflammatory [132], and 
anti-locomotor effect [131]. An in vivo study demonstrated that intra-peritoneal administration of the 
EO improved spatial learning and memory in adult male rats [133]. The reduction of 
pentylenetetrazole-induced seizure manifestations in male Wistar rats was observed after intra-
peritoneal injection of the hydroalcoholic extract [134]. The extract of D. anethifolia reduced the level 
of testosterone and spermatogenesis, and number of germ cells in male Wistar rats [135]. 
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3.4. EREMURUS PERSICUS (JAUB. & SPACH) BOISS. 
The genus Eremurus comprises 50 species, mainly distributed in Central and Western Asia [136–139]. 
 Taxonomy of E. persicus  
The Eremurus genus belongs to the Xanthorrhoeaceae (syn. Asphodelaceae) family, subfamily of 
Asphodeloideae, order of Asparagales, Liliopsida class, Tracheophyta division [140]. 
 Phytochemistry of the Eremurus genus and E. persicus 
The investigation of non-volatile phytoconstituents of Eremurus spp. extracts has been rarely carried 
out. The following compounds have been previously isolated from Eremurus species: aloesaponol III 
8-methyl ether, chrysophanol 8-methyl ether, 2-acetyl-1-hydroxy-8-methoxy-3-methylnaphthalene 
[141–143], methyl linolenate, β-sitosterol, isoorientin, inosine [144], chrysophanol [141–144], 
altaicusin A, emodin [142], a bi-anthraquinone glycoside, 2-acetyl-1,8-dimethoxy-3-methyl-
naphthalene, a pre-anthraquinone, 10-(chrysophanol-7’-yl)-10-hydroxychrysophanol-9-anthrone 
[141], aloesaponol III, and (R)-aloechrysone [143]. By using Folin-Ciocalteu’s method, total phenolic 
contents of various extract of E. spectabilis [10,145,146] were also assessed. 
The phytochemistry of E. persicus has been scarcely studied. Only four compounds have been 
identified from extracts of E. persicus. (R)-(‒)-Aloesaponol III 8-methyl ether [147], 2-acetyl-1-hydroxy-
8-methoxy-3-methylnaphthalene, helminthosporin [148], and 5,6,7-trimethoxy-coumarin [4] were 
isolated from the leaves of E. persicus. 
 Folk medicinal use of the Eremurus genus and E. persicus 
Some species of the genus Eremurus have traditionally been used in Iranian, Turkish, and Chinese folk 
medicine. The roots of E. chinensis Fedtsch and E. anisopterus (Ker. et Kir) Regel. have been used in 
China for medicinal purposes [138,141], whereas the leaves of E. spectabilis (Bieb.) Fedtsch. have been 
used in Iranian and Turkish folk medicine as food additive [149] and as remedy of various disorders 
[4,7,15,146,150–152].  
The studied species E. persicus (Jaub. & Spach) Boiss. is broadly spread out in Iran [4]. In 
Turkish folk medicine, its root is consumed for relieving gastrointestinal disorders and rheumatism 
[13], against inflammatory skin conditions [5,6], and scabies [7]. The leaves are traditionally eaten in 
Iran with rice [153], also used as a remedy of diabetes and constipation, and to treat of different 
disorders of stomach, liver, and the genitourinary system [11,12], and as diuretic [154], against fungal 
skin diseases, as a remedy of atherosclerosis, as well as for inflammation-related diseases [8–11]. 
 Bioactivities of the Eremurus genus and E. persicus 
The bioactivities of different extracts of E. spectabilis populations have been extensively studied. 
Antioxidant and antiradical activities of leaves and roots [10,145,146,155,156], anti-proliferative 
effects [10,151,156,157], cytotoxic, nitric oxide (NO) production inhibitory activity [144], 
gastroprotective effect [158], and antibacterial potential [139,145,156] of E. spectabilis extracts have 
been documented in the literature. Analysis of antioxidant potency of root extract of E. chinensis 
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Fedtch. [157], in vivo hypoglycaemic effect of methanolic extracts of E. himalaicus [159], and protein 
tyrosine phosphatase inhibitory activity of E. altaicus (Pall.) Stev. [142] have also been reported. 
Different extracts of leaves and roots of E. persicus were previously indicated to possess anti-
inflammatory [136], antibacterial and cytotoxic activities [12], dihydrofolate reductase inhibitory 
[160], antiglycation [4], antiradical, anti-inflammatory, anti-proliferative [10], antileishmanial [147], 
and antifungal effects [9]. The antioxidant, anticancer, acetylcholinesterase inhibitory, and 
antimicrobial activities and anti-dermatophyte effects of the EO of E. persicus were also studied [161]. 
3.5. CROCUS SATIVUS L. 
The genus of Crocus includes 85–100 species distributed around the globe, mostly in Western Asia and 
the Mediterranean region. Phytogeographically, Crocus species usually occur within the 
Mediterranean floristic region, extending eastward into the Irano-Turanian region. 
Crocus flowers, having monocot characteristic structure, consist of stamen, stigma and tepal. 
However numerous studies refer to perianth as “sepal” and “petal.” In some cases the investigated 
flower part is not clearly named, but the description narrows it to tepals [24,25,162]. Some of the 
studies are referring to the investigated sample as “petals” without any further description 
[18,19,22,163], while some further studies refer to saffron flower without stigma [20,164–166]. 
From the Crocus genus, C. sativus (saffron crocus) has the highest industrial importance. The 
flowers of the plant compose 6 tepals, 3 yellow stamens, and a white filiform style ending in a stigma 
composed of 3 threads [167]. The tepals are fragrant, have deep lilac purple colour with darker veins 
and a darker violet stain in the throat; the throat is white or lilac, pubescent. The stamen includes 7–
10 mm long filament, and yellowish, 15–20 mm long anther. The style is divided into three deep red 
clavate branches, each branch is 25–32 mm long. Capsules and seeds are rarely produced [168]. 
The stigma of C. sativus is famed as saffron and well-known as the priciest spice in the world. 
At the moment, the stigma is the only utilized plant part. To obtain 1 kg of dried stigma, 300,000 
flowers are approximately needed [167]. The analysis of alternative plant parts (the industrial by-
products tepal and stamen) that are available in larger amounts and considered as waste seems to be 
promising topic for the research, due to increasing scientific interest for the bioactivities of saffron 
crocus. 
 Taxonomy of saffron crocus  
Crocus genus belongs to Iridaceae family, tribe of Croceas, order of Liliales, Liliidae sub-class, class of 
Liliopsida, sub-division of Spermatophyta , and Magnoliophyta division [169]. 
 Folk medicinal application of saffron crocus stigma 
The stigma of saffron crocus is a popular spice and has also been consumed in the traditional Arabic 
and Islamic medicine for several purposes, especially to facilitate difficult labour, as cardiac and liver 
tonic and hepatic deobstruent, and for the treatment of female genito-urinary system disorders and 
male impotence. Its effect on the central nervous system have also been studied. Regarding to Sayyed 
Esmail Jorjani (1042-1136 A.D.): "saffron is astringent and resolvent and its fragrance can strengthen 
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these two effects. Hence, its action on enlivening the essence of the spirit and inducing happiness is 
great". This suggested activity can be interpreted as a positive effect on mood or as an antidepressant 
effect [170]. 
 Phytochemistry of saffron crocus 
3.5.3.1. Chemistry of stigma of saffron crocus 
The characteristic constituents of saffron crocus stigma consist of crocin, crocetin, picrocrocin and 
safranal. The carotenoids of crocin and crocetin are responsible for its color, the specific bitterish taste 
is attributed to the monoterpene glycoside picrocrocin, while safranal (an aromatic aldehyde) 
provides the aroma [170]. 
3.5.3.2. Phytoconstituents of saffron crocus by-products 
Several papers report the chemical composition of sepal and petal samples, however, botanically 
these plant parts should be defined as tepal. Therefore, in case of previous papers we refer to the 
plant parts used by the authors. 
After removing the stigma from flowers of saffron crocus, tepal and stamen parts are 
considered as waste. Many papers studied the major phytoconstituents of saffron crocus by-products. 
The petal contained total phenolic content with 95.3 ± 0.8 mg kaempferol-3-glucoside equivalent 
(KE)/g of dry weight (dw), flavonoids (63.9 ± 1.1 mg KE/g dw), and anthocyanins (16.6 ± 0.1 mg 
malvidin-3-glucoside equivalent/g dw). The stamen comprised lower contents of phenolic, flavonoid, 
and anthocyanin [167]. A mixture of petal and stamen materials possessed the total flavonoid content 
of 55.8 mg rutin equivalent (RE)/g after application of ultrasonic extraction [171]. In another study, by 
using Folin-Ciocalteu method the methanolic extract of petal contained the highest content of 
phenolics and flavonoids with 65.34 ± 1.74 mg of GAE/g of extract and 60.64 ± 2.71 mg of catechin 
equivalent (CE)/g of dry plant material, respectively, compared to the style and stamen parts [172]. 
The flavonol glycosides including kaempferol-3-O-sophoroside, kaempferol-3-O-rutinoside, 
quercetin-3-O-glucoside-7-O-rhamnoside, and isorhamnetin-3-O-sophoroside were identified as the 
petal major compounds [165]. Kaempferol-3-O-sophoroside was isolated as the major compound 
from the flower material of saffron crocus (except stigma) [20]. Several non-flavonoid compounds 
including crocetin derivatives, crocusatin B and C, safranal, picrocrocin, and sinapic acid derivatives 
were previously identified from saffron crocus flowers [173–175]. 
Several glycosylated flavonoids including kaempferol-3-O-β-D-glucopyranoside, kaempferol-
7-O-β-D-glucopyranoside, kaempferol-3-O-sophoroside, kaempferol-3-O-β-D-(2-O-β-D-6-O-
acetylglucosyl)-glucopyranoside, isorhamnetin-3-O-β-D-glucopyranoside, isorhamnetin-3,7-di-O-β-D-
glucopyranoside, and quercetin-3-O-β-D-glucopyranoside were isolated from the methanolic extract 
of the petal. By applying LC-MS/MS, quercetin-3,7-di-O-β-D-glucopyranoside (27.6 mg/g of dry petal), 
and kaempferol-3,7-di-O-β-D-glucopyranoside (20.2 mg/g of dry petal) were quantitatively identified 
as the main constituents of the petal [166]. 
In a further study, the most abundant natural compounds from petal were characterized as 
kaempferol 3-O-α-(2-O-β-glucosyl)-rhamnoside-7-O-β-glucoside and quercetin 3-O-α-(2-O-β-
glucosyl)-rhamnoside-7-O-β-glucoside [176]. Kaempferol and crocin were isolated from methanolic 
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extract of petal with yields of 12.6 and 0.6% (w/w), respectively [164]. In an LC-MS study, kaempferol, 
naringenin, and quercetin, some flavanone and flavanol glycosides and derivatives esterified with 
phenylpropanoic acids were also detected [177]. The presence of 3-hydroxy-γ-butyrolactone, 
kinsenoside, and goodyeroside A was also reported from the petal [163]. 
Three new monoterpenoids crocusatin-J, -K, and -L, a new naturally occurring acid (3S),4-
dihydroxybutyric acid and kaempferol glycosides including kaempferol 3-glucoside (astragalin), 
kaempferol 3-O-sophoroside, and kaempferol 3-O-β-D-(2-O-β-D-6-acetylglucosyl) glucopyranoside 
were furtherly isolated from methanolic extract of petal as the major compounds [22]. Several other 
known compounds including 6-hydroxy-3-(hydroxymethyl)-2,4,4-trimethyl-2,5-cyclohexadien-1-one 
6-O-β-D-glucoside, 3-formyl-6-hydroxy-2,4,4-trimethyl-2,5-cyclohexadien-1-one, 4-hydroxy-3,5,5-
trimethylcyclohex-2-enone, picrocrocin, crocusatin-C, -D, -E, and -I, methylparaben, 4-
hydroxyphenethyl alcohol,  p-coumaric acid, 4-hydroxybenzoic acid, protocatechuic acid methyl ester, 
protocatechuic acid, vanillic acid, methylvanillate, 3-hydroxy-4-methoxybenzoic acid, kaempferol, 
kaempferol 3-O-β-D-(6-O-acetyl) glucopyranoside, kaempferol 3-O-β-D-(2-O-β-D-6-O-acetylglucosyl)-
glucopyranoside, kaempferol 7-O-β-D-glucopyranoside, kaempferol 3,7-di-O-β-D-glucopyranoside, 
kaempferol 3-O-β-D-(6-O-acetyl)-glucopyranoside-7-O-β-D-glucopyranoside, nicotinamide, 
tribulusterine, harman, 1-(9H-β-carbolin-1-yl)-3,4,5-trihydroxypentan-1-one, adenosine were also 
isolated and identified from the petal matters [22]. 
By applying LC-UV-Vis-DAD-MS, the dried petal samples were analysed and three aglycone 
flavonoids kaempferol, quercetin, and isorhamnetin and 17 glycosylated derivatives of them including 
kaempferol 7-O-sophoroside, kaempferol 3,7-di-O-glucoside, kaempferol 7-O-gentobioside, 
kaempferol 3-O-sophoroside, kaempferol 3-O-neohesperidoside, kaempferol 3-O-sophoroside  
acetate, kaempferol 3-O-glucoside, isorhamnetin 3-O-sophoroside, isorhamnetin 3-O-gentobioside, 
isorhamnetin 3-O-neohesperidoside, isorhamnetin 3-O-glucoside, quercetin 3-O-neohesperidoside, 
and quercetin 3-O-sophoroside were characterized [24]. 
In a HPLC fingerprinting study on perianth segments (sepal and petal) of 70 Crocus species, 
numerous glycosylated anthocyanins, including delphinidin 3,5-di-O-β-glucoside, delphinidin 3-O-β-
rutinoside, delphinidin 3-O-β-glucoside-5-O-β-(6-O-malonyl)-glucoside, petunidin 3,5-di-O-β-
glucoside petunidin 3,7-di-O-β-(6-O-malonyl)-glucoside, petunidin 3-O-β-rutinoside, malvidin 3,7-di-
O-β-(6-O-malonyl)-glucoside, and flavonoids with quantity ratio of >20% for quercetin 3-O-β-
sophoroside and kaempferol 3-O-β-sophoroside were identified in saffron crocus [25]. In a comparison 
research performed by HPLC‐DAD, different parts of saffron crocus were qualitatively and 
quantitatively analysed. The results indicated that the major phytoconstituents of tepal are the 
following: kaempferol di‐hexoside > kaempferol 3‐O‐glucoside > kaempferol tri‐hexoside > quercetin 
3,4′‐di‐O‐glucoside. Moreover, delphinidin 3,5‐di‐O‐β‐glucoside was the main anthocyanin from the 
petal materials harvested from diverse origins. The comparison of phytoconstituents of stamen and 
stigma samples revealed that crocin, picrocrocin, safranal, 4‐hydroxy‐2,6,6‐trimethyl‐3‐oxocyclohexa‐
1,4‐diene‐1‐carboxaldehyde, 4‐hydroxy‐2,6,6‐trimethyl‐1‐carboxaldehyde‐1‐cyclohexene, and 4‐
hydroxy‐3,5,5‐trimethyl‐2‐cyclohexen‐1‐one are not present in stamen, whilst they are predominant 
components of stigma sample [178].  
12 
 
In two samples harvested from different regions of Italy, flavonol derivatives (6‒10 mg/g) 
were characterized as the major compounds of stamen and sepal. In this study, sepals mainly 
contained kaempferol-3-O-sophoroside (6.41‒8.30 mg/g of fresh sample), quercetin and methyl-
quercetin glycosides, whereas the stamens mainly contained kaempferol-3-O-sophoroside (1.70‒0.37 
mg/g of fresh sample) [179]. 
 Pharmacological activities of saffron crocus 
The efficacy of saffron crocus has been clinically investigated in diabetes [180], asthma [181,182], 
cognitive impairment [183–186], glaucoma [187], macular degeneration related to age [188,189], 
sexual dysfunction in women [190] and men [191], and premenstrual syndrome [192]. These effects 
are out of the scope of the present thesis, therefore clinical and preclinical studies not related to the 
antidepressant activity are not discussed here.  
3.5.4.1. Antidepressant activity of saffron crocus stigma 
The majority of the preclinical and clinical [18,19,201,202,193–200] studies dealing with saffron crocus 
(stigma) focus on its antidepressant activity. The efficacy in mild to moderate depression (daily dosage: 
30‒100 mg) has been verified by a recent meta-analysis as well [203]. 
Bioactivity-guided studies identified crocin as the active component by means of behavioural 
models of depression [204–206]. The efficacy of crocin was confirmed by a clinical study (30 mg per 
day for 8 weeks); it reduced the symptoms of depression compared to the placebo group in case of 
metabolic syndrome [207]. Furthermore, crocin increased the efficacy of selective serotonin reuptake 
inhibitors in patients with depression [208]. The in vivo anxiolytic effect of crocin was also analysed 
[209,210]. Another study reported anxiolytic effect of safranal [211]. The antidepressant effects of 
crocin and crocetin were assessed on mice after acute and sub-acute administration and crocetin was 
more effective than crocin in the forced swimming and tail suspension tests [212]. 
As observed in an animal experiment, the mechanism of the antidepressant effect might be 
partly mediated by safranal and crocin by inhibiting the uptake inhibition of norepinephrine, 
serotonin, and dopamine [213]. Although crocin is a weak inhibitor of monoamine oxidase, safranal 
did not possess this effect [214]. An animal experiment confirmed that the antidepressant activity of 
crocin may be related to the suppression of oxidative stress and neuroinflammation [206]. The levels 
of brain-derived neurotrophic factor (BDNF), cyclic-AMP response element binding protein (CREB), 
phospho-CREB (p-CREB), and VGF neuropeptide were increased by the aqueous extract of saffron 
crocus in rat hippocampus, where it can be related to the antidepressant effect [215]. The effect on 
CREB might have only insignificant function in the antidepressant activity of crocin, since its level 
changed only slightly in the rat cerebellum, while no change was observed in the levels of BDNF and 
VGF neuropeptide [216]. Nevertheless, a research described that crocin prevented the reducing effect 
of malathion on BDNF in the rat hippocampus [217]. Moreover, crocetin showed antidepressant 
activity in animals exposed to chronic stress, also demonstrated a neuroprotective effect by 
decreasing oxidative damage in their brains [218]. 
Trans-crocetin and a hydro-ethanolic extract of saffron crocus stigma possessed antagonistic 
effect on the N-methyl-D-aspartate receptor in rat cortical brain slices, although only the extract was 
13 
 
active on kainate receptors [219]. Crocetin and saffron crocus stigma extracts showed affinity at the 
phencyclidine binding side of the NMDA receptor and at the sigma-1 receptor, whilst crocin and 
picrocrocin were inactive [220]. Since a connection between depression and hyper-homocysteinemia 
is assumed, the reduction of homocysteine level in patients with high depression by saffron crocus 
might be a part of its mechanism of action; however, the components responsible for this bioactivity 
have not been identified [221]. It is presumed that the clinical effect of the stigma is partly correlated 
with the antioxidant capacity [207]. 
3.5.4.2. Antidepressant activity of saffron crocus by-products 
Since the exact mechanism of action and the full spectrum of active components is still undiscovered, 
other parts of saffron crocus than stigma might be considered as industrially perspective substituents 
of the expensive stigma. Based on this approach, by-products of saffron crocus, including petal (tepal), 
stamen, and corm have also been subjected to scientific studies. 
In an animal experiment, the ethanolic and aqueous saffron crocus extracts of stigma and 
petal samples were studied for their antidepressant effect using FST in mice; both the aqueous and 
ethanolic extracts of stigma and petal decreased immobility time in comparison with normal saline 
[17]. The dichloromethane and petroleum ether fractions gained from the aqueous-ethanol extract of 
C. sativus corms exerted significant antidepressant-like activities in dose-dependent manner in animal 
behavioural models of depression [204]. Kaempferol (one of the major flavonoid of the petal) was 
recorded to possess antidepressant activity on rats and mice in the FST [16]. 
In two clinical trials, the efficacy of petals has been furtherly validated. In a study 40 patients 
with mild to moderate depression were treated with capsules containing 15 mg dried ethanolic extract 
of saffron crocus petal or 20 mg fluoxetine for 8 weeks, in a randomized, double-blind trial. The petal 
was similarly effective to fluoxetine with remission rates of 25% in both groups [18]. In another similar 
trial, the efficacy of saffron crocus petals (same product as above) was compared to placebo in 40 
patients. After 6 weeks of treatment, the petal was more effective than placebo in improving the 
severity of depression as determined by using the Hamilton Depression Rating Scale [19]. 
4. MATERIALS AND METHODS 
4.1. SCIENTIFIC DATA COLLECTION  
Literature search for phytochemical and pharmacological data was carried out in the databases 
Scopus, SciFinder Scholar, Web of Science, Science Direct, and PubMed.  
4.2. IDENTIFICATION AND COLLECTION OF THE PLANT MATERIALS 
 Chamaemelum nobile 
The flowers of Chamaemelum nobile (L.) All. were purchased from Pál Bobvos (Hungary). The identity 
of the plant material was verified according to the requirements of the European Pharmacopoeia. A 
voucher specimen (voucher no.: 886/1) is stored for verification purposes in the herbarium of the 
Department of Pharmacognosy, University of Szeged. The EO of C. nobile was purchased from Aromax 
Ltd. (Hungary). 
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 Matricaria chamomilla 
The flowers of Matricaria chamomilla L. (300 g/sample) were individually harvested from different 
regions of Iran in the flowering period (April) of 2017. The collected populations “Mollasani”, 
“Gotvand”, “Izeh”, “Masjed Soleyman”, “Bagh Malek”, “Lali”, and “Saleh Shahr” from Khuzestan, while 
“Abdanan”, “Murmuri”, “Sarableh”, and “Darreh Shahr” from Ilam province were compared with 
“Bodgold”, which was cultivated at the botanical garden of Department of Horticultural Sciences, 
Shahid Chamran University of Ahvaz, Ahvaz, Iran. The identification of the plants was carried out by 
Dr. Mehrangiz Chehrazi (the same department), and a voucher specimen of each sample is stored in 
the herbarium of the Department. The voucher codes and geographic coordinates including the 
latitude, longitude, altitude using the GPS, along with meteorological data [222] are shown in Table 
S1. The flowers were dried in the shade and finely crushed.  
 Ducrosia anethifolia 
3 kg of the aerial parts of Ducrosia anethifolia (DC.) Boiss.were collected from the southern part of 
Iran (Fars, Neyriz) in April 2016. The plant was identified by Dr. Mohammad Jamal Saharkhiz 
(Department of Horticultural Science, Faculty of Agriculture, Shiraz University, Iran), and a voucher 
specimen is stored in the Herbarium of Department of Pharmacognosy, University of Szeged (voucher 
no.: 880). 
 Eremurus persicus 
1.8 kg aerial parts of Eremurus persicus (Jaub. & Spach) Boiss. were collected in south of Iran (Neyriz, 
Far) in July 2018. A voucher specimen is kept in the Herbarium of Department of Pharmacognosy, 
University of Szeged (voucher no.: 887/1). 
 Crocus sativus 
Saffron crocus (Crocus sativus L.) tepal and stamen samples were collected from 40 different locations 
of Iran during November 2018 at the same harvesting period. All were dried under shade, then the 
tepals were accurately separated from stamens. The sealed plastic bags were used for packing the 
plant samples individually and they were kept at room temperature. The growth locations, altitudes, 
and coordinates of the harvested plant materials are shown in Table S2. For comparison, a commercial 
saffron crocus stigma sample was also analysed (Bahraman Co., Mashhad, Iran). Voucher specimens 
are deposited in the Herbarium of Department of Pharmacognosy, University of Szeged (voucher no.: 
888/1-80). 
4.3. PHYTOCHEMICAL AND BIOACTIVITY ANALYSIS 
 Chamaemelum nobile 
4.3.1.1. Preparation of herbal extracts and isolation of reference standards 
The crude extract of C. nobile was prepared according to the description of the European Medicines 
Agency monograph [223], for the pharmacological studies. The plant material (10 g) was extracted via 
ultrasonic bath with 70% EtOH (3 × 100 mL), then evaporated in vacuum and lyophilized (yield: 
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3.169%). To obtain C. nobile extract fractions with different compositions, a part of the C. nobile crude 
extract was fractionated. VLC on polyamide with elution by MeOH‒H2O (20:80, 40:60, 60:40, 80:20, 
100:0) was used to gain fractions from the crude extract as follows: F20, F40, F60, F80, and F100. 
Four marker compounds (used as reference standards in further experiments) were isolated 
from the methanolic extract of 200 g C. nobile flowers, by using MPLC (silica gel 60, 0.045–0.063 mm, 
Merck, Darmstadt, Germany), GFC (Sephadex® LH-20, 25–100 mm, Pharmacia Fine Chemicals), RP-
PTLC (Silica gel 60, Merck, Darmstadt, Germany), HPLC, and VLC on polyamide (ICN Polyamide for 
column chromatography).  
4.3.1.2. HPLC experiments 
HPLC experiments were performed on a Shimadzu LC-20AD Liquid Chromatograph (SPD-M20A diode 
array detector, CBM-20A controller, SIL-20ACHT autosampler, DGU-20A5R degasser unit, CTO-20AC 
column oven) using a Kinetex 5 µm C-18 100 Å column (150 mm × 4.6 mm) with a gradient of 0.01% 
trifluoroacetic acid in H2O (A) and acetonitrile (B) as follows: 0–5 min 25% B, 14 min 28% B, 15 min 
70% B, 16 min 70% B, 16.5 min 25% B, and 20 min 25% B. The flow was 1.2 mL/min, column oven 
temperature was 55 °C. Detection was carried out within the range of 190–800 nm. For quantification, 
chromatograms were integrated at 344 nm. The reference standards and the evaporated extracts 
were dissolved in MeOH, filtered through a PTFE syringe filter and injected in volumes of 5 or 10 µL. 
Calibration curves were established for all the four reference standards. 
4.3.1.3. GC and GC-MS experiments 
The GC analysis was performed with an HP 5890 Series II gas chromatograph (FID), using a 30 m × 0.35 
mm × 0.25 mm HP-5 fused silica capillary column. The temperature program ranged from 60 °C to 210 
°C at 3 °C/min, and from 210 °C to 250 °C (2 min hold) at 5 °C/min. The temperatures of detector and 
injector were set to 250 °C, while the carrier gas was N2, with split sample introduction. Quantities of 
the individual components of the EO were stated as the percent of the peak area relative to the total 
peak area from the GC-FID analysis. 
The GC-MS analysis was carried out with a Finninan GCQ ion trap bench-top mass 
spectrometer. All conditions were same with GC’s except that the carrier gas was He at a linear velocity 
of 31.9 cm/s equipped with the capillary column was DB-5MS (30 m × 0.25 mm × 0.25 µm). The positive 
ion electron ionization mode was used, with ionization energy of 70 eV, and the mass range of 40–400 
amu. 
The compound identification was based on comparisons with published MS data [224], with a 
computer library search (the database was delivered together with the instrument), and by comparing 
their retention indices with literature values [224]. Retention indices were calculated against C8–C32 
n-alkanes on a CB-5 MS column [225]. A mixture of aliphatic hydrocarbons was injected in n-hexane 
(Sigma-Aldrich, St. Louis, MO, United States) by using the same temperature program that was used 
for analysing of the EO. 
4.3.1.4. Experiments on smooth muscles 
The effects of extracts and essential oil were tested on ileum, jejunum and colon preparations of 
animal and human origin and on guinea pig urinary bladder or rat gastric fundus. These experiments 
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were carried out in the Department of Pharmacology and Pharmacotherapy, University of Pécs, 
Medical School, Pécs, Hungary (Prof. Loránd Barthó et al.). Guinea pigs and Wistar rats were used to 
obtain segments of the ileum or distal colon. Macroscopically intact segments of human jejunum 
which were removed during the surgical treatment of pancreatic cancer, were used. The preparations 
of smooth muscle were used in a traditional organ bath arrangement, movements of the preparations 
were recorded with isotonic transducers. Experiments were carried out at basal tone or after inducing 
spasm by histamine. Certain experiments were performed in the presence of the muscarinic receptor 
antagonist atropine or tetrodotoxin (blocker of voltage sensitive Na+ channels) together with 
histamine. The methods used throughout these experiments are presented in detail elsewhere [226]. 
 Matricaria chamomilla 
4.3.2.1. Hydro-distillation of volatile oils and GC-FID and GC-MS experiments 
From each sample 60 g was individually powdered and subjected to hydro-distillation using a 
Clevenger apparatus for 3 h. The obtained EOs were dehydrated over anhydrous sodium sulphate and 
stored in refrigerator at 4 °C till analysis. Diethyl ether was also applied to elute the whole content of 
EOs from the apparatus, and after evaporating the solvent, the weighing process was performed. 
In the GC-FID measurement, a Shimadzu GC-17A (Kyoto, Japan) equipped with an FID detector 
and SGE™ BP5 capillary column (Trajan Scientific and Medical, Victoria, Australia) (30 m × 0.25 mm 
column with a 0.25 µm film thickness) was applied. The split ratio was 1:100 in GC. The temperatures 
of injector and FID detector were set at 280 and 300 °C, respectively, with 0.2 µL of injection volume. 
The oven temperature was kept at 60 °C for 1 min and then raised to 250 °C at 5.0 °C/min and held 
for 2 min, while the ambient oven temperature range was +4 to +450 °C. Helium gas was applied as a 
carrier gas at a flow rate of 1 mL/min. 
In case of GC-MS analysis an Agilent 7890B gas chromatograph (Agilent Technologies, Inc., 
Santa Clara, CA, USA) equipped with a 5977B mass spectrometry detector was utilized. The GC 
instrument was equipped with a 30 m × 0.25 mm HP-5MS capillary column with a 0.25 µm film 
thickness and 0.25 µm particle size (temperature range: -60 to +320/340 °C), and a split inlet ratio of 
100:1. The injection port temperature was 250 °C. The oven temperature was kept at 60 °C for 1 min 
and then planned from 60 to 250 °C at 5 °C/min; then, the temperature was kept at 250 °C for 2 min. 
As a carrier gas Helium (99.999%) was used (flow rate: 1 mL/min) and inlet pressure was 35.3 kPa. The 
mass spectrometer was operated in the electron impact mode at 70 eV, and the inert ion source (HES-
EI) temperature was set to 350 °C; the temperature of the quadrupole was set at 150 °C, while the MS 
interface was set to 250 °C. A scan rate of 0.6 s (cycle time: 0.2 s) was applied, covering a mass range 
from 35 to 600 amu. 
The identification of the most compounds were performed by two different analytical 
approaches: (a) comparison of Kovats indices of n-alkanes (C8–C24) [224] and (b) comparison of mass 
spectra (using authentic chemicals and Wiley spectral library collection). Identification was considered 
tentative when based on mass spectral data alone. In GC-FID and GC-MS, data acquisition and analysis 
were carried out applying Chrom-cardTM (Scientific Analytical Solutions, Zurich, Switzerland, version 
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DS) and XcaliburTM software (Thermo Fisher Scientific, Waltham, MA, USA, 4.0 Quick Start), 
respectively. 
4.3.2.2. Preparation of extracts and HPLC analysis of apigenin and luteolin contents 
The extraction was done using 5 g of each sample, individually, with MeOH (3 × 75 mL) in an ultrasonic 
bath (VWR-USC300D) for 10 min, at 40 °C under power grade 9. The concentrated extracts were 
subjected to evaluate the antiradical assays and HPLC analysis, after evaporation of the solvent under 
reduced pressure at 50 °C (Rotavapor R-114, Büchi, Switzerland). 
20 µL of each extract (1 mg/mL) was separately injected into an analytical HPLC (Knauer, 
Berlin, Germany) by using an end capped Eurospher II 100-5 C18, Vertex Plus Column (Knauer, Berlin, 
Germany) (250 × 4.6 mm with precolumn, particle size: 5 µm, pore size: 100 Å) in temperature of 30 
°C; coupled to UV detector (Knauer GmbH-Smart line 2600, Berlin, Germany) at a wavelength range 
of 190 to 500 nm (quantification at 330 nm), while MeOH/H2O was used as the mobile phase with a 
gradient system, increasing MeOH from 30% to 70% within 40 min, with a flow rate of 1 mL/min, at 
ambient temperature. Analysis was carried out using SAS software, version 9.2 (SAS Institute Inc., Cary, 
NC, USA). 
4.3.2.3. Evaluation of antiradical activity via DPPH and ORAC assays 
- DPPH assay 
DPPH measurement was done on 96-well microtiter plates. In brief, microdilution series of samples (1 
mg/mL, dissolved in MeOH) were prepared starting with 150 µL. To gain 200 µL of sample, 50 µL of 
DPPH reagent (100 µM) was added to each sample. The microplate was stored at room temperature 
under dark conditions. The absorbance was measured after 30 min at 550 nm using a microplate 
reader. MeOH (HPLC grade) and ascorbic acid (0.01 mg/mL) were used as a blank control and standard, 
respectively. Antiradical activity was calculated using the following equation: I% = [(A0 × A1/A0)/ 100] 
(A0 is the absorbance of the control and A1 is the absorbance of the sample). Anti-radical activity of 
the samples was expressed as EC50 (concentration of the compounds that caused 50% inhibition). 
 
- ORAC assay 
Twelve extracts were subjected to ORAC assay [227] with slight modifications. Microtiter plates (96-
well) were used for measurement of the samples. Briefly, 20 µL of extracts (0.01 mg/mL) was mixed 
with 60 µL of AAPH (peroxyl free radical generator) (12 mM) and 120 µL of fluorescein solution (70 
mM). Then, the fluorescence was measured for 3 h at 1.5 min cycle intervals with the microplate 
reader. The standard Trolox® was used. Activity of all samples was compared with rutin and EGCG as 
positive controls. Antioxidant capacities were presented as µmol TE (Trolox® equivalent)/g of dry 
matter. 
4.3.2.4. Statistical Analysis 
All the tests were carried out in triplicate, and the results are expressed as means ± SD. The data were 
assessed with one-way analysis of variance (ANOVA) using SAS software (version 9.2, SAS institute 
Inc., Cary, NC, USA) and GraphPad Prism version 6.05. The means were compared using Duncan’s 
comparisons test (p < 0.05). 
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 Ducrosia anethifolia 
4.3.3.1. Isolation and identification of the major phytochemicals of D. anethifolia 
3 kg of aerial parts of D. anethifolia (including flower, leaves and stem) were dried in shade at room 
temperature and crushed, then extracted with methanol (40 L). To yield the crude extract, the filtrate 
was concentrated under reduced pressure. The extract (464.1 g) was dissolved with methanol–water 
1:1 (1.5 L) and successively partitioned with n-hexane (4 × 1 L), CHCl3 (4 × 1 L), EtOAc (4 × 1 L) and n-
BuOH (4 × 1 L). The solvents of each extract were evaporated to gain the n-hexane, CHCl3, EtOAc and 
n-BuOH soluble-extracts. 
Initially, the CHCl3‒soluble fraction (20.6 g) was subjected to CC with a gradient system 
consisting of increasing concentration of MeOH in CHCl3 (0–80%); column fractions with similar TLC 
patterns were combined to get six major fractions D1, D2, D3, D4, D5 and D6. D1 was 
chromatographed by MPLC, first eluting with n-hexane–CH2Cl2 (50:50; 0:100), then adding MeOH to 
CH2Cl2 (0–100%), to afford four subfractions (D11, D12, D13 and D14). D11 was separated to 49 
subfractions using CPTLC with an isocratic eluting system n-hexane–EtOAc–MeOH (10:3:1), which 
resulted in the isolation of the pure compound 5 (82.8 mg). 
The RP-HPLC purification of D11 subfractions with MeOH–H2O (1:1) afforded compound 6 (1.7 
mg). D12 was chromatographed by MPLC applying a gradient solvent system with increasing EtOAc in 
n-hexane (5‒100%) to get eight major subfractions (D121–D128). From D123, the pure compound 7 
(3.1 mg) was isolated by using CPTLC with EtOAc in n-hexane (5–100%). D124 was successively 
separated to 81 fractions by CPTLC (same system), then subfractions 49–54 was subjected to RP-HPLC 
with MeOH–H2O (15–50% H2O in MeOH) yielding compound 8 (2.56 mg). 
D13 was separated by MPLC with increasing ratio of EtOAc in n-hexane (5–100%) to get seven 
fractions (D131–D137). D133 was subjected to MPLC with the same solvent system to gain 19 
subfractions. Finally, subfractions 1–2 were purified by using CPTLC with toluene–EtOAc (90:10, 80:20, 
70:30, 60:40, 50:50) as eluents to gain compound 9 (100.4 mg). Subfraction 3 from D133 was subjected 
to CPTLC by eluting with toluene–EtOAc (90:10, 80:20, 70:30, 60:40, 50:50) to yield 32 subfractions. 
Subfractions 18–19 were separated by PTLC with toluene–EtOAc (1:1) to get compound 10 (35.3 mg). 
Besides, subfractions 23–32 were chromatographed by RP-HPLC (MeOH–H2O 1:1) and then by PTLC 
with toluene–EtOAc (1:1) to yield compounds 11 (1.78 mg) and 12 (1.02 mg). By using CPTLC with 
increasing concentration of EtOAc in toluene (5–100%) as eluent, subfraction 6 from D133 was 
chromatographed to get 43 subfractions. Subfractions 24–40 were separated by PTLC with CHCl3–
MeOH–n-hexane (5:1:5) to retrieve compounds 13 (2.5 mg) and 14 (21.7 mg), respectively. 
D3 was separated to five major fractions (D31–D35) by MPLC with a solvent system containing 
increasing ratio of MeOH in CHCl3 (0–100%). D33 was chromatographed by CPTLC with raising the 
concentration of MeOH (0–20%) in the mixture of cyclohexane–EtOAc (1:1) to afford 70 subfractions. 
Subfractions 21–23 contained the pure compound 15 (1.0 mg). 
The main fraction D4 was separated by MPLC to seven subfractions (D41–D47) by increasing 
the ratio of MeOH (0–100%) in acetone–toluene (1:1). Subfraction D42 was subsequently 
chromatographed by PTLC with eluting cyclohexane–EtOAc–MeOH (4.75:4.75:0.5) and compound 16 
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(2.7 mg) was isolated. Furthermore, D46 was purified with CPTLC by increasing ratio of MeOH (0–
100%) in acetone–toluene (1:1); then compound 17 (2.9 mg) was purified by using RP-PTLC (MeOH–
H2O 1:1) from subfractions 35–37 (Figure 1). 
Thin layer chromatography (TLC) (aluminium sheets coated with silica gel 60 F254, 0.25 mm, Merck 
5554 and silica gel 60 RP-C18 F254s, Merck) were used for monitoring in whole separation procedure. 
Open column chromatography (CC) (Silica gel 60, 0.063–0.2 mm, Merck, Darmstadt, Germany) 
Medium pressure liquid chromatography (MPLC) (glass column: length of 460 mm, inner diameter of 
26 mm, BÜCHI, Switzerland; pump: BÜCHI C-605, Switzerland; silica gel 60, 0.045–0.063 mm, Merck, 
Darmstadt, Germany) 
Gel filtration chromatography (GFC) (Sephadex® LH-20, Pharmacia, Uppsala, Sweden) 
Centrifugal PTLC (CPTLC) (Chromatotron®, Harrison Research, USA; Silica gel 60 GF254, Merck, 
Darmstadt, Germany). 
Preparative thin layer chromatography was performed by normal (Silica gel 60, Merck, Darmstadt, 
Germany) and reverse phase (Silica gel 60 RP-18 F254s, Merck, Darmstadt, Germany) (PTLC and RP-
PTLC, respectively). 
High pressure liquid chromatography (HPLC) experiments were carried out on reverse phase (RP-
HPLC) (Kinetex® 5 mm C-18 100 Å, 150 × 4.6mm Phenomenex, Torrance, CA); while the HPLC flow was 
1.2 mL/min, column oven temperature was 24 °C. Detection was carried out within the range of 190–
800 nm. The HPLC system comprised of Waters 600 pump, Waters 2998 PDA detector, Waters in/line 
degasser AF degasser unit connected with Waters 600 control module using Empower Pro 5.00 
software. 
 
Eluents: 
CC: MeOH‒CHCl3 [0‒80%] 
MPLC I: n-hexane‒CH2Cl2 [50:50, 0:100], MeOH‒CH2Cl2 [0‒100%] 
CPTLC I: n-hexane‒EtOAc‒MeOH [10:3:1] 
RP-HPLC I: MeOH‒H2O [1:1] 
MPLC II: EtOAc‒n-hexane [5‒100%] 
CPTLC II: EtOAc‒n-hexane [5‒100%] 
RP-HPLC II: MeOH‒H2O [15‒50%] 
CPTLC III: toluene‒EtOAc [90:10, 80:20, 70:30, 60:40, 50:50] 
PTLC I: toluene‒EtOAc [1:1] 
CPTLC IV: EtOAc‒toluene [5‒100%] 
PTLC II: CHCl3‒MeOH‒n-hexane [5:1:5] 
MPLC III: MeOH‒CHCl3 [0-100%] 
CPTLC V: MeOH [0‒20%] in cyclohexane‒EtOAC [1:1] 
MPLC IV: MeOH [0‒100%] in acetone‒toluene [1:1] 
PTLC III: cyclohexane‒EtOAc‒MeOH [4.75:4.75:0.5] 
CPTLC VI: MeOH [0‒100%] in acetone‒toluene [1:1] 
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Figure 1. Isolation of pure compounds from Ducrosia anethifolia 
 
4.3.3.2. Biological activities of furocoumarins from D. anethifolia 
4.3.3.2.1.1. Assay for anti-proliferative effect 
The effects of increasing concentrations of the analysed compounds on cell proliferation were tested 
in 96-well flat-bottomed microtiter plates [228]. The compounds were diluted in 100 µL of McCoy’s 
5A medium. 6 × 103 mouse T-cell lymphoma cells (PAR or MDR) in medium (100 µL) were added to 
each well, except for the medium control wells. The culture plates were further incubated at 37 °C for 
72 h; at the end of the incubation period, 20 µL of MTT solution (Sigma, St. Louis, MO) (from a 5 mg/mL 
stock) was added to each well. 
After incubation at 37 °C for 4 h, 100 µL of SDS (Sigma, St. Louis, MO) solution (10% in 0.01 M 
HCl) was added to each well and the plates were further incubated at 37 °C overnight. The cell growth 
was determined by measuring the OD at 540 nm (ref. 630 nm) with a Multiscan EX ELISA reader 
(Thermo Labsystems, Waltham, MA). IC50 values were calculated via the following equation: 
 
IC50 =   100 − [
𝑂𝐷𝑠𝑎𝑚𝑝𝑙𝑒−𝑂𝐷⥂𝑚𝑒𝑑𝑖𝑢𝑚 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑂𝐷 𝑐𝑒𝑙𝑙 𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑂𝐷 𝑚𝑒𝑑𝑖𝑢𝑚 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
] 𝑥100 
 
4.3.3.2.2. Assay for cytotoxic effect 
The effects of increasing concentrations of compounds on cell growth were tested in 96-well flat-
bottomed microtiter plates [228]. The compounds were diluted in a volume of 100 μL medium. Then, 
1 × 104 cells in 100 μL of medium were added to each well, except for the medium control wells. The 
culture plates were incubated at 37 °C for 72 h; at the end of the incubation period, 20 μL of MTT 
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solution (from a 5 mg/mL stock) were added to each well. After incubation at 37 °C for 4 h, 100 μL of 
sodium dodecyl sulphate (SDS, Sigma, USA) solution (10% in 0.01 M HCI) was added to each well and 
the plates were further incubated at 37 °C overnight. Cell growth was determined by measuring the 
optical density (OD) at 550 nm (ref. 630 nm) with a Multiscan EX ELISA reader. Inhibition of the cell 
growth was determined according to the formula: 
IC50 =  100 − [
𝑂𝐷𝑠𝑎𝑚𝑝𝑙𝑒−𝑂𝐷⥂𝑚𝑒𝑑𝑖𝑢𝑚 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑂𝐷 𝑐𝑒𝑙𝑙 𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑂𝐷 𝑚𝑒𝑑𝑖𝑢𝑚 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
] 𝑥100 
Results are expressed as IC50 values: the inhibitory dose that reduces by a 50% the growth of the cells 
exposed to the tested compound. 
4.3.3.2.3. Assay for multidrug resistance reversing activity 
The inhibition of the cancer MDR efflux pump ABCB1 by the tested compounds was assessed by flow 
cytometry measuring the retention of rhodamine 123 by ABCB1 (P-glycoprotein) in MDR mouse T-
lymphoma cells, as the L5178Y human ABCB1-gene transfected mouse T-lymphoma cell line (MDR) 
overexpress P-glycoprotein [229]. This method is a fluorescence-based detection system which uses 
verapamil as reference inhibitor. Briefly, cell number of L5178Y MDR and PAR cell lines were adjusted 
to 2 × 106 cells/mL, re-suspended in serum-free McCoy’s 5A medium and distributed in 0.5 mL aliquots 
into Eppendorf centrifuge tubes. The tested compounds were added at different concentrations and 
the samples were incubated for 10 min at room temperature. Verapamil (Sigma, USA) and tariquidar 
(Sigma, USA) were applied as positive controls. Next, 10 µL (5.2 µM final concentration) of the 
fluorochrome and ABCB1 substrate rhodamine 123 (Sigma, USA) were added to the samples and the 
cells were incubated for 20 min at 37 °C, washed twice and re-suspended in 0.5 mL PBS for analysis. 
The fluorescence of the cell population was measured with a Partec CyFlow® flow cytometer (Partec, 
Germany). The percentage of mean fluorescence intensity was calculated for the treated MDR cells as 
compared with the untreated cells. A fluorescence activity ratio (FAR) was calculated based on the 
following equation which relates the measured fluorescence values: 
 
𝐹𝐴𝑅 =
𝑀𝐷𝑅𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑀𝐷𝑅𝑐𝑜𝑛𝑡𝑟𝑜𝑙⁄
𝑝𝑎𝑟𝑒𝑛𝑡𝑎𝑙𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑝𝑎𝑟𝑒𝑛𝑡𝑎𝑙𝑐𝑜𝑛𝑡𝑟𝑜𝑙⁄
𝐹𝐴𝑅 =
𝑀𝐷𝑅𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑀𝐷𝑅𝑐𝑜𝑛𝑡𝑟𝑜𝑙⁄
𝑝𝑎𝑟𝑒𝑛𝑡𝑎𝑙𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑝𝑎𝑟𝑒𝑛𝑡𝑎𝑙𝑐𝑜𝑛𝑡𝑟𝑜𝑙⁄
 
 
The results attained from a representative flow cytometry experiment in which 10,000 individual cells 
of the population were evaluated for amount of rhodamine 123 retained with the aid of the Partec 
CyFlow® flow cytometer, are first presented by the histograms and this data converted to FAR units 
that define fluorescence intensity, standard deviation, peak channel in the total- and in the gated-
populations. Parameters calculated are: SSC (of cells in the samples); FL-1; FSC (of cells in the samples 
or cell size ratio); and FAR, whose values were calculated using the equation given above. 
4.3.3.2.4. Checkerboard combination assay 
A checkerboard microplate method was used to evaluate the effect of drug interactions between 
furocoumarins and the chemotherapeutic drug doxorubicin [230]. This assay was carried out by 
multidrug resistant mouse T-lymphoma cells overexpressing the ABCB1 transporter. Doxorubicin is 
classified in the anthracycline antitumor agents, and it exerts anticancer activity as a topoisomerase-
II (TI-2) inhibitor. The dilutions of doxorubicin (Teva, Hungary, stock solution: 2 mg/mL) were made in 
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a horizontal direction in 100 μL (final concentration: 17.242 μM), and the dilutions of the test 
compounds vertically in the microtiter plate in 50 μL volume. 
The plates were incubated for 72 h at 37 °C in 5% CO2 atmosphere. The cells were re-
suspended in McCoy’s 5A culture medium and distributed into each well in 50 μL containing 6 × 103 
cells each. The cell growth rate was determined after MTT staining. 20 μL of MTT solution (from a 
stock solution of 5 mg/mL) was added to each well, at the end of the incubation period. After 
incubation at 37 °C for 4 h, 100 μL of SDS solution (10% in 0.01 M HCI) was added to each well and the 
plates were further incubated at 37 °C overnight. OD was measured at 540/630 nm with Multiscan EX 
ELISA reader (Thermo Labsystems, USA) as described elsewhere [230]. CI values at 50% of the growth 
inhibition dose (ED50), were determined using CompuSyn software (ComboSyn, Inc., USA) to plot four 
to five data points to each ratio. CI values were calculated by means of the median-effect equation, 
where CI < 1, CI = 1, and CI > 1 represent synergism, additive effect (or no interaction), and antagonism, 
respectively [231,232]. 
 Eremurus persicus 
1.8 kg of the aerial part materials (flowers, stems and leaves) were shade-dried at room temperature 
and finely ground. Methanol (50 L) was applied for the extraction procedure. After filtration and 
concentration under reduced pressure, 127.75 g crude extract was obtained. The extract was 
dissolved with methanol-water 1:1 (1 L), subsequently by using separating funnel partitioned 
successively with n-hexane (4 × 1 L), CHCl3 (4 × 1 L), and EtOAc (4 × 1 L). Then, the solvents were 
evaporated to achieve the n-hexane, CHCl3 and EtOAc extracts. 
The EtOAc-soluble extract (3.5 g) was initially subjected to flash chromatography with a 
gradient solvent system by increasing the ratio of CHCl3‒MeOH (1:1) from 20% to 100% in n-hexane. 
Column fractions with similar TLC patterns were combined to obtain six major fractions E1, E2, E3, E4, 
E5 and E6. By applying flash chromatography with increasing concentration of CHCl3‒MeOH (9:1) from 
10% to 100% in n-hexane, E1 was separated to six fractions (E11, E12, E13, E14, E15, E16). E15 was further 
chromatographed by flash chromatography applying the same solvent system to afford four 
subfractions (E151–E154). E153 was separated to 60 subfractions with CPTLC by increasing MeOH in 
toluene (0-100%). Subfraction 39-49 was also purified to get compound 18 (1.41 mg) by RP-PTLC 
(MeOH‒H2O 1:1). 
E16 was subjected to CPTLC with two gradient solvent systems, first with increasing ratio of 
solvent mixture of EtOAc‒acetone (1:1) 50‒100% in n-hexane, then increasing MeOH (0‒50%) in 
EtOAc‒acetone (1:1). From the obtained six fractions (E161‒E166), GFC (MeOH as eluent) was developed 
to separate E166 and compound 19 (1.24 mg) was finally isolated. 
MPLC was exploited for further separation of the major fraction E2 with increasing 
concentration of MeOH (0‒100%) in EtOAc‒n-hexane (1:2). From eight gained fractions (E21‒E28), E24 
was subsequently chromatographed to 40 subfractions by GFC (MeOH as eluent). Subfractions 25 and 
26 contained the pure compound 20 (22.22 mg).  
The CHCl3-soluble fraction (4.7 g) was also separated to 7 major fractions (C1‒C7) by applying 
MPLC eluting with EtOAc in n-hexane (0‒50%), then increasing ratio of MeOH (0‒100%) in EtOAc‒n-
23 
 
hexane (1:1). By using GFC (eluent: MeOH), C4 was also separated to 50 sub-fractions, and sub-
fractions 22-24 contained the pure compound 21 (1 mg). C7 was fractionated by GFC (eluent: CH2Cl2‒
MeOH 1:1) to get three major fractions (C71, C72 and C73). Then, C72 was purified with the same method 
to yield five fractions (C721‒C725). By applying CPTLC with MeOH in toluene (10‒100%) as a gradient 
solvent system, 38 subfractions were afforded. Subfraction 1-12 was chromatographed by PTLC with 
toluene‒MeOH (9.8:0.2), and pure compounds 22 (1.03 mg) and 23 (0.95 mg) were isolated (Figure 
2). 
 
Figure 2. Isolation of the compounds from Eremurus persicus 
 
Flash chromatography (FC) Biotage® Instrument (Isolera™ Spektra Systems with ACI™ and Assist) with 
integrated UV, UV-Vis, and ELS detection using RediSep Rf Gold normal phase flash columns (10, 50 
and 80 g) (Biotage® SNAP cartridge, KP-Sil) 
Thin layer chromatography (TLC) (aluminium sheets coated with silica gel 60 F254, 0.25 mm, Merck 
5554 and silica gel 60 RP-C18 F254s, Merck) was applied to monitor in whole separation procedure. 
Medium pressure liquid chromatography (MPLC) (glass column: length of 460 mm, inner diameter of 
26 mm, BÜCHI, Switzerland; pump: BÜCHI C-605, Switzerland; silica gel 60, 0.045–0.063 mm, Merck, 
Darmstadt, Germany) 
Gel filtration chromatography (GFC) (Sephadex® LH-20, Pharmacia, Uppsala, Sweden) 
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Centrifugal PTLC (CPTLC) (chromatotron®, Harrison Research, USA; Silica gel 60 GF254, Merck, 
Darmstadt, Germany). 
Preparative thin layer chromatography was performed by normal (Silica gel 60, Merck, Darmstadt, 
Germany) and reverse phase (Silica gel 60 RP-18 F254s, Merck, Darmstadt, Germany) (PTLC and RP-
PTLC, respectively). 
 
Eluents: 
FC I: CHCl3‒MeOH [1:1] (20‒100%) in n-hexane 
FC II: CHCl3‒MeOH [9:1] (10‒100%) in n-hexane 
CPTLC I: MeOH‒toluene (0‒100%) 
GFC I: MeOH as eluent 
RP-PTLC I: MeOH‒H2O [6:4] 
RP-PTLC II: MeOH‒H2O [1:1] 
CPTLC II: EtOAc‒acetone [1:1] (50‒100%) in n-hexane; MeOH (0‒50%) in EtOAc‒acetone [1:1] 
MPLC I: MeOH (0‒100%) in EtOAc‒n-hexane [1:2] 
MPLC II: EtOAc‒n-hexane (0‒50%); MeOH (0‒100%) in EtOAc‒n-hexane [1:1] 
GFC II: MeOH‒CH2Cl2 [1:1] as eluent 
CPTLC III: MeOH‒toluene (10‒100%) 
PTLC I: MeOH‒toluene [0.2:9.8] 
4.4. CHARACTERIZATION AND STRUCTURE ELUCIDATION 
NMR spectra were recorded in CD3OD and CDCl3 on a Bruker Avance DRX 500 spectrometer at 500 
MHz (1H) and 125 MHz (13C). The peaks of the residual solvent (δH 3.31 and 7.26, δC 49.0 and 77.2, 
respectively) were taken as reference. The data were acquired and processed with MestReNova 
v6.0.2e-5475 software. Chemical shifts are expressed in parts per million and J values are reported in 
Hz. All solvents were used in analytical grade (Molar Chemicals Kft, Halásztelek, Hungary). By applying 
a Perkin-Elmer 341 polarimeter, optical rotation was also established in CHCl3 at room temperature. 
4.5. ANALYSIS OF C. SATIVUS L. SAMPLES 
 Extract preparation 
20 mg of tepal, 10 mg of stigma, and 50 mg of stamen samples were separately extracted by ultrasonic 
bath for 15 min with mixture of solvents of EtOH‒H2O (1:1), then diluted with the above solvents to 
10.0 mL (tepal) and 5.0 mL (stigma and stamen) in volumetric flasks, respectively. 
In case of filtered samples, the extracts were filtered via a filter membrane (PTFE-L syringe 
filter, hydrophilic, FilterBio®, diameter: 13 mm, pore size: 0.45 µm), the first 1 mL was unused, and 
the rest 1.5 mL was analysed by HPLC-DAD. The samples were centrifuged for 1 min at 7000 rpm. In 
case of all samples, three extracts were prepared and analysed in triplicate. 
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 HPLC apparatus and measurement conditions  
HPLC-DAD analysis was performed on a Shimadzu SPD-M20A (Shimadzu Corporation, Kyoto, Japan), 
equipped with a Shimadzu SPD-M20A photodiode array detector, an on-line degasser unit (Shimadzu 
DGU-20A5R), a column oven (Shimadzu CTO-20AC column oven) and autosampler (Shimadzu SIL-
20ACHT) using a RP Kinetex® C8 column (5 μm, 100 Å, 150 × 4.6 mm, Phenomenex, Torrance, USA) at 
30 °C. Chromatographic elution of the samples was accomplished with a gradient solvent system by 
increasing the ratio of MeOH in H2O (containing 0.066% of H3PO4) from 0 to 30% (0‒1 min), 30 to 57% 
(1‒7 min), 57 to 76% (7‒12 min), and 76 to 100% (12‒13 min) at a flow rate of 1.5 mL/min. UV-Vis 
range of 190–800 nm was used to detect the compounds. The samples were monitored at the UVmax 
of the standards (picrocrocin: 247 nm, quercetin-3-O-sophoroside: 360 nm, kaempferol-3-O-
sophoroside: 354 nm, kaempferol-3-O-glucoside: 348 nm, crocin: 441 nm, safranal: 316 nm, and 
crocetin: 427 nm). Data assessment and acquisition was performed with LabSolutions (Version 5.82) 
software (Shimadzu, Kyoto, Japan). The volume of 10 and 20 µL of tepal and stamen samples were 
injected, respectively. 
 System validation 
Validation of the analytical method was developed by us, done according to the ICH Harmonised 
Guideline [233], and completed with further experiments. Validation was accomplished by 
establishing the calibration curves of 7 reference compounds, determining the LoD and LoQ values, 
assessing system suitability, accuracy, precision, repeatability, stability and filter compatibility of the 
extracts. 
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5. RESULTS 
5.1. CHAMAEMELUM NOBILE 
 Chemical characterization of the extracts 
Four characteristic peaks in the HPLC were detected in the crude C. nobile extract and its fractions 
F40–F100 at retention time range of 4–9 min. The corresponding components were isolated from the 
plant material and identified by 1H and 13C NMR experiments as the flavonoids apigenin, eupafolin, 
hispidulin, and luteolin (Figure 3, and Figures S1–S6). These compounds were further used as 
reference standards to characterize the C. nobile extracts. The identification of reference compounds 
in different extracts was based on matching the retention times and UV spectra. Retention times of 
luteolin, eupafolin, apigenin, and hispidulin were 4.5, 5.0, 7.5, and 8.5 min, respectively (Figure 4). The 
baseline separation of these compounds allowed their reliable quantification in different extracts. 
The crude extract of C. nobile comprised eupafolin as the main flavonoid, followed by luteolin, 
hispidulin, and apigenin (Table 1). The fractionation on polyamide resulted in subfractions F20–F100 
with different compositions, as demonstrated by the differences in their flavonoid content. In F20, the 
quantities of flavonoids were below the level of quantification. The flavonoid content of the fractions 
increased with increasing MeOH content of the eluting solvent. The highest flavonoid levels were 
measured in F80, except for luteolin and apigenin, which were mainly concentrated in F100. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The chemical structures of the isolated flavonoids from Chamaemelum nobile; 1: luteolin; 2: 
eupafolin; 3: apigenin; 4: hispidulin 
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Figure 4. HPLC chromatogram of the crude C. nobile extract with the peaks of luteolin (1), eupafolin 
(2), apigenin (3), and hispidulin (4) (344 nm). 
 
Table 1. Flavonoid content of C. nobile crude extract and its fractions as determined by HPLC 
Sample Luteolin 
(mg/g extract) 
Eupafolin 
(mg/g extract) 
Apigenin 
(mg/g extract) 
Hispidulin (mg/g 
extract) 
Crude extract 4.167 ± 0.616 18.756 ± 2.121 0.298 ± 0.027 1.584 ± 0.181 
F20 Not detected Not detected Not detected Not detected 
F40 0.578 ± 0.001 1.800 ± 0.001 0.179 ± 0.001 0.231 ± < 0.001 
F60 1.904 ± 0.001 62.591 ± 0.025 0.151 ± < 0.001 5.951 ± 0.004 
F80 22.605 ± 0.001 223.488 ± 0.036 0.859 ± < 0.001 17.060 ± < 0.006 
F100 55.305 ± 0.002 150.206 ± 0.005 2.055 ± < 0.001 4.983 ± < 0.001 
 
 Chemical characterization of the essential oil 
Based on their retention times and mass spectrometric data, methallyl angelate, 3-methyl pentyl 
angelate, and 3-methylamylisobutyrate were identified as the major constituents of C. nobile EO (19.0, 
18.2, and 10.4%, respectively) (Table 2). The identified components comprised 97% of the EO.  
 
Table 2. Chemical composition of C. nobile essential oil 
Compoundsa RIb % in samples 
Methyl tiglate 867 tr 
n-Hexanol 875 1.1 
2-Methylbutyl acetate 897 0.4 
Isobutyl isobutyrate 925 0.8 
Acetonylacetone 932 0.7 
α-Pinene 935 2.4 
Camphene + allyl methacrylate 958 0.6 
Thuja-2,4(10)-diene 960 1.1 
Isoamyl propionate 966 tr 
β-Pinene 969 0.3 
Myrcene 973 0.6 
Propyl angelate 993 1.1 
Isobutyl 2-methylbutyrate 998 tr 
Datafile Name:hi0,0097mg$mllu0,01mg$mlE0,0220mg$mlA$0,0091mg$ml 10ul003_Cikkhez kalibráló_2017.12.
04._011.lcd
Sample Name:hi0,0097mg/mllu0,01mg/mlE0,0220mg/mlA:0,0091mg/ml 10ul003
0,0 2,5 5,0 7,5 10,0 12,5 15,0 17,5 min
-5
0
5
10
15
20
25
mAU
334nm,4nm /smth
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Compoundsa RIb % in samples 
Isoamyl isobutyrate 1004  1.5 
2-Methylbutyl isobutyrate 1006  2.7 
1,8-Cineol 1035 tr 
Isoamyl methacrylate 1037 1.1 
Isobutyl angelate 1058 4.9 
Methallyl angelate 1068 19.0 
2-Butenyl angelate 1119 tr 
3-Methylamyl isobutyrate 1122 10.4 
3-Methylamyl methacrylate 1150 6.6 
trans-Pinocarveol + isoamyl angelate 1153 8.6 
2-Methylbutyl angelate 1168 8.3 
Pinocarvone 1177 3.9 
Prenyl angelate 1213 1.5 
Myrtenal 1217 1.2 
3-Methyl pentyl angelate 1264 18.2 
Identified components  97.0 
aCompounds listed in sequence of elution from a DB-5 MS column.  
bRetention indices calculated against C8 to C32 n-alkanes on a DB-5MS column. tr, in traces. 
 
 Effects on smooth muscles 
The crude extract of C. nobile induced a transient longitudinal contraction on guinea pig ileum 
preparations. Both atropine (an antagonist of acetylcholine at the muscarinic receptors) and 
tetrodotoxin (an inhibitor of voltage-sensitive Na+ channels; hence, of neuronal axonal conduction) 
inhibited the contractile effect of C. nobile crude extract. The functional blockade of capsaicin-
sensitive neurons did not inhibit, whereas the cyclooxygenase inhibitor indomethacin moderately 
inhibited the contraction in response to the C. nobile extract. Subfractions of the crude extract also 
possessed contracting activity.  
After transient contraction, smoot muscle relaxing activity was observed. On histamine-
precontracted preparations (in the presence of atropine and tetrodotoxin), concentration-dependent 
relaxation was observed in response to treatment with C. nobile crude extract (60–200 µg/mL). The 
highest tested concentration induced full relaxation. The relaxation induced by the 60 µg/mL extract 
was not significantly altered by the adrenergic β-receptor antagonist propranolol or by the NO 
synthase inhibitor NG-nitro-L-arginine. Different fractions of the C. nobile extract demonstrated 
distinct relaxant effects. F20 and F40 (60 or 200 µg/mL) produced no relaxation, whereas F60, F80 and 
F100 had remarkable and dose-dependent spasmolytic activity in this concentration range (up to 
100%). This observation refers to the potential role of flavonoids in the relaxant effect, and 
experiments with four flavonoids isolated from the plant material reassured this hypothesis. The four 
major flavonoids of the extracts (hispidulin, luteolin, eupafolin and apigenin) had relaxant activities at 
2 µM ranging between 18.2‒24.2%, whereas at 20 µM between 64.5‒81.9%. The EO (0.1‒10 µg/mL) 
induced 12.8‒69.7% relaxation in dose-dependent manner with no pre-contraction. 
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5.2. MATRICARIA CHAMOMILLA 
 Essential oil yields 
The studied plant samples were characterized mainly with similar EO yields. Populations “B” (1.03 ± 
0.003%) and “BM” (0.78 ± 0.017%) contained the highest and lowest amount of EO, respectively, as 
shown in Table 3. As the plant sample “B” was cultivated in the university’s garden and it was regularly 
irrigated, the highest EO content can be predicted. 
 Chemical profiles of volatile oils 
Seventeen compounds were detected in these twelve populations. The sesquiterpene α-bisabolone 
oxide A (45.64–65.41%) was the major EO constituent in the samples except “B” and “S”, whereas its 
concentration was the highest in population “Mu” (Table 3). 
The cultivated sample “B” was rich in α-bisabolol oxide B (21.88%) and chamazulene (19.22%), 
while the percentages of these compounds were lower under the wild growth conditions. The blue 
colour of EOs in all samples except “S” represented their chamazulene contents, whereas, “S” due to 
lack of this compound showed a yellowish green colour. Accordingly, oxygenated sesquiterpenes 
(53.31–74.52%) were the predominant chemical group of EO constituents in all studied samples, 
excluding “S”, which was rich in sesquiterpene hydrocarbons (Figure 5). 
 
Figure 5. Volatile oil components from M. chamomilla populations in percentage of total identified 
compounds 
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Table 3. Essential oil constituents and yields of twelve harvested M. chamomilla populations 
 
A Relative retention index to C8–C24 n-alkanes on HP-5MS column; B Retention times; C Compounds listed in order of elution from HP-5MS column; nd: not detected; the 
means were compared using Duncan’s comparisons test (p < 0.05); small letters (a, b, c) in each row show the significant difference of related component among various 
populations
No. RI A RT B 
              Populations 
 
 
Compounds C 
B I BM L MS Mo G SS Mu A DS S 
Amount (%) 
1 1063 7.79 Artemisia ketone nd 0.65 nd nd nd nd nd nd nd nd nd nd 
2 1423 17.75 Trans-caryophyllene nd nd nd nd nd nd nd nd nd nd nd 0.5 
3 1454 18.75 (E)-β-Farnesene 8.51b 16.68a 9.58ab 10.60ab 13.92ab 13.91ab 9.82ab 6.61b 10.33ab 15.29a 12.37ab 5.25b 
4 1484 19.45 Germacrene D 1.31 nd nd nd nd nd nd nd nd 0.55 nd 2.21 
5 1500 20 Bicyclo-germacrene 2.01 nd nd nd nd nd nd nd nd nd nd nd 
6 1506 20.21 (Z)-α-Bisabolene nd nd nd nd nd 0.81 nd nd nd nd nd nd 
7 1514 20.3 (Z)-γ-Bisabolene nd nd nd nd nd nd nd nd nd nd nd 40.08 
8 1529 20.7 (E)-γ-Bisabolene nd nd nd nd nd nd nd nd nd nd nd 42.76 
9 1561 21.65 (E)-Nerolidol 1.76 nd nd nd nd nd nd nd nd nd nd nd 
10 1577 22.1 )+(-Spathulenol 1.53 nd nd nd nd nd nd nd nd nd nd nd 
11 1630 23.18 (γ)-Eudesmol nd nd nd nd nd nd nd nd nd nd nd 1.78 
12 1656 24.16 α-Bisabolol oxide-B 21.88a 1.55bc 1.52bc 1.59bc 1.39c 1.65bc 1.68bc 1.80b 1.58bc 1.64bc 1.37c nd 
13 1685 24.56 α-Bisabolol nd nd nd nd 1.32 2.86 2.07 nd nd nd nd nd 
14 1693 24.9 α-Bisabolone oxide A 11.36d 47.91bc 53.28b 52.14bc 46.98c 46.74c 45.64c 51.87bc 65.41a 47.7bc 49.18bc nd 
15 1730 25.76 Chamazulene 19.22a 8.29bc 9.74b 4.74e 8.44bc 6.14d 8.02c 9.3bc 4.18e 2.58f 6.06d nd 
16 1748 26.18 α-Bisabolol oxide A 16.78bc 14.03c 13.93c 19.35b 16.75bc 19.41b 24.02a 22.26ab 7.53d 20.25b 17.22bc nd 
17 1890 26.31 (E)-Spiroether 8.37a 7.51ab 4.70c 5.75bc 7.12ab 6.41b 6.49b 3.73c 5.31bc 5.96b 7.26ab nd 
Total identified compounds % 92.73 96.64 92.76 94.2 95.27 96.51 97.71 95.59 94.35 94.53 93.47 93.08 
EOs yield % 
1.03 ± 
0.003 
0.84 ± 
0.006 
0.78 ± 
0.17 
0.88 ± 
0.012 
0.94 ± 
0.035 
0.79 ± 
0.006 
0.88 ± 
0.021 
0.91 ± 
0.009 
0.9 ± 
0.023 
0.89 ± 
0.006 
0.83 ± 
0.009 
0.98 ± 
0.021 
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 Apigenin and luteolin quantification of methanolic extracts 
Methanolic extracts of samples “L” and “A” contained the highest amounts of apigenin, with 1.19 ± 
0.01 mg/g and 1.02 ± 0.01 mg/g, respectively. Luteolin was present in higher concentrations in “BM” 
(2.20 ± 0.0 mg/g) and “A” (1.01 ± 0.02 mg/g) extracts (Figure 6). 
 
Figure 6. Apigenin and luteolin contents of twelve plant samples (mg/g of dry weight)  
 
 Classification of M. chamomilla populations 
To characterize and identify the different chemotypes of Iranian M. chamomilla populations, their EO 
compositions and main flavonoids (apigenin and luteolin) were subjected to CA and PCA. As shown in 
Figures 7 and 8, the dendrograms allowed the separation of M. chamomilla populations into three 
main groups, each representing a distinct chemotype. 
 
 
Figure 7. Dendrogram of the M. chamomilla populations resulting from the cluster analysis (based on 
Euclidean distances) of the volatile oil components. chemotype I (α-bisabolone oxide A and α-
bisabolol oxide A), chemotype Ⅱ (chamazulene and α-bisabolol oxide B), chemotype Ⅲ ((Z) and (E)-
γ-bisabolene). 
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Figure 8. Principal component analysis (PCA) of the M. chamomilla populations. ABOA: α-bisabolol 
oxide A, ABOB: α-bisabolol oxide B, PEO: percentage of essential oil, CH: chamazulene, SP: (E)-
spiroether, ABNOA: α-bisabolone oxide A, BEF: (E)-β-farnesene, BZY: (Z)-γ-bisabolene, BEY: (E)-γ-
bisabolene, LUT: luteolin, API: apigenin. 
 
PCA is a mathematical procedure that transforms several correlated variables into various 
uncorrelated variables called principal components (PC). PC1, PC2, and PC3 showed the highest 
variation of phytochemicals among the studied populations. PC1 explained 41.57% of total variation 
and had a positive correlation with α-bisabolol oxide A, (E)-β-farnesene, α-bisabolone oxide A and (E)-
spiroether, and negative correlation with (Z)-γ-bisabolene and (E)-γ-bisabolene. The second PC (PC2), 
with 24.98% of variance, demonstrated positive correlation with chamazulene, α-bisabolol oxide B, α-
bisabolone oxide A and the EO content. Furthermore, PC3 represented positive correlation in the case 
of apigenin and luteolin, which accounted for 12.02% of the total variance (Table 4). 
 
Table 4. Eigenvalues, variance and cumulative variance for three principal components 
Major phytochemicals 
Principal components 
PC1 PC2 PC3 
Chamazulene 0.377 0.881 0.023 
α-Bisabolol oxide A 0.760 0.126 0.114 
(E)-β-Farnesene 0.679 -0.293 -0.004 
α-Bisabolol oxide B 0.044 0.961 0.011 
α-Bisabolone oxide A 0.742 0.525 0.104 
(E)-Spiroether 0.849 0.377 -0.032 
(Z)-γ-Bisabolene -0.965 -0.119 -0.130 
(E)-γ-Bisabolene -0.965 -0.119 -0.130 
Essential oil content -0.480 0.600 -0.348 
Apigenin 0.002 -0.295 0.638 
Luteolin 0.160 0.235 0.857 
PCA2 (24.98%) 
PCA1 (41.57%) 
Principle Component Biplot 
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Regarding a significant contribution of phytochemical variation in PC1 and PC2, the scatter plot of PC1 
and PC2 was used to specify phytochemical distance. The studied populations were classified in three 
groups, which confirmed the CA results. 
In accordance with the CA, the populations “I”, “DS”, “Mo”, “MS”, “Mu”, “G”, “SS”, “L”, “A” 
and “BM” were classified into the same category, while, “B” and “S” were grouped into the individual 
subclasses. The first group possessed α-bisabolone oxide A and α-bisabolol oxide A as the major 
constituents as well as apigenin and luteolin (chemotype I). The second chemotype (II), was 
characterized by high amounts of chamazulene and α-bisabolol oxide B. The chemotype (III) was the 
richest in (Z) and (E)-γ-bisabolene. 
 Effect of environmental factors on secondary metabolite production 
In order to assess the effect of environmental factors on EO components, along with apigenin and 
luteolin contents, CCA was applied based on a matrix of three environmental factors including altitude, 
mean annual temperature (MAT), and mean annual precipitation (MAP) [222] and major EO 
compounds, along with apigenin and luteolin contents (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Canonical correspondence analysis (CCA) biplot of M. chamomilla populations, linking 
percentages of the major constituents, collected from different environmental conditions. 
Populations B: Bodgold, I: Izeh, BM: Bagh Malek, L: Lali, MS: Masjed Soleyman, Mo: Mollasani, SS: 
Saleh Shahr, Mu: Murmuri, A: Abdanan, DS: Darreh Shahr, and S: Sarableh, MAT: mean annual 
temperature; MAP: mean annual precipitation; ABOA: α-bisabolol oxide A, ABOB: α-bisabolol oxide B, 
PEO: essential oil percentage, CH: chamazulene, SP: (E)-spiroether, ABNOA: α-bisabolone oxide A, BEF: 
(E)-β-farnesene, BZY: (Z)-γ-bisabolene, BEY: (E)-γ-bisabolene, LUT: luteolin, API: apigenin. 
 
Eigenvalues 4.57 2.74 1.32 
Variance (%) 41.57 24.98 12.02 
Cumulative variance (%) 41.57 66.55 78.57 
CCA2 (3.2%) 
CCA1 (96.6%) 
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According to the CCA, phytochemicals of populations in first group were significantly affected by 
ecological parameters (altitude, temperature and precipitation) while the main oil composition and 
flavonoids of “Sarableh” and “Boldgold” were changed by genetic factors. Therefore, the “Sarableh” 
population can be introduced as a new chemotype. 
 Antiradical activity of the extracts 
In the evaluation of the antioxidant potential of the twelve selected populations, “S” showed the most 
significant antiradical capacity, with EC50 = 7.76 ± 0.3 µg/mL and 6.51 ± 0.63 mmol TE/g measured by 
DPPH and ORAC assays, respectively. However, the extracts showed lower activity compared to 
ascorbic acid (EC50 = 0.3 ± 0.02 µg/mL) in the DPPH and rutin (20.22 ± 0.63 mmol TE/g) and EGCG 
(11.97 ± 0.02 mmol TE/g) in the ORAC assay (Figures 10 and 11). 
 
 
Figure 10. Antiradical scavenging activity of twelve plant samples of M. chamomilla in the DPPH assay 
 
 
 
Figure 11. Antiradical capacity of M. chamomilla selected populations in the ORAC assay 
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5.3. DUCROSIA ANETHIFOLIA 
 Isolation of the pure compounds 
Repeated column chromatography of the bioactive fractions resulted in the isolation of 13 
compounds. The compounds were identified by careful interpretation of NMR data and comparison 
of 1H and 13C chemical shifts with those reported in literature. Nine linear furocoumarin derivatives, 
namely imperatorin (5) [234], oxypeucedanin (7) [235], heraclenol (8) [236], (+)-oxypeucedanin 
hydrate (aviprin) (9) [235], heraclenin (10) [237], pabulenol (11) [235], oxypeucedanin methanolate 
(13) [238], isogospherol (14) [239], (–)-oxypeucedanin hydrate (prangol) (16) [240]; along with vanillic 
aldehyde (6) [241], 3-hydroxy-α-ionone (12), harmine (15), and 2-C-methyl-erythrytol (17) were 
identified (1H-NMR spectra see in Supporting Information Figure S7) (Figure 12). 
The diastereomers (+)-oxypeucedanin hydrate and (‒)-oxypeucedanin hydrate were 
distinguished by determining their optical rotations and comparing with literature [242]. The 1H and 
13C-NMR spectral data of 12, 15, and 17 in CD3OD are reported here for the first time. 
Compound 12 (3-hydroxy-α-ionone): 1H-NMR (500 MHz, CD3OD) δ = 6.67 (H-7, dd, J = 15.8 Hz, 10.3 
Hz), 6.13 (H-8, d, J = 15.8 Hz), 5.60 (H-4, br s), 4.22 (H-3, br s), 2.58 (H-6, d, J = 10.3 Hz), 2.27 (H3-10, 
s), 1.80 (H-2b, dd, J = 13.2 Hz, 5.9 Hz), 1.63 (H3-13, s), 1.38 (H-2a, dd, J = 13.2 Hz, 7.2 Hz), 1.01 (H3-11, 
s), 0.90 (H3-12, s); 13C-NMR (125 MHz, CD3OD) δ = 200.8, 149.8, 135.9, 134.7, 127.3, 65.9, 55.6, 45.0, 
35.0, 29.8, 27.1, 24.5, 22.8. 
Compound 15 (harmine): 1H-NMR (500 MHz, CD3OD) δ = 8.11 (H-3, d, J = 5.5 Hz), 8.02 (H-5, d, J = 8.7 
Hz), 7.86 (H-4, d, J = 5.5 Hz), 7.06 (H-8, d, J = 1.9 Hz), 6.89 (H-6, dd, J = 8.7 Hz, 1.9 Hz), 3.92 (s, 7-OCH3), 
2.80 (s, 1-CH3); 13C-NMR (125 MHz, CD3OD) δ  = 162.9, 144.6, 141.6, 137.0, 136.2, 130.7, 123.7, 116.3, 
113.5, 111.4, 95.4, 56.0, 19.1. 
Compound 17 (2-C-methyl-erythrytol): 1H-NMR (500 MHz, CD3OD) δ = 3.80 (H-4a, dd, J = 10.4 Hz, 2.5 
Hz), 3.61 (H-3, m), 3.59 (H-4b, m), 3.52 (H- 1a, d, J = 11.1 Hz), 3.44 (H-1b, d, J = 11.1 Hz), 1.11 (2-CH3, 
s); 13C-NMR (125 MHz, CD3OD) δ = 76.2, 75.0, 68.5, 63.8, 19.7. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Secondary metabolites isolated from D. anethifolia 
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 Antiproliferative and cytotoxic activities on cancer cell lines 
Furocoumarins isolated from D. anethifolia were subjected to bioassay for cytotoxic and 
antiproliferative activity against cancer cell lines. All compounds exerted potent antiproliferative 
effect on sensitive and resistant mouse T-lymphoma cells (Table 5). 
 
Table 5. Antiproliferative (AA) and cytotoxic activities (CA) of the furocoumarins against PAR, MDR 
and NIH/3T3 cells presented as IC50 values 
 
Compounds 
AA on PAR 
cells (µM) 
AA on MDR 
cells (µM) 
CA on PAR 
cells (µM) 
CA on MDR 
cells (µM) 
CA on NIH/3T3 
cells (µM) 
imperatorin (5) 36.12 ± 0.91 42.24 ± 0.88 52.56 ± 4.19 > 100 47.16 ± 1.28 
oxypeucedanin (7)  25.98 ± 1.27 28.89 ± 0.73 40.33 ± 0.63 66.68 ± 0.00 57.18 ± 3.91 
heraclenol (8)  52.31 ± 2.12 46.57 ± 0.47 > 100 > 100 70.91 ± 4.26 
aviprin (9) 41.96 ± 0.88 60.58 ± 2.74 > 100 > 100 83.55 ± 0.57 
heraclenin (10)  32.73 ± 2.40 46.54 ± 1.22 65.81 ± 1.00 83.94 ± 1.68 54.82 ± 1.99 
pabulenol (11) 30.47 ± 0.47 29.28 ± 0.45 51.32 ± 3.32 > 100 54.09 ± 3.83 
oxypeucedanin methanolate (13) 35.88 ± 0.96 33.23 ± 0.51 56.42 ± 5.23 > 100 65.78 ± 0.46 
isogospherol (14) 46.53 ± 0.47 48.75 ± 0.28 > 100 > 100 92.41 ± 2.80 
doxorubicin 0.054 ± 0.005 0.468 ± 0.065 0.377 ± 0.02 7.152 ± 0.358 5.71 ± 0.50 
 
Data were expressed as mean ± standard deviation (n = 3). Different letters represent significant differences (p 
< 0.05). 
 
However, they did not show any selectivity towards the resistant cell line. The most potent compound 
was oxypeucedanin (7) on both cell lines. Some compounds had no toxic effects heraclenol (8), ((+)-
oxypeucedanin hydrate (9), isogospherol (14)); furthermore, imperatorin (5), pabulenol (11), 
oxypeucedanin methanolate (13) and were more toxic on the sensitive PAR cell line (IC50 between 52 
and 57 mM) without any toxicity on MDR cells (Table 5). 
Oxypeucedanin (7) and heraclenin (10) exhibited cytotoxic activity; however, they were more 
potent on the sensitive PAR cell line (Table 5). Using NIH/3T3 normal murine fibroblast cells, the 
cytotoxic activity of furocoumarins was evaluated. Some compounds indicated slight toxic effect on 
normal fibroblasts, namely (+)-oxypeucedanin hydrate (9), heraclenol (8) and isogospherol (14) with 
IC50 values of 83.55, 65.78 and 54.82 mM, respectively. Pabulenol (11) possessed similar activity on 
fibroblast and parental mouse lymphoma cells. In addition, oxypeucedanin (7), heraclenin (10), and 
oxypeucedanin methanolate (13) exhibited mild toxicity on fibroblasts and parental lymphoma cells. 
Imperatorin (5) had no toxic activity on fibroblasts. 
 Multidrug resistance reversing activity 
Regarding the efflux pump inhibiting activity of the compounds on ABCB1 overexpressing MDR mouse 
T-lymphoma cells, only oxypeucedanin (7) showed moderate ABCB1 inhibiting effect (FAR: 2.22); 
however, this inhibition was lower than in case of the positive controls tariquidar (FAR: 100) and 
verapamil (FAR: 8.2) (Table 6, Figure S8 in Supporting Information). 
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Table 6. Efflux pump inhibiting activities of furocoumarins 
 
 Combination assay results on MDR cells 
The two most promising compounds in the previous assays were investigated in combination with the 
standard chemotherapeutic drug doxorubicin. Oxypeucedanin (7) and heraclenin (10) showed slight 
synergistic effect with doxorubicin, for this reason, they might be potential adjuvants in combined 
chemotherapy applying standard anticancer drugs with compounds that can act synergistically (Table 
7). 
 
Table 7. Checkerboard combination assay of selected compounds with doxorubicin 
 
  
Samples Conc. μM FSC SSC FL-1 FAR 
PAR - 2069 658 98.20 - 
MDR 
- 2152 725 1.79 - 
 
MDR mean 
 
1.182 - 
tariquidar 0.02 2156 719 119 100.68 
verapamil 20 2143 740 9.69 8.20 
imperatorin (5) 
2 2165 749 0.727 0.62 
20 2161 750 0.783 0.66 
oxypeucedanin (7) 
2 2190 749 0.9 0.76 
20 2164 763 2.62 2.22 
heraclenol (8) 
2 2300 742 0.995 1.37 
20 2317 740 0.348 1.30 
(+)-oxypeucedanin hydrate (9) 
2 2325 725 0.715 0.98 
20 2305 769 0.583 0.80 
heraclenin (10) 
2 2318 723 0.942 1.29 
20 2294 764 0.57 0.78 
pabulenol (11) 
2 2324 728 0.596 0.82 
20 2323 750 0.544 0.75 
oxypeucedanin methanolate (13) 
2 2310 737 0.58 0.80 
20 2290 766 0.499 0.68 
isogospherol (14) 
2 2305 741 0.531 0.73 
20 2326 741 0.548 0.75 
DMSO 2% (V/V) 2308 762 0.497 0.68 
MDR - 2301 746 0.535 - 
Compound Best ratio CI at ED50 Interaction SD (±) 
oxypeucedanin 1:50 0.85537 Slight synergism 0.07800 
heraclenin 4:100 0.88955 Slight synergism 0.06334 
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5.4. ISOLATION OF THE MAJOR PHYTOCHEMICALS FROM EREMURUS PERSICUS 
The successive chromatography techniques were led to isolate six pure compounds. A rare glucoside 
aliphatic alcohol corchoionoside A (18) [243,244], 4-amino-4-carboxychroman-2-one (19) [245,246], a 
C-glycosyl flavone isoorientin (20) [247], ziganein 5-methyl ether (21) [248], and two coumarin 
derivatives namely auraptene (22) [249,250], and imperatorin (23) [251]. Except isoorientin (20) all 
the compounds were isolated for the first time in the Eremurus genus. The chemical structures of the 
isolated compounds are given in Figure 13. The 1H-NMR spectra of the isolated compounds are 
illustrated in Figure S9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The chemical structures of the isolated phytochemicals of Eremurus persicus 
 
5.5. HPLC-DAD FINGERPRINTING OF SAFFRON CROCUS SAMPLES 
 Method validation  
Our aim was to validate and develop an analytical method that is suitable for the analysis of saffron 
crocus stigma and by-products samples. Marker compounds, that were used as reference standards 
during our experiments were chosen based on literature data as follows: safranal (24), picrocrocin 
(25), crocetin (26), crocin (27), kaempferol-3-O-glucoside (K.G.) (28), quercetin-3-O-sophoroside (Q.S) 
(29), and kaempferol-3-O-sophoroside (K.S.) (30). During validation, tepal samples and the mixture of 
the reference compounds were used. Validation was carried out for all the analytes, where possible. 
The validation was partial for crocin, crocetin, picrocrocin, and safranal, due to these compounds did 
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not contain in saffron crocus tepal. The chemical structures of the marker compounds are displayed 
in Figure 14. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. The chemical structures of the reference compounds of Crocus sativus L.; 24: safranal; 25: 
picrocrocin; 26: crocetin; 27: crocin; 28: kaempferol-3-O-glucoside; 29: quercetin-3-O-sophoroside; 
30: kaempferol-3-O-sophoroside 
 
5.5.1.1. Calibration and linearity 
To establish calibration curves and limit of detection (LoD) and limit of quantitation (LoQ) values, 
seven major components of saffron crocus including kaempferol-3-O-sophoroside, kaempferol-3-O-
glucoside, quercetin-3-O-sophoroside, crocetin, picrocrocin, safranal, and crocin were utilized (Table 
8). Calibration curves are based on 8‒11 calibration points. The correlation coefficient of the 
calibration curves was at least 0.998, while these curves covered 2 orders of magnitude of analyte 
concentration. 
 
Table 8. Calibration curve characteristics and limit of detection and quantification values 
Standard 
LoD 
(µg/inj) 
LoQ 
(µg/inj) 
Calibration 
points 
Range covered 
(µg/inj) 
Regression equations R2 
Picrocrocin 0.00245 0.00741 8 0.03-0.9 y = (1.10320 x 109)x -10690.0 0.9997394 
Q.S. 0.02554 0.07739 10 0.082-6.15 y = (6.55841 x 108)x -5275.02 0.9996089 
K.S. 0.02277 0.06901 9 0.076-3.04 y = (5.96019 x 108)x -20062.4 0.9996702 
K.G. 0.06763 0.20495 9 0.1075-4.3 y = (1.36039 x 108)x -4682.70 0.9984738 
Crocin 0.00128 0.00386 10 0.0145-0.58 y = (2.92163 x 109)x -13570.0 0.9994265 
Safranal 0.00177 0.00536 8 0.08-2.4 y = (2.06147 x 109)x +37991.1 0.9982921 
Crocetin 0.00032 0.00097 11 0.00172-0.129 y = (9.35271 x 109)x -5778.24 0.9999475 
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5.5.1.2. Filter compatibility  
In order to choose the best method for sample preparation, one tepal specimen was extracted by 
ultrasonic bath, then filtered or centrifuged. The sample preparation by filtration or centrifugation 
had no major impact on quantitative results, however in case of crocetin, the amount of the analyte 
decreased with 17.3% as the result of filtration. For the other analytes, slighter higher values were 
measured in filtered samples (picrocrocin: 0.311 ± 0.0011 mg; Q.S.: 1.51 ± 0.0047 mg; K.S.: 0.935 ± 
0.0027 mg; K.G.: 1.148 ± 0.0161 mg; safranal: 1.046 ± 0.0143 mg). 
5.5.1.3. Stability 
The stability of the solutions of reference compounds was assessed. For this case, the standard 
mixtures were prepared by filter and centrifuge methods, stored at 4 °C and room temperature 
(23 °C), then injected at day 0, 1, 3, 5, and 7 (Table 9). In case of picrocrocin and the flavonoids (K.S., 
K.G., and Q.S.), temperature and storage time did not influence the concentration of the analytes, 
whereas in case of crocin and safranal, decomposition was observed especially at room temperature. 
Interestingly, after one day, the concentration of crocetin significantly decreased, while temperature 
had no major impact on this process. 
 
Table 9. Stability of the dissolved reference compounds after 1, 3, 5 and 7 days (values compared to 
100% day 0 values) 
 
Sample Days Picrocrocin Q.S. K.S. K.G. Crocin Safranal Crocetin 
23 °C 
1 100.97 101.08 100.92 101.77 101.18 99.84 86.28 
3 104.06 100.59 100.69 101.80 95.93 87.89 76.71 
5 100.37 99.97 100.53 102.74 91.29 85.89 76.47 
7 100.59 99.70 101.12 105.00 90.65 83.71 78.94 
4 °C 
1 100.51 100.66 100.56 101.05 100.84 100.29 86.52 
3 104.09 100.66 100.56 101.82 100.57 99.74 85.92 
5 100.69 100.41 100.67 102.30 100.30 96.44 84.48 
7 100.77 100.89 101.27 104.98 100.50 94.64 85.44 
 
5.5.1.4. System suitability 
5 times of injection was carried out for the mixture of the reference standards to investigate suitability 
of the analytical system. The low RSD% values of the AUCs and retention times, together with the 
tailing factors below 2 confirm that the system is suitable for the measurement of these compounds 
(Table 10). 
 
Table 10. System suitability of the standards compared to the prepared mixture of standards 
RT: retention time 
System suitability 
characteristic 
Picrocrocin Q.S. K.S. K.G. Crocin Safranal Crocetin 
RSD% of AUC 0.47 0.18 0.43 2.53 0.38 0.41 1.11 
Tailing factor 1.139 - 1.145 1.043 - 1.067 1.113 - 1.127 1.356 - 1.408 1.177 - 1.910 1.171 - 1.184 1.310 - 1.334 
RSD% of RT 0.66 0.62 0.36 0.22 0.19 0.14 0.10 
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5.5.1.5. Accuracy 
By the determination of recoveries, the accuracy of the method was evaluated (Table 11). Recoveries 
of the marker compounds was assessed by adding known amounts of the standards to a tepal (or in 
case of crocin, picrocrocin, crocetin, and safranal to stigma) sample at three different concentrations 
(50, 100, and 150% of the previously determined amounts). Three independent samples were 
prepared for each concentration levels and injected in triplicates. The recovery values ranged between 
96.09‒111.92%, 83.69‒112.25%, and 89.40‒116.26% in case of 50%, 100%, and 150% of 
concentration, respectively, therefore the accuracy of the method was considered to be acceptable.  
 
Table 11. Mean recovery values (%) of the controls 
Level Picrocrocin (stigma) Q.S. K.S. K.G. Crocin (stigma) Safranal (stigma) Crocetin (stigma) 
% RSD% % RSD% % RSD% % RSD% % RSD% % RSD% % RSD% 
50% 111.92 0.27 106.54 0.12 100.95 0.29 96.09 0.62 - - - - 99.54 1.33 
100% 101.80 0.07 112.25 0.10 99.60 0.06 103.36 2.03 97.89 0.27 - - 83.69 1.73 
150% 110.32 1.32 116.26 0.30 101.54 0.12 97.57 2.77 108.10 0.06 - - 89.40 0.42 
 
5.5.1.6. Precision 
One tepal and one stigma sample were individually extracted and injected 10 times, to determine the 
precision of the analytical method. Precision was established by calculating RSD% values of the AUCs 
(Table 12). The RSD% values below 1% confirm the precision of the method. 
 
Table 12. Precision of the analytical method as determined by RSD% 
Samples Picrocrocin Q.S. K.S. K.G. Crocin Crocetin 
Tepal - 1.72 0.07 0.53 - - 
Stigma 1.86 0.30 2.26 2.68 0.58 1.86 
 
5.5.1.7. Repeatability 
The repeatability of the experiment was carried out by analysis of six tepal sample extracts within 24 h 
(intra-assay precision). Repeatability is described by RSD% values of the whole datasets for Q.S., K.S., 
and K.G., where RSD% values were 3.38%, 3.71% and 3.44%, respectively.  
5.5.1.8. Intermediate precision 
The same tepal sample was examined by two analysts and intermediate precision was determined as 
RSD% of the means, to assess intermediate precision. For Q.S., K.S., and K.G. the RSD% values were 
3.81%, 2.29%, and 6.85%, respectively. 
 HPLC-DAD analysis of tepal and stamen samples 
40 different tepal and stamen samples were subjected to HPLC-DAD analysis to qualitatively and 
quantitatively analyse their selected markers. Our developed HPLC method allowed the good 
separation and hence the reliable analysis of these compounds in saffron crocus samples. 
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In tepal and stamen samples only three glycosylated flavonols including quercetin-3-O-
sphoroside, kaempferol-3-O-sophoroside, and keampferol-3-O-glucoside were detected. We analysed 
a saffron stigma sample as well. From this sample picrocrocin, crocin, and crocetin were identified, 
which is in line with previous data.  
The amounts of reference standards in tepal and stamen samples are presented in Table S3 
(Supplementary materials) as average (mg/g plant material) and standard deviation values. The tepal 
samples comprised Q.S., K.S. and K.G., in the ranges of 6.20‒10.82, 62.18‒99.48, and 27.38‒45.17 
mg/g, respectively, whereas the amount of these compounds was lower in stamen (1.72‒6.07, 0.89‒
6.62 and 1.72‒7.44 mg/g, respectively). Sample 1 contained K.S. (99.48 mg/g) as the major constituent 
of tepal. Moreover, the tepal sample 23 possessed the highest amount of Q.S. (10.82 mg/g), while the 
tepal sample 5 contained the lowest amounts of Q.S. and K.S. with 6.21 and 62.19 mg/g, respectively. 
In tepal samples the K.G. content ranged between 27.74 to 45.18 mg/g in samples 40 and 1, 
respectively. In general, the stamen samples contained less flavonoids than tepals. The highest 
amount of Q.S. in stamens was observed in sample 29 with 6.08 mg/g, whilst sample 3 contained the 
lowest concentration (1.63 mg/g). The quantity of K.S. ranged from 6.62 to 0.93 mg/g in stamen 
samples 40 and 3, respectively. The quantity of the flavonoid K.G. was also variable, the highest and 
lowest amounts determined in sample 31 and 8 with 7.44 and 1.72 mg/g, respectively. 
 Classification of saffron crocus populations 
CA and PCA were applied to characterize and classify saffron crocus samples (tepal and stamen) 
collected from different locations in Iran according to their Q.S., K.S., and K.G. contents. In accordance 
with the CA analysis, the saffron crocus samples harvested from various locations were categorized in 
three major groups showing three distinct chemotypes based on their flavonoid contents. Chemotype 
I was characterized with the highest Q.S. content of in tepal samples, including the populations 2, 3, 
6-12, and 39, samples belonging to chemotype II contained high quantity of K.G. in tepal samples 
(populations 4, 5, 13, 14, 16‒18, 22, 24, 26‒30, 32-34, and 37), whereas chemotype III was the richest 
in Q.S., K.S., and K.G. in stamen, and K.S. in tepal (populations 1, 15, 16, 19-21, 23, 25, 31, 35, 36, 38, 
40). The PCA results are given on a dendrogram in Figure 15 and PCA biplot which is reported in Figure 
16. 
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Figure 15. Dendrogram of cluster analysis (based on Euclidean distances) of the saffron crocus 
samples: chemotype I (Q.S. in tepal), chemotype II (K.G. in tepal), chemotype III (Q.S., K.S., and K.G. in 
stamen, and K.S. in tepal). 
 
 
Figure 16. Principal component biplot (PCA) of the saffron crocus samples; L: Location; PQS: quercetin-
3-O-sophoroside in tepal; PKS: kaempferol-3-O-sophoroside in tepal; PKG: kaempferol-3-O-glucoside 
in tepal; SQS: quercetin-3-O-sophoroside in stamen; SKS: kaempferol-3-O-sophoroside in stamen; 
SKG: kaempferol-3-O-glucoside in stamen 
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6. DISCUSSION 
6.1. SMOOTH MUSCLE-RELAXANT ACTIVITY OF CHAMAEMELUM NOBILE  
Our experiments aimed at the analysis of the effect of C. nobile extracts, pure compounds and 
essential oil on smooth muscle cells. Previous studies reported sesquiterpenes, coumarin derivatives 
as characteristic compounds of the flower, flavonoids being the qualitatively most abundant 
compounds [223]. Taking into account the spasmolytic effect of some flavonoids (eg. that of apigenin 
and luteolin on guinea pig ileum [59]), we hypothesized that the assumed spasmolytic effect of the 
plant may be related to its flavonoid contents. 
As a result of our work, we isolated the flavonoids apigenin, luteolin, eupafolin, and hispidulin 
using an activity-guided approach. The EtOH extract of C. nobile possessed both stimulatory and 
relaxant effects on small intestine of guinea-pig and on the urinary bladder, the stimulatory effect 
being transient. Based on experiments with the concurrent use of tetrodotoxin and atropine, it can be 
suggested that the site of action for the relaxant effect on the smooth muscle itself, and it was 
assumed that the excitatory activity was related to capsaicin-sensitive sensory [252]. The relaxant 
effect was confirmed in experiments on human jejunal preparations as well. The transient contraction 
was independent from the flavonoid content of fractions, whereas for relaxant activity there was a 
clear-cut correlation. The EO produced no contraction on the test preparations. A consequent relaxant 
effect was detected with the oil. 
We analysed the chemical composition of the EO as well. Previous articles reported isobutyl 
angelate as the major constituent of C. nobile EO (21.6–38.5%), followed by 2-methylbutyl angelate 
(11.6–20.3%) [48,253–256], and propyl tiglate (10.8–13.1%) [255,256] or isobutyl isobutyrate (3.3%) 
[48] or 2-butenyl angelate (7.9–8.4%) [253] or 2-methyl-2- propenyl angelate (9.1%) [254]. However, 
several commercial samples have similar compositions to the sample analysed by us, with methallyl 
angelate and 3-methyl pentyl angelate as the major components [29]. 
6.2. PHYTOCONSTITUENTS OF MATRICARIA CHAMOMILLA POPULATIONS, AND 
BIOACTIVITIES OF VOLATILE OILS 
The results of the carried-out study confirm the impact of variation of ecological conditions on the 
variability of EO contents, phenolic profile and antiradical activity. 
The abiotic factors (e.g. moisture, topography, temperature, and edaphic factors) affect the 
variation of phytoconstituents and/or biotic factors significantly influenced the chemotype profiles 
and biosynthesis pathways of terpenes [257]. Nevertheless, the role of other ecological effects 
including physiographic factors (e.g. steepness and sunlight on vegetation and direction of slopes), 
edaphic factors (soil attributes), climatic factors (e.g. light, wind, temperature, humidity, and 
atmosphere gases), and biotic factors (e.g. the existence of parasites, epiphytes, lianas, etc.) can also 
be impressive in variation of chemotypes. 
According to our findings, M. chamomilla samples were rich in oxygenated sesquiterpenes 
(53.31‒74.52%) as the most dominant EO compounds, which corroborates the former reports. In case 
of EO composition, the wild populations were significantly different compared with the cultivated 
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sample (Bodgold). Among the populations, α-bisabolone oxide A was identified as the major EO 
constituent. 
α-Bisabolone oxide A was previously detected from M. chamomilla; for instance, the EO, 
dichloromethane and diethyl ether fractions of EO contained α-bisabolone oxide A with 47.7, 50.5 and 
57.7%, respectively [63]; whereas high bisabolone oxide A content (13.9%) was characterized in the 
EO of an Estonian M. chamomilla sample [79]. Also in M. chamomilla samples harvested from Italy 
(9.2‒11.2%) [258], Iran (53.45%) [259], India (20.4 and 8.9%) [260] and Turkey (47.7%) [62] this 
compound was detected as the main EO constituent. In a study the daily fluctuation of α-bisabolol 
oxide A content in M. chamomilla EOs was determined and the highest content was measured 
between 16:00‒18:00 (55.41%) [261].  
The sample “Sarableh” collected from the highest altitude with lowest minimum and 
maximum annual temperatures was identified as a new chemotype with the highest content of the 
isomers of γ-bisabolene (82.84%), whilst these sesquiterpenes were not detected in other plant 
populations. This plant sample also exerted the most potent antiradical capacity compared with those 
populations. 
γ-Bisabolene was previously identified as the major characteristic EO constituent of several 
plant species [262–264]. In Iranian populations, the main EO constituents of M. chamomilla were 
formerly identified as α-bisabolol oxide A (17.14%) [265], α-bisabolol (7.27%) [266], (Z,Z)-farnesol 
(39.70‒66.00%), and (E)-β-farnesene (24.19%) [267]. EOs containing significant quantities of γ-
bisabolene exhibited anti-inflammatory properties and anti-proliferative activities on human prostate 
cancer, breast, lung carcinoma, glioblastoma carcinoma, human oral squamous cell lines and colon 
adenocarcinoma [268–271]. 
In a former study, apigenin, luteolin, and their derivatives, along with cynaroside, and 
chlorogenic acid were identified as the significant phytoconstituents of M. chamomilla extract [272]. 
Our results showed the plant samples were much richer in luteolin than in apigenin. Interestingly, in 
populations “MS” and “Mo” no luteolin and apigenin was detected. Due to the low concentration of 
apigenin and luteolin in “Sarableh”, the high free radical scavenging capacity of this sample is 
obviously correlated to other polyphenolics. 
6.3. ISOLATION OF SECONDARY METABOLITES FROM DUROSIA ANETHIFOLIA 
AND ANTIPROLIFERATIVE POTENTIAL OF ISOLATED FUROCOUMARINS 
Chromatographic separation of D. anethifolia extract led to the isolation of 13 compounds, including 
9 furocoumarins. Compounds 6, 7, 9, 12, 14‒17 were identified for the first time from Ducrosia genus. 
In literature, the furocoumarin derivatives including psoralen, xanthotoxin, bergapten, 
imperatorin, iso-oxypeucedanin, pabulenol, pangelin, heraclenin, heraclenol, oxypeucedanin 
methanolate, oxypeucedanin hydrate have been isolated as major components of the D. anethifolia 
[14,106,107]. Furocoumarins iso-psoralen and psoralen have been also isolated from D. ismaelis [109]. 
The analysed furocoumarins exerted antiproliferative activities on sensitive and resistant 
mouse T-lymphoma cells with no selectivity towards the resistant cell line. This is the first 
comprehensive study on this plant and its furocoumarins on these cells. Among the isolated 
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furocoumarins, oxypeucedanin (7) possessed the most significant activity on both tested cell lines 
(PAR and MDR). Insignificant toxicity on normal fibroblast cells and sensitive parental mouse 
lymphoma cells was measured in case of the most effective furocoumarins oxypeucedanin (7) and 
heraclenin (10), also they showed less toxicity on multidrug resistant lymphoma cells. From the 
studied compounds, only oxypeucedanin (7) demonstrated moderate multidrug resistance reversing 
activity. Oxypeucedanin (7) and heraclenin (10) also showed slight synergistic effect with doxorubicin 
in the checkerboard assay. These compounds can improve the cytotoxic effect of the standard 
chemotherapeutic drug doxorubicin. 
In the literature, several papers report the antiproliferative, and cytotoxicity potencies of 
furocoumarins. For instance, imperatorin isolated from Angelica dahurica exhibited antiproliferative 
effect on human hepatoma HepG2 cells [273]; besides, induction of apoptosis in Jurkat leukemia cells 
was observed in this compound and in heraclenin. In Jurkat cells treated with heraclenin and 
imperatorin for 72 h, most of the DNA fragmentation occurred at the G2/M and G1/S phases of the 
cell cycle, respectively [274]. Xanthotoxin showed an inhibition against the growth of neuroblastoma 
(IC50 = 56.3 µM) and metastatic colon cancer cells (IC50 = 88.5 µM) by triggering both extrinsic and 
intrinsic apoptotic pathways, independently of photoactivation [275]. Moreover, in a dose-dependent 
manner, imperatorin, isoimperatorin, oxypeucedanin, cnidicin, byakangelicol, and oxypeucedanin 
hydrate exhibited a significant inhibition on cell proliferation, particularly oxypeucedanin against HCT-
15 (colon cancer) cells with ED50 = 3.4 ± 0.3 μg/mL [276]. 
Furocoumarins affect MDR, beside direct antiproliferative and cytotoxic activities. Among 
twenty selected furocoumarin derivatives, phellopterin (IC50 = 8.0 ± 4.0 µM) and isopimpinellin (IC50 = 
26.0 ± 5.7 µM) demonstrated the highest activity against CEM/C1 and HL-60/MX2 (MDR) cell lines, 
respectively [277]. A novel furocoumarin feroniellin A reverted MDR in A549RT-eto lung cancer cells 
[278]. Also, furocoumarins xanthotoxin (IC50 = 1.10 ± 0.91 nM) and bergapten (IC50 = 40.29 ± 0.30 nM) 
indicated remarkable anticancer activity against MCF7MX, and EPG85.257RDB, respectively [279].  
The results of the comprehensive analysis of furocoumarins on tumor cells reassure previous 
findings and highlight the need of further investigations of these compounds with the perspective of 
potential use against cancer cells, possibly as additional treatment. 
6.4. ISOLATION OF MAJOR CONSTITUENTS FROM EREMURUS PERSICUS 
The phytochemical composition of Eremurus species have been rarely investigated. In general, 
isoorientin and methylnaphthalene derivatives have been identified as the predominant 
phytoconstituents of the plants in this genus [141–144]. In our study, by extracting of CHCl3 and EtOAc 
soluble fractions, six pure compounds including corchoionoside A (18), a rare dihydro-coumarin 4-
amino-4-carboxychroman-2-one (19), C-glycosyl flavone isoorientin (20), a very scarce anthraquinone 
ziganein 5-methyl ether (21), auraptene (22), and imperatorin (23) were isolated from E. persicus. 
All the isolated compounds are new in E. persicus. Although isoorientin (20) was isolated from 
leaves of E. spectabilis [144], the other identified constituents are reported for the first time in 
Eremurus genus. 4-Amino-4-carboxychroman-2-one (19) was isolated only in two studies from 
Centipeda minima and Prunus domestica L. [245,246]. Ziganein 5-methyl ether (21) was isolated for 
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the first time from Aloe hijazensis as a new natural product and here we isolated for the second time 
in the nature [248]. 
Isoorientin (20), a C-glycosyl flavone was identified as the major compound of the plant 
species with significant amount, thus they can be considered as a rich source of this compound. Many 
reports have been reported the pharmacological activities of it; for instance, antinociceptive, anti-
inflammatory [280], antiproliferative [281,282], and gastroprotective effects [158]. Therefore, E. 
persicus is a promising raw material to supply this valuable flavonoid for application in the related 
phytopharmaceutical industries. 
6.5. HPLC-DAD ANALYSIS OF THE MAIN COMPOUNDS OF SAFFRON CROCUS BY-
PRODUCTS 
In stamen and tepal samples, three flavonol glycosides, namely Q.S., K.S., and K.G. were detected as 
major components. For comparison, we analyzed a stigma sample as well. From this sample 
picrocrocin, crocin, and crocetin were identified, which is in line with previous data. There is only one 
report on the presence of crocin in saffron crocus tepal, however, very low amount (0.6%) was 
reported in hydrolysed extracts compared to kaempferol (12.6%) [164]. A comparative study of the 
stamen and stigma revealed that crocin, picrocrocin, and safranal are not present in stamen, whilst 
they are major components of stigma sample [178].  
Our results showed tepal and stamen samples contained Q.S., K.S. and K.G. In general, the 
stamen samples contained less flavonoids than tepals. The content of Q.S., K.S. and K.G. and stamen 
samples were in the ranges of 6.20‒10.82, 62.19‒99.48, and 27.38‒45.17 mg/g in tepal, and 1.72‒
6.07, 0.89‒6.62 and 1.72‒7.44 mg/g for stamens, respectively. K.S., was quantified as the major 
constituent of tepal, while sample 1 (99.48 mg/g) was the richest sample. Also, the tepal sample 23 
contained the highest amount of Q.S. (10.82 mg/g), while the tepal sample 5 contained the lowest 
amounts of Q.S. and K.S. with 6.21 and 62.19 mg/g, respectively. The content of K.G. in tepal samples 
(27.74 to 45.18 mg/g) was significantly different in samples 40 and 1, respectively. 
Our results confirmed some previous findings. K.S., K.G., and Q.S. were characterized as major 
or characteristic flavonoid components of flowers, sepals or tepals by some authors 
[20,22,24,25,163,165,166,178,179]. Nevertheless, from two different regions of Italy, flavonol 
derivatives (6‒10 mg/g) were characterized as the major compounds of stamen and sepal samples. 
K.S. was the major compound (6.41‒8.30 mg/g of fresh sepals and 1.70‒0.37 mg/g of fresh stamen) 
[179]. 
The analysis of a large sample set presented here might be a starting point for the 
determination of quality specifications for these so far not utilized, but industrially perspective plant 
parts of saffron crocus. 
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7. SUMMARY 
The work presented here was aimed at investigating the secondary metabolites of Iranian and 
European medicinal plants. As a part of the research, we verified the folk medicinal use of 
Chamaemelum nobile for its spasmolytic effect in gastrointestinal disorders. For this purpose, the 
smooth muscle-relaxant effect of various extracts, essential oil, and isolated flavonoids (luteolin, 
apigenin, hispidulin, and eupafolin) in vitro was analyzed. Our results suggest that C. nobile extract has 
a direct smooth muscle-relaxant effect related to its flavonoid content. The essential oil also has a 
remarkable smooth muscle relaxant effect in this setting. Our study is the first report on the activity 
of this plant on smooth muscles that may reassure the rationale of the traditional use of this plant in 
spasmodic gastrointestinal disorders. 
The impact of growth environmental factors on chemodiversity and antiradical potential of 
twelve Iranian populations of Matricaria chamomilla was furtherly investigated. Among seventeen 
identified volatile components, representing more than 90% of the total oil, α-bisabolone oxide A 
(45.64‒65.41%) was the major constituent, except the sample “Sarableh”, a new chemotype, where 
(E)- and (Z)-γ-bisabolene (42.76 and 40.08%, respectively) were the predominant components. 
Oxygenated sesquiterpenes (53.31‒74.52%) were the most abundant compounds in the samples 
excluding “Sarableh”. “Sarableh” also possessed the most potent antioxidant capacity. In addition, 
populations “Lali” and “Bagh Malek” contained the highest amounts of apigenin and luteolin with 1.19 
± 0.01 mg/g and 2.20 ± 0.0 mg/g of plant material, respectively. Our findings depict a correlation 
between phytochemical profiles and antiradical potential of M. chamomilla and geographical factors. 
From the Iranian species Ducrosia anethifolia, nine linear furocoumarin derivatives, namely 
imperatorin (5), oxypeucedanin (7), heraclenol (8), (+)-oxypeucedanin hydrate (aviprin) (9), heraclenin 
(10), pabulenol (11), oxypeucedanin methanolate (13), isogospherol (14), (–)-oxypeucedanin hydrate 
(prangol) (16); along with vanillic aldehyde (6), 3-hydroxy-α-ionone (12), harmine (15), and 2-C-
methyl-erythrytol (17) were identified. Compounds 7, 9, 12, 14‒17 were reported for the first time 
from the Ducrosia genus. Furthermore, we measured in vitro antiproliferative and cytotoxic activities 
of the furocoumarins on multidrug resistant and sensitive L51787Y mouse T-lymphoma cell lines. A 
checkerboard microplate method was applied to study the interactions of furocoumarins and 
doxorubicin. Oxypeucedanin (7) demonstrated a promising potency and may be considered for further 
anticancer effects investigations. 
A rare Iranian plant species, Eremurus persicus was also subjected to phytochemical analysis. 
Six pure compounds, including corchoionoside A (18), 4-amino-4-carboxychroman-2-one (19), 
isoorientin (20), ziganein 5-methyl ether (21), auraptene (22), and imperatorin (23) were isolated. 
Except isoorientin (20), which is considered as the predominant secondary metabolite of the Eremurus 
genus and previously isolated from E. spectabilis [144], all the other compounds were isolated and 
characterized for the first time in this genus. Among the identified phytochemicals, 4-amino-4-
carboxychroman-2-one (19) has been previously isolated in only two species, including Centipeda 
minima and Prunus domestica L. [245,246]. An anthraquinone derivative ziganein 5-methyl ether (21) 
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was isolated for the first time from Aloe hijazensis as a new natural product and here we isolated for 
the second time in the nature [248]. 
The stigma of Crocus sativus (known as saffron) has been used in Iranian traditional folk 
medicine as antidepressant and anxiolytic agent, along with its application in the cuisine as spice. 
Several studies (preclinical and clinical) reported the antidepressant effect of saffron, however, 
recently these bioactivities have been reported for other parts of the flower as well. We collected 40 
different tepal and stamen samples growing from Iran and quantitatively and qualitatively analysed 
their main components of flower parts (kaempferol-3-O-sophoroside, keampferol-3-O-glucoside, 
quercetin-3-O-sphoroside, picrocrocin, crocin, crocetin, and safranal) by HPLC-DAD using a validated 
method. Tepal and stamen samples contained three flavonol glycosides. Kaempferol-3-O-sophoroside 
(62.19‒99.48 mg/g) and kaempferol-3-O-glucoside (1.72‒7.44 mg/g) were identified as the most 
dominant phytochemicals in tepal and stamen samples, respectively. Crocin, crocetin, picrocrocin, and 
safranal were not detected in any of the analysed samples (except stigma). Our results point out that 
C. sativus by-products, particularly tepals might be considered as rich sources of flavonol glycosides. 
The data presented here can be useful in setting quality standards for plant parts of C. sativus that 
might be used for medicinal purposes in the future.  
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9. SUPPLEMENTARY MATERIALS 
 
Table S1. Geographic locations and climatic conditions of the studied Matricaria chamomilla populations from Iran 
 
Population Name Voucher’s 
Code 
Abbreviated 
Name 
Altitude 
(m) 
Latitude Longitude 
MAP 
(mm/year) 
MAT 
(°C) 
MMaxAT 
(°C) 
MminAT 
(°C) 
Bodold (Ahvaz) KHAU_236 B 16 31°18’ N 48°39’ E 9820 22.62 35.77 9.47 
Izeh KHAU_237 I 428 31°57’ N 48°49’ E 472.80 18.35 31.28 5.42 
Bagh Malek KHAU_238 BM 907 31°19’ N 50°05’ E 285.90 20.28 32.17 8.4 
Lali KHAU_239 L 373 32°20’ N 49°05’ E 280.60 21.26 33.57 8.95 
Masjed Soleyman KHAU_240 MS 250 32°02’ N 49°11’ E 241.30 22.67 34.27 11.07 
Mollasani KHAU_241 Mo 51 31°39’ N 48°57’ E 100.80 22.26 36.35 8.17 
Gotvand KHAU_242 G 70 32°14’ N 48°48’ E 159.70 21.08 34.96 7.21 
Saleh Shahr KHAU_243 SS 65 32°04’ N 48°40’ E 164.30 20.69 34.07 7.32 
Murmuri KHAU_244 Mu 530 32°46’ N 47°37’ E 213.90 23.35 35.17 11.53 
Abdanan KHAU_245 A 740 32°55’ N 47°31’ E 363.60 19.62 30.44 8.8 
Darreh Shahr KHAU_246 DS 629 33°05’ N 47°28’ E 463.00 17.85 30.9 4.8 
Sarableh KHAU_247 S 1037 33°47’ N 46°35’ E 345.80 15.01 27.31 2.71 
 
MAP: mean annual precipitation; MAT: mean annual temperature; MmaxAT: mean maximum annual temperature; MminAT: 
mean minimum annual temperature 
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Table S2. Geographical, coordinate, and locations of the harvested saffron plant samples 
 
Code location Altitude 
(m) 
Latitude Longitude 
1T, 1S Dehouye, Meshkan, Neyriz, Fars 1567 29° 15’ N 53° 56’ E 
2T, 2S Dehouye, Meshkan, Neyriz, Fars 1567 29° 15’ N 53° 56’ E 
3T, 3S Dehouye, Meshkan, Neyriz, Fars 1567 29° 15’ N 53° 56’ E 
4T, 4S Dehouye, Meshkan, Neyriz, Fars 1567 29° 15’ N 53° 56’ E 
5T, 5S Dehouye, Meshkan, Neyriz, Fars 1567 29° 15’ N 53° 56’ E 
6T, 6S Meshkan, Neyriz, Fars 2167 29° 28’ N 54° 20’ E 
7T, 7S Meshkan, Neyriz, Fars 2167 29° 28’ N 54° 20’ E 
8T, 8S Meshkan, Neyriz, Fars 2167 29° 28’ N 54° 20’ E 
9T, 9S Meshkan, Neyriz, Fars 2167 29° 28’ N 54° 20’ E 
10T, 10S Meshkan, Neyriz, Fars 2167 29° 28’ N 54° 20’ E 
11T, 11S Meshkan, Neyriz, Fars 2167 29° 28’ N 54° 20’ E 
12T, 12S Meshkan, Neyriz, Fars 2167 29° 28’ N 54° 20’ E 
13T, 13S Meshkan, Neyriz, Fars 2167 29° 28’ N 54° 20’ E 
14T, 14S Meshkan, Neyriz, Fars 2167 29° 28’ N 54° 20’ E 
15T, 15S Meshkan, Neyriz, Fars 2167 29° 28’ N 54° 20’ E 
16T, 16S Dehchah, Neyriz, Fars 2188 29° 13’ N 54° 26’ E 
17T, 17S Dehchah, Neyriz, Fars 2188 29° 13’ N 54° 26’ E 
18T, 18S Dehchah, Neyriz, Fars 2188 29° 13’ N 54° 26’ E 
19T, 19S Dehchah, Neyriz, Fars 2188 29° 13’ N 54° 26’ E 
20T, 20S Dehchah, Neyriz, Fars 2188 29° 13’ N 54° 26’ E 
21T, 21S Abadeh Tashk, Neyriz, Fars 1608 29° 48’ N 53° 43’ E 
22T, 22S Abadeh Tashk, Neyriz, Fars 1608 29° 48’ N 53° 43’ E 
23T, 23S Neyriz, Fars 1606 29° 11’ N 54° 19’ E 
24T, 24S MahmoudAbad, Neyriz, Fars 1579 29° 14’ N 54° 17’ E 
25T, 25S MahmoudAbad, Neyriz, Fars 1579 29° 14’ N 54° 17’ E 
26T, 26S MahmoudAbad, Neyriz, Fars 1579 29° 14’ N 54° 17’ E 
27T, 27S Roniz, Estahban, Fars 1593 29° 11’ N 53° 46’ E 
28T, 28S Roniz, Estahban, Fars 1593 29° 11’ N 53° 46’ E 
29T, 29S HasanAbad, Neyriz, Fars 1579 29° 44’ N 53° 54’ E 
30T, 30S Estahban, Fars 1797 29° 7’ N 54° 2’ E 
31T, 31S Estahban, Fars 1797 29° 7’ N 54° 2’ E 
32T, 32S Estahban, Fars 1797 29° 7’ N 54° 2’ E 
33T, 33S Estahban, Fars 1797 29° 7’ N 54° 2’ E 
34T, 34S Estahban, Fars 1797 29° 7’ N 54° 2’ E 
35T, 35S Estahban, Fars 1797 29° 7’ N 54° 2’ E 
36T, 36S Estahban, Fars 1797 29° 7’ N 54° 2’ E 
37T, 37S Ghaen, Khorasan e Jonoubi 1445 33° 43’ N 59° 11’ E 
38T, 38S Torbatejam, Khorasan e Razavi 894 35° 14’ N 60° 37’ E 
39T, 39S Dehdez, Khoozestan 1439 31° 42’ N 50° 17’ E 
40T, 40S Dehdez, Khoozestan 1439 31° 42’ N 50° 17’ E 
MAT: mean annual temperature; MAP: mean annual precipitation; T: tepal; S: stamen 
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Figure S1. 1H-NMR spectrum of luteolin (1) (500 MHz, CD3OD) 
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Figure S2. 1H-NMR spectrum of eupafolin (2) (500 MHz, CD3OD) 
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Figure S3. JMOD spectrum of eupafolin (2) (125 MHz, CD3OD) 
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Figure S4. 1H-NMR spectrum of apigenin (3) (500 MHz, CD3OD) 
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Figure S5. JMOD spectrum of apigenin (3) (125 MHz, CD3OD) 
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Figure S6. 1H-NMR spectrum of hispidulin (4) (500 MHz, CD3OD) 
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Figure S7. 1H-NMR spectra of the compounds isolated from Ducrosia anethifolia 
 
 
Imperatorin (5) 
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Vanillic aldehyde (6) 
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Oxypeucedanin (7) 
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Heraclenol (8) 
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Aviprin (9) 
  
79 
 
 
 
 
Heraclenin (10) 
 
  
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pabulenol (11) 
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3-Hydroxy-α-ionone (12) 
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Oxypeucedanin methanolate (13) 
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Isogospherol (14) 
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Harmine (15) 
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Prangol (16) 
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2-C-methyl-erythrytol (17) 
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Figure S8. Inhibition of the ABCB1 transporter on multidrug resistant (MDR) L51787Y mouse T-lymphoma cells by flow 
cytometry 
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Figure S9. 1H-NMR spectra of the compounds isolated from Eremurus persicus 
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91 
 
 
4-Amino-4-carboxychroman-2-one (19) 
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Isoorientin (20) 
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Ziganein 5-methyl ether (21) 
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Auraptene (22) 
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Imperatorin (23) 
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Table S3. Levels of marker compounds in Crocus sativus L. samples 
Sample 
Q.S. K.S. K.G. 
T S T S T S 
1 10.24 ± 0.23 4.23 ± 0.14 99.48 ± 0.07 1.82 ± 0.10 45.18 ± 0.24 3.65 ± 0.21 
2 6.29 ± 0.04 3.49 ± 0.14 76.40 ± 1.37 1.47 ± 0.06 37.31 ± 0.77 2.47 ± 0.12 
3 6.23 ± 0.15 1.63 ± 0.18 62.41 ± 1.41 0.93 ± 0.02 33.71 ± 0.98 2.42 ± 0.46 
4 9.19 ± 0.32 5.60 ± 0.20 74.82 ± 3.32 1.53 ± 0.26 36.01 ± 1.60 3.69 ± 0.15 
5 6.21 ± 0.20 4.56 ± 0.20 62.19 ± 2.06 2.21 ± 0.09 35.73 ± 1.23 4.88 ± 0.29 
6 7.92 ± 0.34 2.11 ± 0.12 71.81 ± 3.67 1.03 ± 0.03 39.25 ± 2.27 2.05 ± 0.01 
7 7.61 ± 0.30 1.72 ± 0.02 77.35 ± 3.96 1.03 ± 0.06 37.38 ± 1.73 2.01 ± 0.11 
8 9.43 ± 0.23 1.98 ± 0.06 75.00 ± 0.55 0.90 ± 0.03 37.30 ± 0.46 1.72 ± 0.12 
9 8.68 ± 0.29 1.80 ± 0.06 74.88 ± 2.84 1.20 ± 0.03 34.09 ± 1.09 2.72 ± 0.24 
10 8.26 ± 0.10 1.79 ± 0.04 71.45 ± 1.51 1.03 ± 0.00 32.08 ± 0.07 2.17 ± 0.09 
11 8.51 ± 0.38 2.02 ± 0.08 68.55 ± 1.88 1.20 ± 0.04 32.08 ± 0.82 2.33 ± 0.05 
12 10.26 ± 0.03 2.15 ± 0.10 82.91 ± 2.41 1.07 ± 0.07 38.75 ± 0.44 2.76 ± 0.09 
13 8.24 ± 0.04 4.43 ± 0.15 72.94 ± 2.02 2.49 ± 0.13 32.58 ± 0.61 4.00 ± 0.08 
14 8.37 ± 0.34 5.16 ± 0.06 79.83 ± 0.13 1.78 ± 0.04 35.34 ± 0.56 4.30 ± 0.06 
 15 7.10 ± 0.08 4.65 ± 0.20 77.79 ± 0.33 2.24 ± 0.25 38.77 ± 0.47 3.72 ± 0.22 
16 9.14 ± 0.48 4.45 ± 0.11 86.50 ± 0.85 1.64 ± 0.06 34.83 ± 0.06 3.45 ± 0.09 
17 8.34 ± 0.41 4.77 ± 0.11 72.03 ± 3.65 1.68 ± 0.06 30.28 ± 1.62 4.39 ± 0.23 
18 7.47 ± 0.28 5.95 ± 0.60 72.28 ± 3.47 1.51 ± 0.01 34.49 ± 1.82 3.55 ± 0.10 
19 7.56 ± 0.07 3.54 ± 0.11 83.01 ± 0.74 4.63 ± 0.26 38.17 ± 0.30 5.94 ± 0.01 
20 7.91 ± 0.02 5.32 ± 0.14 86.22 ± 2.77 3.08 ± 0.12 37.44 ± 1.21 5.00 ± 0.14 
21 9.25 ± 0.17 5.08 ± 0.19 85.59 ± 2.04 3.40 ± 0.02 37.59 ± 0.82 4.16 ± 0.14 
22 7.45 ± 0.21 4.10 ± 0.23 79.01 ± 2.93 2.09 ± 0.13 33.23 ± 1.12 4.67 ± 0.22 
23 10.82 ± 0.38 4.53 ± 0.19 98.99 ± 2.85 5.21 ± 0.22 36.44 ± 0.88 7.31 ± 0.05 
24 7.24 ± 0.04 4.82 ± 0.03 67.80 ± 2.72 2.07 ± 0.00 37.28 ± 0.19 5.34 ± 0.53 
25 8.25 ± 0.22 4.55 ± 0.24 79.30 ± 1.54 1.99 ± 0.09 40.96 ± 1.40 3.11 ± 0.09 
26 7.58 ± 0.17 5.52 ± 0.13 71.07 ± 0.07 2.04 ± 0.07 33.31 ± 0.43 5.19 ± 0.10 
27 8.63 ± 0.07 4.43 ± 0.08 75.66 ± 2.47 2.06 ± 0.06 33.22 ± 1.11 5.15 ± 0.24 
28 7.83 ± 0.30 3.95 ± 0.22 76.59 ± 1.52 2.02 ± 0.03 34.77 ± 0.66 4.03 ± 0.17 
29 7.44 ± 0.20 6.08 ± 0.36 75.61 ± 1.07 2.20 ± 0.05 36.73 ± 0.73 5.23 ± 0.41 
30 7.39 ± 0.23 5.28 ± 0.28 80.46 ± 4.01 2.01 ± 0.02 34.76 ± 1.79 5.96 ± 0.43 
31 7.16 ± 0.06 4.29 ± 0.21 87.52 ± 1.50 3.09 ± 0.19 42.51 ± 1.15 7.44 ± 0.31 
32 8.37 ± 0.26 5.14 ± 0.30 74.16 ± 1.03 2.33 ± 0.13 33.61 ± 1.30 4.83 ± 0.01 
33 7.83 ± 0.06 4.43 ± 0.08 75.77 ± 1.56 2.24 ± 0.13 36.99 ± 0.63 4.71 ± 0.15 
34 8.35 ± 0.10 4.49 ± 0.30 74.16 ± 1.12 2.45 ± 0.17 34.69 ± 0.42 4.80 ± 0.25 
35 7.83 ± 0.33 5.74 ± 0.09 75.86 ± 0.83 2.19 ± 0.08 41.03 ± 0.47 5.13 ± 0.05 
36 9.43 ± 0.36 4.77 ± 0.13 88.63 ± 3.41 3.34 ± 0.19 43.68 ± 1.13 5.10 ± 0.11 
37 6.75 ± 0.04 5.40 ± 0.31 76.00 ± 1.31 1.83 ± 0.10 34.32 ± 0.39 5.70 ± 0.05 
38 8.96 ± 0.12 5.13 ± 0.15 81.03 ± 3.35 1.96 ± 0.10 36.87 ± 1.00 6.78 ± 0.04 
39 6.87 ± 0.11 2.87 ± 0.06 74.44 ± 1.20 2.59 ± 0.15 29.04 ± 1.19 4.30 ± 0.22 
40 6.42 ± 0.21 2.86 ± 0.12 73.91 ± 2.85 6.62 ± 2.06 27.74 ± 1.22 5.26 ± 1.03 
The amounts are presented as mg of samples; Q.S.: quercetin-3-O-sophoroside; K.S.: kaempferol-3-O-
sophoroside; K.G.: kaempferol-3-O-glucoside; T: tepal; S: stamen. 
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The dried flowers of Chamaemelum nobile (L.) All. have been used in traditional medicine
for different conditions related to the spasm of the gastrointestinal system. However,
there have been no experimental studies to support the smooth muscle relaxant effect
of this plant. The aim of our research was to assess the effects of the hydroethanolic
extract of Roman chamomile, its fractions, four of its flavonoids (apigenin, luteolin,
hispidulin, and eupafolin), and its essential oil on smooth muscles. The phytochemical
compositions of the extract and its fractions were characterized and quantified by
HPLC-DAD, the essential oil was characterized by GC and GC-MS. Neuronally mediated
and smooth muscle effects were tested in isolated organ bath experiments on guinea
pig, rat, and human smooth muscle preparations. The crude herbal extract induced an
immediate, moderate, and transient contraction of guinea pig ileum via the activation
of cholinergic neurons of the gut wall. Purinoceptor and serotonin receptor antagonists
did not influence this effect. The more sustained relaxant effect of the extract, measured
after pre-contraction of the preparations, was remarkable and was not affected by an
adrenergic beta receptor antagonist. The smooth muscle-relaxant activity was found to
be associated with the flavonoid content of the fractions. The essential oil showed only
the relaxant effect, but no contracting activity. The smooth muscle-relaxant effect was
also detected on rat gastrointestinal tissues, as well as on strip preparations of human
small intestine. These results suggest that Roman chamomile extract has a direct and
prolonged smooth muscle-relaxant effect on guinea pig ileum which is related to its
flavonoid content. In some preparations, a transient stimulation of enteric cholinergic
motoneurons was also detected. The essential oil also had a remarkable smooth muscle
relaxant effect in this setting. Similar relaxant effects were also detected on other visceral
preparations, including human jejunum. This is the first report on the activity of Roman
chamomile on smooth muscles that may reassure the rationale of the traditional use of
this plant in spasmodic gastrointestinal disorders.
Keywords: Roman chamomile, Chamaemelum nobile, Asteraceae, organ bath experiment, gastrointestinal
preparations, spasmolytic effect, contractile action
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INTRODUCTION
Chamaemelum nobile (L.) All. (Asteraceae), widely known
as Roman chamomile, is a perennial herb native to South-
Western Europe, but it is cultivated as a medicinal plant
all over Europe and in Africa as well. Dried flowers of the
cultivated, double-flowered variety of the species are official in
the European Pharmacopoeia (European Pharmacopoeia, 2008).
Incorporating the plant in traditional herbal medicinal products
has been acknowledged by the European Medicines Agency. The
comminuted herbal substance (as tea) and a liquid extract of
the plant (extraction solvent: ethanol 70% v/v) may be used for
the symptomatic treatment of mild, spasmodic gastrointestinal
complaints including bloating and flatulence. The British Herbal
Pharmacopoeia indicates its use as carminative, anti-emetic,
antispasmodic, and sedative (British Herbal Pharmacopoeia,
1971).
Roman chamomile (RC) has been used as a medicinal plant
from the middle ages. The cultivation of the plant started in
England in the 16th century (Hiller and Melzig, 1999). The
double variety of the flower, which now serves as the main
commercial drug, has certainly been known since the 18th
century (Evans, 1989). The plant gained the name “nobile”
(Latin, noble) to illustrate its superior therapeutic efficacy over
Matricaria recutita L. (German chamomile) (Hiller and Melzig,
1999). The plant was first listed in the Pharmacopoeia of
Württemberg (1741) as a carminative, painkiller, diuretic, and
digestive aid (Lukacs, 1990). In the folk medicine of different
regions of Europe, RC has been used for numerous conditions,
including dyspepsia, flatulence, nausea and vomiting, anorexia,
vomiting of pregnancy, dysmenorrhoea, and specifically for
gastrointestinal cramps and flatulent dyspepsia associated with
mental stress (Augustin et al., 1948; Rápóti and Romváry, 1974;
Melegari et al., 1988; Rossi et al., 1988; Bradley, 1992). In
the Mediterranean region, RC tea is consumed to improve
appetite and also after meal to prevent indigestion (Rivera and
Obon, 1995; Menendez-Baceta et al., 2014; Alarcün et al., 2015).
Traditional use of RC is largely related to its supposed smooth
muscle-relaxant activity.
The majority of the secondary metabolites described from the
plant belong to the aliphatic esters (essential oil) (Fauconnier
et al., 1996), sesquiterpene lactones (Bisset, 1994) and flavonoids
(Herisset et al., 1971, 1973; Abou-Zied and Rizk, 1973; Pietta
et al., 1991). The polysaccharide content of the dried flower
is noteworthy, 3.9% (Lukacs, 1990). The supposed smooth
muscle-relaxant activity of the plant might be attributed to its
flavonoid content. Apigenin and luteolin possess remarkable
smooth muscle relaxant effects on guinea pig ileum (Lemmens-
Gruber et al., 2006).
Although several studies on the bioactivities of RC are
available, the majority of these studies were carried out using
the essential oil, which is not used medicinally, or the observed
activities are not related to the traditional use of the plant. Several
studies demonstrate the antimicrobial effects of RC essential oil
against different bacterial and fungal strains (Hänsel et al., 1993;
Piccaglia et al., 1993; Chao et al., 2000; Bail et al., 2009), and
antifungal activity was demonstrated also for the aqueous extracts
of RC (Magro et al., 2006). The anti-inflammatory capacity and
heat shock protein modulating effects of the flavonoids apigenin
and quercetin, as well as the anti-inflammatory activities of
α-bisabolol, guajazulene, and chamazulene have been reported
in preclinical studies (Viola et al., 1995; Baghalian et al., 2008,
2011; Hernández-Ceruelos et al., 2010). The polysaccharides of
RC exerted antiphlogistic effect in vivo (Lukacs, 1990).
Although the use of RC extract for gastrointestinal problems
seems to be related to its presumptive smooth muscle-relaxant
effect, interestingly no in vitro or in vivo studies have been
carried out so far to assess this bioactivity. However, in an
in vitro study an aqueous extract of C. nobile was demonstrated
to induce a vasorelaxant effect through the NO-cGMP pathway or
possibly through a combination of Ca2+ channel inhibition plus
NO-modulating and phosphodiesterase inhibitory mechanisms.
After the oral administration of RC aqueous extract, significant
hypotensive effect was observed in an animal study on
spontaneously hypertensive rats (Zeggwagh et al., 2009), which
may be related to the flavonoid content of the plant (Jouad et al.,
2001). The clinical efficacy of orally applied preparations has not
been studied yet, only the effects of external application (Schrader
et al., 1997) and aromatherapeutic use (Wilkinson et al., 1999)
have been reported.
The aim of the current study was to assess the effects of
a hydroethanolic RC extract, its fractions and essential oil
on gastrointestinal and urogenital smooth muscles, including
preparations of human jejunum, in order to clarify the rationale
for the use of this plant for smooth muscle relaxation.
Experiments were carried out with an extract conforming to the
monograph of the European Medicines Agency (see in section
“Preparation of Herbal Extracts and Isolation of Reference
Standards”), and also with the fractions of this extract and with
the essential oil of the plant.
MATERIALS AND METHODS
Plant Material
Roman chamomile flowers were purchased from Pál Bobvos
(Hungary). The identity of the plant material was confirmed
according to the requirements of the European Pharmacopoeia.
A voucher specimen is stored for verification purposes in the
herbarium of the Department of Pharmacognosy, University
of Szeged. RC essential oil was purchased from Aromax Ltd.
(Hungary).
Chemicals
For the pharmacological experiments the following drugs were
used: atropine sulfate (Sigma), α,β-methylene ATP lithium
salt (Tocris), capsaicin, histamine dihydrochloride, indo-
methacin, isoprenaline hydrochloride, NG-nitro-L-arginine,
papaverine hydrochloride, prostaglandin F2α (Sigma),
methysergide (Sandoz), (±)-propranolol hydrochloride
(Sigma), pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid
tetrasodium salt (PPADS), tetrodotoxin (Tocris), 8-amino
-7-chloro-2,3-dihydro-1,4-benzodioxan-5-carboxylic acid,1′-
butyl-4′-piperidinylmethyl ester (SB204070), N-(1-azabicyclo
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[2.2.2]oct-3-yl)-6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-1,4-
benzoxazine-8-carboxamide hydrochloride (Y25130) (all from
Tocris). For dissolving and diluting of these drugs the following
solvents were used: 96% ethanol for capsaicin, indomethacin,
and prostaglandin F2α, DMSO for SB204070 and isotonic NaCl
solution for the rest of the drugs. Solutions in organic solvents
were administered at a maximum of 1 µl/ml, aqueous solutions
at 1 or 3 µl/ml bathing solution.
Millipore Direct-Q UV3 clarifier (Molsheim, France) was used
to produce purified water for the HPLC measurements. Methanol
and ethanol (LiChrosolv R© HPLC grade) was obtained from
Merck (Darmstadt, Germany). For chromatographic separation,
polyamide (ICN Polyamide for Column Chromatography),
Sephadex LH-20 (25–100 µm, Pharmacia Fine Chemicals), SiO2
(Silica gel 60 G, 15 µm, Merck), and SiO2 plates (20 cm × 20 cm
Silica gel 60 F254, Merck) were used.
Preparation of Herbal Extracts and
Isolation of Reference Standards
For the pharmacological experiments, RC crude extract was
prepared according to the description of the European Medicines
Agency monograph (EMA-HMPC, 2012). Ten grams of plant
material was extracted with 70% EtOH (3× 100 ml) via ultrasonic
bath, evaporated in vacuum and lyophilized (yield, 3.169%). Part
of the RC crude extract was fractionated to gain RC extract
fractions with different compositions for further experiments.
Vacuum liquid chromatography on polyamide with elution by
MeOH-H2O (20:80, 40:60, 60:40, 80:20, 100:0) was used to gain
fractions from the crude extract as follows: F20, F40, F60, F80,
and F100.
From the methanolic extract of 200 g RC flowers, four marker
compounds (used as reference standards in further experiments)
were isolated using medium pressure liquid chromatography
(SiO2 as stationary phase), gel chromatography (Sephadex
LH-20), preparative HPLC (RP), and preparative TLC (SiO2).
The purity and identity of these compounds were analyzed
by NMR. NMR spectra were recorded in MeOD on a Bruker
Avance DRX 500 spectrometer (Bruker, Fallanden, Switzerland)
at 500 MHz (1H) or 125 MHz (13C).
HPLC Experiments
HPLC experiments were carried out on a Shimadzu LC-20AD
Liquid Chromatograph (SPD-M20A diode array detector,
CBM-20A controller, SIL-20ACHT autosampler, DGU-20A5R
degasser unit, CTO-20AC column oven) using a Kinetex 5 µm
C-18 100A (150 mm × 4.6 mm) with a gradient of 0,01%
trifluoroacetic acid in H2O (A) and acetonitrile (B) as follows:
0–5 min 25% B, 14 min 28% B, 15 min 70% B, 16 min
70% B, 16.5 min 25% B, and 20 min 25% B. The flow was
1.2 ml/min, column oven temperature was 55◦C. Detection was
carried out within the range of 190–800 nm. For quantification,
chromatograms were integrated at 344 nm. The reference
standards and the evaporated extracts were dissolved in MeOH,
filtered through a PTFE syringe filter and injected in volumes of
5 or 10 µl. Calibration curves were established for all the four
reference standards.
GC and GC-MS Experiments
The GC analysis was carried out with an HP 5890 Series II gas
chromatograph (FID), using a 30 m × 0.35 mm × 0.25 µm
HP-5 fused silica capillary column. The temperature program
ranged from 60◦C to 210◦C at 3◦C min−1, and from 210◦C to
250◦C (2 min hold) at 5◦C min−1. The detector and injector
temperature was set to 250◦C and the carrier gas was N2,
with split sample introduction. Quantities of the individual
components of the essential oil were expressed as the percent of
the peak area relative to the total peak area from the GC/FID
analysis.
The GC-MS analysis was performed with a Finninan GCQ
ion trap bench-top mass spectrometer. All conditions were
as above except that the carrier gas was He at a linear
velocity of 31.9 cm s−1 and the capillary column was DB-5MS
(30 m × 0.25 mm × 0.25 µm). The positive ion electron
ionization mode was used, with ionization energy of 70 eV, and
the mass range of 40–400 amu.
Identification of the compounds was based on comparisons
with published MS data (Adams, 2007) and with a computer
library search (the database was delivered together with the
instrument) and also by comparing their retention indices
with literature values (Adams, 2007). Retention indices were
calculated against C8–C32 n-alkanes on a CB-5 MS column
(Kovats, 1965). A mixture of aliphatic hydrocarbons was injected
in hexane (Sigma-Aldrich, St. Louis, MO, United States) by using
the same temperature program that was used for analyzing the
essential oil.
Guinea Pig and Rat Preparations
Guinea pigs (short-haired, colored, 350–450 g) or Wistar rats
(220–300 g) of either sex were killed by a blow to the head and
exsanguination. Three centimeter segments of the ileum or distal
colon were placed into the organ bath in a vertical position, under
a constant tension of 7 mN. Longitudinal strip preparations
(approximately 2–3 cm in length) of guinea pig urinary bladder
or rat gastric fundus were fixed under a tension of 5 mN.
This study was carried out in accordance with University
guidelines. The protocol was approved by the Animal Welfare
Committee, University of Pécs (registration number, BA02/2000-
1/2012) with the understanding that isolated organ studies after
stunning the animal cannot be regarded as animal experiments.
Organ Bath Experiments
Smooth muscle preparations were used in a traditional organ
bath arrangement. The preparations were suspended in Krebs–
Henseleit solution of 5 or 7 ml, kept at 37◦C, and aerated with
a mixture of 95% O2 and 5% CO2. The solution contained
119 mM NaCl, 25 mM NaHCO3, 2.5 mM KCl, 1.5 mM
MgSO4, 2.5 mM CaCl2, 1.2 mM KH2PO4, and 11 mM glucose
(pH = 7.4). Movements of the preparations were recorded with
isotonic transducers (Hugo Sachs Elektronik-Harvard Apparatus,
March, Germany) on ink writers or stored online on a personal
computer.
The guinea pig ileum is a preparation of a low spontaneous
tone. In part of the experiments the effects of RC extract,
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its fractions, essential oil, or flavonoids were studied at basal
tone. All experiments commenced with determining the maximal
longitudinal spasm by adding histamine (10 µM) to the organ
bath for 2 min. This response served as reference for determining
the relative amplitude of any contractile effect that the samples to
be tested might have had.
In another set of experiments the possible relaxant effect of the
materials was tested. For this reason, a tonic, approximately half-
maximal contraction of the ileum was provoked by a moderate
concentration of histamine (0.5 µM, added for 15 min). In
preliminary experiments, no pretreatment was used. In the bulk
of the experiments, however, the muscarinic receptor antagonist
atropine, as well as tetrodotoxin, an inhibitor of nerve axonal
conduction (blocker of voltage-sensitive Na+ channels) was
added prior to the histamine administration. This was done to
avoid the interference with a possible contractile effect of the
material to be examined, i.e., to create a methodologically clear
situation.
All experiments commenced after an equilibration period
of 45 min. Relaxant effects were studied on pre-contracted
preparations (see below). Maximal spasm of the tissue was evoked
to serve as a basis for the comparisons to evaluate the responses
obtained by our test materials. The materials examined were
administered in a single concentration (i.e., in a non-cumulative
manner).
Human Jejunal Preparations
Macroscopically intact segments of human jejunum, removed
during the surgical treatment of pancreatic cancer were used.
Strips of either longitudinal or circular orientation were prepared
(the mucosa and submucosa were removed) and fixed as
described above, under a tension of 10 mN. Freeze-dried extracts
of RC, as well as the essential oil of the plant were mixed in and
further diluted with DMSO. The amounts of DMSO administered
to the jejunum preparations are indicated in the Section “Results”.
This study was carried out in accordance with the Declaration
of Helsinki and the guidelines set by the Research Ethics
Committee, Scientific Council of the Ministry of Health,
Hungary. This Committee agreed to the use of discarded
human tissue for the experimental work. The protocol was
approved by the ETT-TUKEB (Scientific Council of the Ministry
of Health, Research Ethical Committee) [No. 17861-0/2010-
1018EKU (749/PI/10)]. All subjects gave written informed
consent in accordance with the Declaration of Helsinki.
Statistical Analysis
Results of the pharmacological experiments are given as
mean ± SEM, with N denoting the number of preparations
used for testing efficacy. At most 2 preparations from the
same animal were used for each type of experiment. Results
are provided in relative values, where 100% contraction means
maximal spasm of the preparations from the basal tone and, in
pre-contracted preparations, 100% relaxation means relaxation
of the preparation to the level before adding the precontracting
agent. The Mann–Whitney U test was used for the comparisons
of two independent groups, more than two independent samples
were compared by the Kruskal–Wallis test, and two dependent
samples were compared by the Wilcoxon test. The statistical
program GraphPad Prism 5 was used throughout. A probability
of P < 0.05 or less indicated statistical significance.
RESULTS
Chemical Characterization of RC
Extracts
In the HPLC retention time range of 4–9 min, four characteristic
peaks were detected in the crude RC extract and its fractions
F40–F100. The corresponding components were isolated from
the plant material and were identified as the flavonoids
apigenin, eupafolin, hispidulin, and luteolin by 1H and 13C
NMR experiments (see Supplementary Figures S1–S6). These
compounds were further used as reference standards to
characterize the RC extracts. The identification of reference
compounds in different extracts was based on matching the
retention times and UV spectra. Retention times of luteolin,
eupafolin, apigenin, and hispidulin were 4.5, 5.0, 7.5, and
8.5 min, respectively (Figure 1). The baseline separation of
these compounds allowed their reliable quantification in different
extracts.
The crude RC extract contained eupafolin as the main
flavonoid, followed by luteolin, hispidulin, and apigenin
(Table 1). The fractionation on polyamide resulted in
subfractions F20–F100 with different compositions, as
demonstrated by the differences in their flavonoid content.
In F20, the quantities of flavonoids were below the level of
quantification. The flavonoid content of the fractions increased
with increasing MeOH content of the eluting solvent. The
highest flavonoid levels were measured in F80, except for luteolin
and apigenin, which were mainly concentrated in F100.
Chemical Characterization of RC
Essential Oil
Based on their retention times and mass spectrometric data,
methallyl angelate, 3-methyl pentyl angelate, and 3-methylamyl
isobutyrate were identified as the major constituents of RC
essential oil (19.0, 18.2, and 10.4%, respectively) (Table 2).
The identified components comprised 97% of the essential
oil. Previous articles reported isobutyl angelate as the major
constituent of RC essential oil (21.6–38.5%), followed by
2-methylbutyl angelate (11.6–20.3%) (Antonelli and Fabbri, 1998;
Farkas et al., 2003; Omidbaigi et al., 2003, 2004; Bail et al., 2009),
and propyl tiglate (10.8–13.1%) (Omidbaigi et al., 2003, 2004)
or isobutyl isobutyrate (3.3%) (Bail et al., 2009) or 2-butenyl
angelate (7.9–8.4%) (Antonelli and Fabbri, 1998) or 2-methyl-2-
propenyl angelate (9.1%) (Farkas et al., 2003). However, several
commercial samples have similar compositions to the sample
analyzed by us, with methallyl angelate and 3-methyl pentyl
angelate as the major components.
Effects on Guinea Pig Ileum
The crude RC extract induced a transient longitudinal
contraction on guinea pig ileum preparations (Figure 2).
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FIGURE 1 | HPLC chromatogram of the crude RC extract with the peaks of luteolin (1), eupafolin (2), apigenin (3), and hispidulin (4) (344 nm).
TABLE 1 | Flavonoid content of RC crude extract and its fractions as determined by HPLC.
Sample Luteolin (mg/g extract) Eupafolin (mg/g extract) Apigenin (mg/g extract) Hispidulin (mg/g extract)
Crude extract 4.617 ± 0.616 18.756 ± 2.121 0.298 ± 0.027 1.584 ± 0.181
F20 Not detected Not detected Not detected Not detected
F40 0.578 ± 0.001 1.800 ± 0.001 0.179 ± 0.001 0.231 ±< 0.001
F60 1.904 ± 0.001 62.591 ± 0.025 0.151 ±< 0.001 5.951 ± 0.004
F80 22.605 ± 0.001 223.488 ± 0.036 0.859 ±< 0.001 17.060 ± 0.006
F100 55.305 ± 0.002 150.206 ± 0.005 2.055 ±< 0.001 4.983 ±< 0.001
The amplitudes of the contractions were related to the maximal
longitudinal spasm evoked with 10 µM of histamine at the
beginning of the experiments. The threshold concentration
for this effect was equal to or below 20 µg/ml of the extract
(which was the lowest concentration tested) and reached a
plateau with 60 and 200 µg/ml. Quantitative results were as
follows (expressed as % of the maximal spasm): 18.8 ± 3.1%
at 20 µg/ml (N = 6), 40.1 ± 3.3% at 60 µg/ml (N = 11), and
36.3 ± 4.9% at 200 µg/ml (N = 7). A second administration
of the same concentration after a 40-min washout period
usually had a qualitatively similar effect. Yet, because of
variable reproducibility, we examined the effects on separate
preparations with only one administration of the extract.
The solvent of the extract (DMSO; 0.3 or 1 µl/ml) caused no
or minimal contraction (on average, 0 and 2%, respectively;
N = 12).
The 60 µg/ml concentration of the extract was used for
pharmacological analysis. Both atropine (0.5 µM), an antagonist
of acetylcholine at the muscarinic receptors and tetrodotoxin
(0.5 µM), an inhibitor of voltage-sensitive Na+ channels (hence,
of neuronal axonal conduction) inhibited the contractile effect
of RC crude extract. In contrast, the purinoceptor antagonist
PPADS (50 µM) or a combination of serotonin (5-HT) receptor
antagonists methysergide (0.3 µM), SB204070 (1 µM) and
Y25130 (1 µM) failed to influence the contractile effect of
the extract (Table 3). This combination of 5-HT antagonists is
suitable for blocking the contractile effect of 5-HT (Sandor et al.,
2016).
The functional blockade of capsaicin-sensitive neurons did
not inhibit the contractile effect of the RC extract (Barthó et al.,
2004) as compared to time-matched, solvent-treated controls
(Table 3). The cyclooxygenase inhibitor indomethacin (3 µM)
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TABLE 2 | Chemical composition of RC essential oil.
Compoundsa RIb % in samples
Methyl tiglate 867 tr
n-Hexanol 875 1.1
2-Methylbutyl acetate 897 0.4
Isobutyl isobutyrate 925 0.8
Acetonyl acetone 932 0.7
α-Pinene 935 2.4
Camphene + allyl methacrylate 958 0.6
Thuja-2,4(10)-diene 960 1.1
Isoamyl propionate 966 tr
β-Pinene 969 0.3
Myrcene 973 0.6
Propyl angelate 993 1.1
Isobutyl 2-methylbutyrate 998 tr
Isoamyl isobutyrate 1,004 1.5
2-Methylbutyl isobutyrate 1,006 2.7
1,8-Cineol 1,035 tr
Isoamyl methacrylate 1,037 1.1
Isobutyl angelate 1,058 4.9
Methallyl angelate 1,068 19.0
2-Butenyl angelate 1,119 tr
3-Methylamyl isobutyrate 1,122 10.4
3-Methylamyl methacrylate 1,150 6.6
trans-Pinocarveol + isoamyl angelate 1,153 8.6
2-Methylbutyl angelate 1,168 8.3
Pinocarvone 1,177 3.9
Prenyl angelate 1,213 1.5
Myrtenal 1,217 1.2
3-Methyl pentyl angelate 1,264 18.2
Identified components 97.0
aCompounds listed in sequence of elution from a DB-5 MS column. bRetention
indices calculated against C8 to C32 n-alkanes on a DB-5MS column. tr, in traces.
moderately but significantly inhibited the contraction in response
to the RC extract.
Fractions of the RC extract were also tested for contracting
activity. Fraction F20 induced a moderate contraction
(approximately 20% of the maximum) (Table 4). Similar
results were obtained with F40, F60, F80, and F100, although the
extent of contraction tended to decline with F60, F80, and F100.
Our experiments revealed the smooth muscle relaxing activity
of RC extract, fractions and essential oil in this experimental
setting. On histamine-precontracted preparations (treated with
0.5 µM histamine for 15 min, in the presence of atropine
and tetrodotoxin, both 0.5 µM), concentration-dependent
relaxation was observed in response to treatment with RC crude
extract (60–200 µg/ml) (Figure 3 and Table 5). The highest
concentration tested induced full relaxation. The relaxation
detected with the 20µg/ml test sample did not exceed the changes
evoked by the solvent itself (1 µl/ml DMSO; see below). In several
cases the relaxation was preceded by a little contraction. The
relaxation induced by the 60 µg/ml extract was not significantly
altered by the adrenergic β-receptor antagonist propranolol
(1 µM; 51.3 ± 7.8% relaxation, N = 6) or by the NO synthase
inhibitor NG-nitro-L-arginine (100 µM; 47.4 ± 7.4% relaxation,
FIGURE 2 | Contractile effect of RC extract (60 µg/ml, added at the square
symbol) on the guinea pig ileum. Calibrations, vertical: 50% of the maximal
longitudinal spasm evoked by histamine (10 µM), horizontal: 1 min.
TABLE 3 | Effects of drugs on the contractile response to RC crude extract
(60 µg/ml) on guinea pig small intestine (mean ± SEM).
Pretreatment Contraction (% of maximal spasm) N
No pretreatment (control) 40.1 ± 3.3 11
Tetrodotoxin (0.5 µM) 15.0 ± 1.8∗ 6
Atropine (0.5 µM) 8.2 ± 2.0∗ 6
PPADS (50 µM) 49.7 ± 2.7 9
5-HT receptor antagonists# 52.1 ± 3.0 11
Solvent for capsaicin 51.1 ± 5.2 7
Capsaicin& 46.9 ± 6.0 9
Solvent for indomethacin 46.4 ± 4.0 6
Indomethacin (3 µM) 31.2 ± 5.6∗ 10
Values significantly different from the respective control group are indicated by
asterisks (∗). #methysergide (0.3 µM), SB204070 (1 µM) and Y25130 (1 µM).
&10 µM of capsaicin for 10 min, followed by a 60-min washout period.
N = 10) (both compared with the group indicated in Table 5).
The solvent DMSO (0.3 or 1 µl/ml) had a slight relaxant effect in
this experimental arrangement (histamine-precontracted ileum
pretreated with atropine and tetrodotoxin); it amounted to
3.0 ± 1.6% at 0.3 µl/ml and 7.9 ± 1.4% at 1 µl/ml; N = 11 and
17, respectively.
On histamine-precontracted, atropine- and tetrodotoxin-
treated ileum, different fractions of RC extract showed
distinct relaxant effects (Table 6). F20 and F40 (60 or
200 µg/ml) practically produced no relaxation (N = 5 for
both concentrations). This observation refers to the potential
role of flavonoids in the relaxant effect, and experiments with
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FIGURE 3 | Long-lasting relaxant effect of RC extract (60 µg/ml, added at the
square symbol) on the pre-contracted guinea pig ileum, in the presence of
tetrodotoxin and atropine (0.5 µM each). Calibrations, vertical: 100%
relaxation from the pre-contracted baseline, horizontal: 1 min.
TABLE 4 | Contractile effects of RC extract fractions on guinea pig ileum
(longitudinally oriented preparations, mean ± SEM).
Bath concentration Contraction (% of the maximal spasm) N
F20
2 µg/ml 5.2 ± 2.4% 5
20 µg/ml 18.2 ± 6.1% 5
60 µg/ml 18.5 ± 4.4% 6
200 µg/ml 22.2 ± 3.1%∗ 5
F40
2 µg/ml 2.5 ± 1.2% 5
20 µg/ml 18.2 ± 5.9% 5
60 µg/ml 15.5 ± 3.3% 5
200 µg/ml 22.8 ± 8.4%∗ 5
F60
2 µg/ml 8.4 ± 1.3% 6
20 µg/ml 21.8 ± 6.4%∗ 5
60 µg/ml 20.9 ± 8.2%∗ 5
200 µg/ml 4.0 ± 2.7% 6
F80
2 µg/ml 0.4 ± 0.4% 5
20 µg/ml 13.0 ± 3.2% 5
60 µg/ml 12.0 ± 4.0% 5
200 µg/ml 2.5 ± 1.5% 5
F100
20 µg/ml 12.4 ± 2.1% 6
60 µg/ml 26.4 ± 5.8%∗ 5
200 µg/ml 15.1 ± 2.7% 6
Asterisks denote values significantly different from a pooled group of solvent effects
(Kruskal–Wallis test for several unrelated samples).
four flavonoids isolated from the plant material reassured
this hypothesis. All the flavonoids exerted a dual effect on the
guinea pig ileum, i.e., a short-lived contraction at basal tone
and a long-lasting relaxation on the histamine-pre-contracted,
atropine- and tetrodotoxin-pretreated preparations (Table 7). At
TABLE 5 | Relaxing effect of RC crude extract and essential oil on the
pre-contracted ileum.
Bath concentration of
RC crude extract
Relaxation (% of the maximum) N
20 µg/ml 18 ± 5.2% 6
60 µg/ml 76.2 ± 8.5%∗ 9
200 µg/ml 100%∗ 5
Bath concentration of
RC essential oil
Relaxation % N
0.1 µg/ml 12.8 ± 3.5% 6
1 µg/ml 30.8 ± 5.9%∗ 9
10 µg/ml 69.7 ± 5.6%∗ 6
Atropine and tetrodotoxin (0.5 µM each) were present in the medium in order to
inhibit the contractile effect of the RC extract. Tonic submaximal contraction was
evoked with histamine (0.5 µM for 15 min). Values are given in %, where 100%
means full relaxation reaching the pre-histamine values (mean ± SEM). Asterisks
denote values significantly different from a pooled group of solvent effects (0.3 or
1 µl/ml of DMSO, see text) (Kruskal–Wallis test for several unrelated samples).
TABLE 6 | Relaxant effects of RC extract fractions on pre-contracted guinea pig
ileum (mean ± SEM).
Bath concentration Relaxation % N
F60
20 µg/ml 18.7 ± 5.7% 5
60 µg/ml 96.0 ± 3.0%∗ 6
200 µg/ml 93.5 ± 4.9%∗ 6
F80
20 µg/ml 47.2 ± 7.7% 5
60 µg/ml 93.0 ± 5.9%∗ 6
200 µg/ml 100%∗ 4
F100
6 µg/ml 12.5% 4
20 µg/ml 61 ± 13.7% 5
60 µg/ml 69.4 ± 7.5%∗ 6
200 µg/ml 100%∗ 4
100% relaxation denotes that tone returns to baseline. Asterisks denote values
significantly different from a pooled group of solvent effects (0.3 or 1 µl/ml DMSO)
(Kruskal–Wallis test for several unrelated samples).
a concentration of 1 µM, the flavonoids did not exert contractile
activities, however, at 10 µM, a slight effect (34.6 ± 7.4% for
hispidulin, 32.0 ± 3.1% for luteolin, 27.1 ± 4.2% for eupafolin,
and 20.5 ± 5.1% for apigenin, N = 5 each) was observed. The
relaxant activities at 2 µM ranged between 18.2 ± 5.4% and
24.2 ± 3.7%, whereas at 20 µM between 64.5 ± 4.1% and
81.9± 5.3%.
The essential oil of RC (0.1, 1, 10, or 30 µg/ml) showed no
contractile effect on the ileum (N = 6–8). RC oil (1 or 10 µg/ml)
induced considerable relaxation on histamine-precontracted,
atropine- and tetrodotoxin-pretreated preparations (Table 5).
Similar results were obtained on preparations without atropine
and tetrodotoxin pretreatment (N = 6–8, data not shown).
Papaverine was used as positive control. As with other
experiments for studying relaxation, the drug was administered
to histamine-precontracted, atropine- and tetrodotoxin-treated
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TABLE 7 | Relaxant effects of flavonoids on pre-contracted guinea pig ileum
(mean ± SEM).
Bath concentration Relaxation % N
Hispidulin
2 µM 19.4 ± 3.5% 5
20 µM 64.5 ± 4.1% 6
Luteolin
2 µM 19.6 ± 1.6% 5
20 µM 80.0 ± −4.5% 6
Eupafolin
2 µM 18.2 ± 5.4% 5
20 µM 68.7 ± 6.8% 6
Apigenin
2 µM 24.2 ± 3.7% 5
20 µM 81.9 ± 5.3% 6
100% relaxation denotes that tone returns to baseline. The solvent contained a
maximum of 10% DMSO and had no relaxant effect in the volumes used.
TABLE 8 | Contractile effect of RC extract on guinea pig urinary bladder strip,
without pretreatment and following treatment with capsaicin or its solvent
(mean ± SEM).
Bath concentration of
RC crude extract
Contraction (% of the maximal spasm) N
20 µg/ml No pretreatment 8.0 ± 4.2% 7
200 µg/ml No pretreatment 20.0 ± 5.1% 7
200 µg/ml Ethanol
pretreatment#
21.6 ± 4.9% 8
200 µg/ml Capsaicin
(10 µM) pretreatment&
9.1 ± 1.3%∗ 8
#Solvent and time control for capsaicin. &Capsaicin was added and incubated for
10 min. This was followed by a 90-min washout period. ∗Significantly different from
the ethanol control.
ileum preparations, in a non-cumulative manner. The relaxant
responses obtained were as follows, 0.3 µM: 19.7± 4.7% (N = 6);
1 µM: 29.1 ± 3.5% (N = 6); 3 µM: 30.1 ± 4.8% (N = 7); 10 µM:
92.9 ± 4.2% (N = 6), where, as also elsewhere in this paper,
relaxation to the pre-histamine baseline was taken as 100%.
Effects on Guinea Pig Urinary Bladder
The effects of the RC extract and the essential oil were tested on
guinea pig urinary bladder strips as well. RC crude extract evoked
concentration-dependent contraction at 20 and 200 µg/ml
(Table 8 and Figure 4 for 200 µg/ml). The solvent of the extract
had no contractile effect on the bladder (N = 4). The effect of
the 200 µg/ml extract was diminished (approximately halved) by
in vitro capsaicin pretreatment (Table 8). Contractile responses
were compared to the maximal spasm evoked by 100 mM of KCl
at the end of the experiment.
To study the relaxant effect of the crude extract, the
bladder strips were sub-maximally pre-contracted with histamine
(1–3 µM). Atropine and tetrodotoxin were present in the bathing
fluid. Since excitatory purinergic mechanisms are present in the
bladder, α,β-methylene ATP desensitization (10 + 10 µM for
10 min each) was also performed. RC crude extract had no
FIGURE 4 | Contraction, in response to 200 µg/ml RC extract (added at the
square symbol), on the guinea pig urinary bladder detrusor strip. Calibrations,
vertical: 50% of the maximal spasm in response to 100 mM KCl, horizontal:
1 min.
effect at a concentration of 20 µg/ml, whereas a concentration
of 200 µg/ml induced 58.3 ± 4.6% relaxation (N = 7 and 8,
respectively). The solvent itself (1 µl/ml DMSO) exerted no
effect.
Roman chamomile essential oil caused no contraction in
a concentration of 10 µg/ml. Similarly to the extract, RC oil
exerted a moderate relaxing effect on the pre-contracted bladder:
17.9 ± 6.1% and 34.1 ± 5.8% relaxation was evoked with 1 and
10 µg/ml, N = 7 and 6, respectively.
Effects on Rat Gastrointestinal
Preparations
The relaxant effect of RC essential oil was confirmed on
longitudinally oriented preparations of the rat gastrointestinal
tract. Rat whole ileum and distal colon preparations are
characterized by high intrinsic tone, therefore no pre-
contraction was needed. RC oil (10 µg/ml) induced relaxation
(41.4 ± 7.4% and 21.8 ± 3.7%, N = 7 and 10, respectively,
on these preparations, where 100% means the relaxant
response to 3 µM isoprenaline, given at the end of the
experiment). A concentration of 1 µg/ml was barely effective.
No contractile effect was observed. Rat stomach fundus strips
were pre-contracted with 0.1–0.3 µM acetylcholine. RC oil
produced relaxation (on average 44 and 70.3% relaxation
in response to concentrations of 1 and 10 µl/ml, N = 4
each, where 100% means relaxation to the pre-acetylcholine
level).
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Effects on Human Jejunal Preparations
In untreated longitudinally oriented human jejunal preparations
RC crude extract induced transient contraction amounting to
12.4± 3.5% and 30.5± 0.6% at 20 and 200 µg/ml concentrations,
respectively (N = 8). Atropine- and tetrodotoxin-pretreated
preparations were pre-contracted with PGF2α (1 or 2 µM).
RC extract showed a concentration-dependent relaxant effect
(25.8 ± 4.3% at 20 µg/ml, N = 8; 68.5 ± 8.5% at 60 µg/ml,
N = 7; 50.8 ± 3.7% at 200 µg/ml, N = 9). RC essential oil
produced no contraction. A lasting relaxant effect was detected
on pre-contracted preparations (in the presence of atropine and
tetrodotoxin). The relaxant effect reached 26.9± 5.2% at 1 µg/ml
and 81.4 ± 8.2% at 10 µg/ml concentrations (N = 8 and 7,
respectively).
In untreated circularly oriented human jejunal preparations
the RC crude extract evoked transient contraction (43.4 ± 10%
at 200 µg/ml, N = 5), while the 20 µg/ml concentration sample
had a negligible effect (2.8% contraction on 5 preparations). RC
extract induced relaxation in PGF2α-precontracted preparations
(in the presence of atropine and tetrodotoxin). This effect reached
45% with 60 µg/ml concentration (N = 4), while a concentration
of 200 µg/ml produced full relaxation (N = 6), where a relaxation
to the pre-prostaglandin level was taken as 100%.
The solvent itself (1 µl/ml DMSO) did not evoke either
contraction or relaxation on this preparation (N = 4–6).
DISCUSSION
The experiments presented here have been carried out with RC,
which has been used traditionally for the symptomatic treatment
of mild, spasmodic and other gastrointestinal complaints,
however, the presumed smooth muscle-relaxant effect has not
been confirmed experimentally. The aim of our study was to
investigate the effect of a traditionally used extract of the plant,
its fractions and the essential oil of the plant, as well as of four of
its flavonoid components.
The phytochemical analysis of the extract revealed the
presence of flavonoids in the plant, four of which (apigenin,
luteolin, eupafolin, and hispidulin) were isolated and identified.
The hydroethanolic extract was fractionated on polyamide
to gain fractions with different flavonoid content in order
to examine the role of these compounds in the effect on
smooth muscles. The flavonoid content of the extract and
fractions was analyzed by HPLC. The flavonoid content of the
extract was fractionated successfully, fractions F80, F100 (and
to some extent F60) containing higher amounts of flavonoids
than the crude extracts. The flavonoid pattern of fractions
also differed. The essential oil analyzed by us belongs to the
chemotype characterized by the predominance of methallyl
angelate.
Pharmacological experiments were carried out with the
hydroethanolic extract, its fractions (F20, F40, F60, F80, and
F100), four flavonoids (apigenin, eupafolin, hispidulin, and
luteolin) and the essential oil of the plant on different
smooth muscles in vitro. The hydroethanolic extract of RC
has both stimulatory and relaxant effects on guinea pig
ileum. The moderate, transient stimulatory activity results
from the activation of cholinergic neurons, as confirmed
by its inhibition by tetrodotoxin (an inhibitor of neuronal
voltage-sensitive Na+ channels) and atropine (antagonist on
muscarinic receptors for acetylcholine). Although capsaicin,
a stimulant of a certain class of sensory receptors (through
which it evokes a “local efferent” response) shows a similar
cholinergic, neurogenic effect in guinea pig small intestine
preparations (see Barthó et al., 2004 for review), a functional
blockade of capsaicin-sensitive nerve endings by capsaicin
pretreatment failed to inhibit the contractile action of RC
extract. The contractile action of RC extract was moderately,
yet significantly reduced by the cyclooxygenase inhibitor
indomethacin, which may indicate a modulatory role of
endogenous prostanoids. Other pharmacological inhibitors
tested had no contraction-reducing effect, therefore it is
proposed that neither endogenous serotonin, nor PPADS-
sensitive purinergic mechanisms play a role in the excitatory
action of RC extract. It should be noted that both serotonin and
ATP or the P2X receptor agonist α,β-methylene ATP are able
to evoke cholinergic contractions in guinea pig ileum (Benko
et al., 2005; Barthó et al., 2006; Sandor et al., 2016 for recent
data).
Following the transient and mild-to-moderate stimulant
effect, the RC crude extract exhibited a sustained relaxant
effect on the guinea pig ileum in the presence of tetrodotoxin
and atropine, and preliminary experiments indicated a similar
relaxant effect also in the absence of atropine and tetrodotoxin.
Yet, atropine and tetrodotoxin were included into these
experiments for creating a methodologically clear situation,
where an initial, neuronally mediated excitatory action would
hardly interfere with the relaxant one. The concentrations
of the extract causing relaxation were roughly the same as
those causing contraction. Based on these data we propose
that the site of action for the relaxant effect of RC is on
the smooth muscle itself. Neither the adrenergic β-receptor
antagonist propranolol nor the NO synthase inhibitor NG-
nitro-L-arginine significantly reduced the relaxant effect of
the RC extract, hence, no evidence was found for these
mechanisms to be involved in the relaxant response. In fact,
a direct relaxant effect of the extract was demonstrated on all
gastrointestinal preparations tested, including human and rat
gastrointestinal preparations, as well as in guinea pig bladder.
In preparations with high intrinsic tone (rat ileum and rat
colon), relaxant activity was practically the only response to be
seen.
Different RC extract fractions evoked both contraction and
relaxation on guinea pig ileum. While there was a clear-cut
tendency correlation between the flavonoid content and the
relaxant effect, in case of contractile action such correlation was
not observed (on the contrary, fractions with lower flavonoid
content exerted slightly higher contractile activities). Fractions
with high flavonoid content (F60, F80, and F100) had remarkable
relaxant effects, whereas fractions with no (F20) or low (F40)
flavonoid content exerted no such activity. The pure flavonoids
of the extract showed dual effects in the guinea pig ileum, much
similarly to the crude extract. Moreover, there was no substantial
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difference between the potencies of the flavonoids. This means
that any of these flavonoids may contribute to the sustained
relaxant and the transient contractile effect of the extract. The
essential oil of RC caused no contraction on the test preparations;
nevertheless, a consistent relaxant effect was detected. This seems
to indicate that (i) chemical components responsible for the
stimulant effect may be absent in the essential oil; (ii) it may
be that several types of compounds present in the extract are
responsible for the smooth muscle-relaxant action. This point
needs to be clarified in subsequent experiments.
The contraction of guinea pig bladder in response to the
RC extract proved to be special, in that it was reduced by half
following in vitro capsaicin pretreatment. This indicates that
capsaicin-sensitive sensory nerves of the bladder wall are in some
way involved in the excitatory effect of the RC extract (see Barthó
et al., 2004). Nevertheless, the RC extract and oil also induced
bladder relaxation in pre-contracted preparations.
Roman chamomile extract was effective in human jejunal
preparations as well. Both an excitatory and a tetrodotoxin-
and atropine-resistant relaxing effect were demonstrated, again,
the smooth muscle relaxant one being more sustained than the
excitatory one. Preliminary experiments have shown that this
early contraction is reduced by atropine. Due to limited access
to human tissue, no further analysis of these responses could be
performed.
In terms of possible medical uses it may be noted
that a combination of nerve-mediated, mild-to moderate
excitatory effect and a smooth muscle-relaxant action may
even be advantageous for some gastrointestinal problems, e.g.,
diminished peristaltic activity, while for spasms in the stomach or
large intestine it is obviously the smooth muscle relaxing activity
that offers benefits.
CONCLUSION
Our results support the overall smooth muscle relaxant effect of
a hydroethanolic RC extract and of the essential oil of RC. The
predominant effect of the extract, its fractions and flavonoids is
relaxation, being more sustained than the transient contraction
observed in some cases. This activity is in correlation with
the flavonoid content of the extract. Since the components
of the essential oil are partly extracted with alcohols, the
constituents of the oil also contribute to the overall effect
of the hydroethanolic RC extract. The extract used in our
experiments was prepared in accordance with the European
Medicines Agency monograph for this plant, therefore our study
contributes to the body of evidence relating the traditional use of
this plant.
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ABSTRACT
Context: Phytochemical and pharmacological data on Ducrosia anethifolia (DC.) Boiss. (Apiaceae), an
Iranian medicinal plant, are scarce; however, furocoumarins are characteristic compounds of D. anethifolia.
Objective: Our experiments identify the secondary metabolites of D. anethifolia and assess their antitu-
mor and anti-multidrug resistance activities.
Materials and methods: Pure compounds were isolated from the extract of aerial parts of the plant by
chromatographic methods. Bioactivities were tested on multidrug resistant and sensitive mouse T-lymph-
oma cell lines. The inhibition of the cancer MDR efflux pump ABCB1 was evaluated by flow cytometry (at
2 and 20 mM). A checkerboard microplate method was applied to study the interactions of furocoumarins
and doxorubicin. Toxicity was studied using normal murine NIH/3T3 fibroblasts.
Results: Thirteen pure compounds were isolated, nine furocoumarins namely, pabulenol (1), (þ)-oxypeuce-
danin hydrate (2), oxypeucedanin (3), oxypeucedanin methanolate (4), ()-oxypeucedanin hydrate (5),
imperatorin (6), isogospherol (7), heraclenin (8), heraclenol (9), along with vanillic aldehyde (10), harmine
(11), 3-hydroxy-a-ionone (12) and 2-C-methyl-erythrytol (13). Oxypeucedanin showed the highest in vitro
antiproliferative and cytotoxic activity against parent (IC50 ¼ 25.98± 1.27, 40.33 ± 0.63 mM) and multidrug
resistant cells (IC50 ¼ 28.89 ± 0.73, 66.68 ± 0.00mM), respectively, and exhibited slight toxicity on normal
murine fibroblasts (IC50 ¼ 57.18± 3.91mM).
Discussion and conclusions: Compounds 2, 3, 5, 7, 10–13 were identified for the first time from the
Ducrosia genus. Here, we report a comprehensive in vitro assessment of the antitumor activities of D. ane-
thifolia furocoumarins. Oxypeucedanin is a promising compound for further investigations for its anti-
cancer effects.
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Introduction
The genus Ducrosia (Apiaceae) consists of six species: Ducrosia
ismaelis Asch., D. flabellifolia Boiss., D. assadii Alava., D. areysiana
(Deflers) Pimenov & Kljuykov, D. inaccessa (C.C.Towns.) Pimenov
& Kljuykov and D. anethifolia (DC.) Boiss. D. anethifolia is one of
the three species growing wild in several areas of Iran,
Afghanistan, Pakistan, Syria, Lebanon, Iraq, and some other Arab
states and countries along the Persian Gulf (Aynehchi 1991;
Ghahreman 1993; Mozaffarian 1996). The whole herb, especially
its aerial part, has been used in Iranian folk medicine as an anal-
gesic and in case of anxiety and insomnia (Shalaby et al. 2014).
The aerial part, including the seed was reported to be carminative
and useful for irregularities of menstruation and galactagogue
(Amiri and Joharchi 2016). The herb is added to a variety of
Persian foods for flavouring (Aynehchi 1991; Haghi et al. 2004).
The phytochemical profile of D. anethifolia has only been
partly explored. In the literature, the majority of papers deal
with the composition of the essential oil (EO). As major constit-
uents, a-pinene (11.6% (Mostafavi et al. 2008), 70.3%
(Mottaghipisheh et al. 2014), 59.2% (Janssen et al. 1984)); n-
decanal (1.4-45% (Karami and Bohlooli 2017), 45.06%
(Vazirzadeh et al. 2017), 70% (Hajhashemi et al. 2010), 57%
(Mahboubi and Feizabadi 2009), 25.6–30.3% (Mazloomifar and
Valian 2015), 18.8% (Sefidkon and Javidtash 2002)), dodecanal
(28.8% (Shahabipour et al. 2013)), cis-chrysanthenyl acetate
(72.28%) (Ashraf et al. 1979; Habibi et al. 2017) have
been reported.
Furocoumarins and terpenoids are characteristic components
of the Ducrosia genus. From the seeds of D. anethifolia, two new
terpenoids, the monoterpene ducrosin A and the sesquiterpene
ducrosin B were isolated along with stigmasterol and the furo-
coumarins heraclenin and heraclenol (Queslati et al. 2017).
Psoralen, 5-methoxypsoralen, 8-methoxypsoralen, imperatorin,
isooxypeucedanin, pabulenol, pangelin, oxypeucedanin methano-
late, oxypeucedanin hydrate, 3-O-glucopyranosyl-b-sitosterol and
8-O-debenzoylpaeoniflorin were also isolated from the extract of
D. anethifolia (Stavri et al. 2003; Shalaby et al. 2014). GC analysis
of the fatty acids showed high percentages of elaidic acid and
oleic acid (Queslati et al. 2017), beside 58.8% petroselinic acid in
the seed oil of D. anethifolia (Khalid et al. 2009). Apart from
D. anethifolia, furocoumarins (psoralen, isopsoralen) have been
reported only from D. ismaelis from this genus (Morgan
et al. 2015).
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The bioactivities of the extracts of aerial parts of D. anethifo-
lia have been studied in vitro and in vivo. Different extracts of
the plant exerted moderate anti-radical scavenging
(Mottaghipisheh et al. 2014; Shahat et al. 2015); and antibacterial
effects (Syed et al. 1987; Mahboubi and Feizabadi 2009).
Pangelin isolated from D. anethifolia demonstrated activity
against a panel of fast growing mycobacteria (Stavri et al. 2003).
Essential oil of the seeds and methanol extract showed a weak
antibacterial effect against 14 Gram positive and negative bac-
teria (Javidnia et al. 2009; Habibi et al. 2017). In an experiment
on three human cancer cell lines (K562, LS180 and MCF-7), D.
anethifolia EO demonstrated remarkable to moderate cytotoxic
activity, while EO of D. flabellifolia showed less pronounced
activity (Shahabipour et al. 2013). Ducrosin B exerted remarkable
cytotoxicity against the human colon HCT-116 and ovary
SKOV-3 cancer cell lines in vitro (Queslati et al. 2017).
The crude D. anethifolia extract and the isolated furocoumar-
ins exhibited in vivo antidiabetic activities (Shalaby et al. 2014).
The in vivo anxiolytic (Hajhashemi et al. 2010; Shokri et al.
2013; Zamyad et al. 2016), sedative (Hajhashemi et al. 2010),
analgesic and anti-inflammatory (Asgari Nematian et al. 2017)
and also anti-locomotor activities (Zamyad et al. 2016) of D. ane-
thifolia EO have been tested. Intra-peritoneal administration of
the D. anethifolia EO improved spatial learning and memory in
adult male rats (Abbasnejad et al. 2017). The intra-peritoneal
injection of the hydroalcoholic extract of D. anethifolia effectively
reduced the pentylenetetrazole-induced seizure manifestations in
male Wistar rats (Nyasty et al. 2017). Moreover, D. anethifolia
extract reduced the number of germ cells, the level of testoster-
one and spermatogenesis in male Wistar rats (Rahimi
et al. 2016).
As presented above, furocoumarins are the most characteristic
compounds of the Ducrosia and their activities against cancer
cells seem to be promising. Imperatorin showed antiproliferative
effect on human hepatoma HepG2 cells (Luo et al. 2011); fur-
thermore, this compound and heraclenin induced apoptosis in
Jurkat leukemia cells. In Jurkat cells treated for 72 h with hera-
clenin and imperatorin, most of the DNA fragmentation
occurred at the G2/M and G1/S phases of the cell cycle, respect-
ively (Appendino et al. 2004). 8-Methoxypsoralen inhibited the
growth of neuroblastoma (IC50¼ 56.3 mM) and metastatic colon
cancer cells (IC50¼ 88.5 mM) by triggering both extrinsic and
intrinsic apoptotic pathways, independently of photoactivation
(Bartnik et al. 2017). Isoimperatorin, cnidicin, imperatorin, oxy-
peucedanin, byakangelicol and oxypeucedanin hydrate exhibited
a significant inhibition on cell proliferation in a dose-dependent
manner, particularly oxypeucedanin against HCT-15 (colon can-
cer) cells with ED50¼ 3.4 ± 0.3 lg/mL (Kim et al. 2007).
Beside direct antiproliferative and cytotoxic activities, furocoumar-
ins affect multidrug resistance (MDR) as well. Among 20 selected
furocoumarin derivatives, phellopterin (IC50¼ 8.0± 4.0 mM) and iso-
pimpinellin (IC50¼ 26.0± 5.7 mM) exhibited the highest activity
against CEM/C1 (lymphoblastic leukaemia) and HL-60/MX2 (MDR)
cell lines, respectively (Kubrak et al. 2017). Feroniellin A reverted
MDR in A549RT-eto lung cancer cells (Kaewpiboon et al. 2014).
Bergapten (IC50¼ 40.29±0.30nM) and xanthotoxin (IC50¼ 1.10±
0.91nM) showed remarkable anticancer activity against EPG85.
257RDB (MDR1 overexpressing human gastric adenocarcinoma cell
line) and MCF7MX (BCRP overexpressing human epithelial breast
cancer cell line), respectively (Mirzaei et al. 2017).
Our work explores the phytochemical composition of D. ane-
thifolia, examines the complex in vitro anticancer activities,
including antiproliferative, cytotoxic and anti-MDR effects of its
isolated compounds, and analyses the interaction of compounds
possessing promising bioactivities with chemotherapeutics.
Materials and methods
General procedures
NMR spectra were recorded in CD3OD and CDCl3 on a Bruker
Avance DRX 500 spectrometer at 500MHz (1H) and 125MHz
(13C). The peaks of the residual solvent (dH 3.31 and 7.26, dC 49.0
and 77.2, respectively) were taken as reference. The data were
acquired and processed with MestReNova v6.0.2e-5475 software.
Chemical shifts are expressed in parts per million and coupling
constants (J) values are reported in Hz. All solvents were used in
analytical grade (Molar Chemicals Kft, Halasztelek, Hungary).
Pure compounds were isolated by using open column chroma-
tography (Silica gel 60, 0.063–0.2mm, Merck, Darmstadt,
Germany) (CC), medium pressure liquid chromatography (MPLC,
silica gel 60, 0.045–0.063mm, Merck, Darmstadt, Germany), gel
chromatography (SephadexVR LH-20, Pharmacia, Uppsala,
Sweden), normal (Silica gel 60, Merck, Darmstadt, Germany) and
reverse phase (Silica gel 60 RP-18 F254s, Merck, Darmstadt,
Germany) preparative thin layer chromatography (PTLC and RP-
PTLC, respectively), centrifugal PTLC (Silica gel 60 GF254, Merck,
Darmstadt, Germany) (CPTLC) and reverse phase preparative
HPLC (KinetexVR 5 mm C-18 100 Å, 150 4.6mm Phenomenex,
Torrance, CA) (RP-HPLC). The HPLC flow was 1.2mL/min, col-
umn oven temperature was 24 C. Detection was carried out within
the range of 190–800 nm. The HPLC system comprised of Waters
600 pump, Waters 2998 PDA detector, Waters in/line degasser AF
degasser unit connected with Waters 600 control module using
Empower Pro 5.00 software.
Plant material
The aerial parts of Ducrosia anethifolia were collected by JM
from south of Iran (Fars, Neyriz, Iran) in April 2016.
Identification of the plant was done by Dr. Mohammad Jamal
Saharkhiz at Department of Horticultural Science, Faculty of
Agriculture, Shiraz University, Iran, and a voucher specimen was
deposited in the Herbarium of Department of Pharmacognosy,
University of Szeged (voucher no.: 880).
Isolation of compounds
Aerial parts (flower, leaves and stem, 3 kg) were dried in shade
at room temperature and powdered, then extracted with metha-
nol (40 L). After filtration, the filtrate was concentrated under
reduced pressure to yield the crude extract. The extract (464.1 g)
was dissolved with methanol–water 1:1 (1.5 L) and then parti-
tioned successively with n-hexane (4 1 L), CHCl3 (4 1 L),
EtOAc (4 1 L) and n-BuOH (4 1 L). The solvents were
removed from each extract to yield the n-hexane extract, CHCl3
extract, EtOAc extract and n-BuOH extract.
The CHCl3-soluble fraction (20.6 g) was initially subjected to
CC with a gradient system consisting of increasing concentration
of MeOH in CHCl3 (0–80%); column fractions with similar TLC
patterns were combined to get six major fractions D1, D2, D3,
D4, D5 and D6. D1 was chromatographed by MPLC, first eluting
with n-hexane–CH2Cl2 (50:50; 0:100), then adding MeOH to
CH2Cl2 (0–100%), to afford four subfractions (D11, D12, D13 and
D14). D11 was separated to 49 subfractions using CPTLC with an
isocratic eluting system n-hexane–EtOAc–MeOH (10:3:1), which
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resulted in the isolation of the pure compound 6 (82.8mg). The
RP-HPLC purification of D11 subfractions with MeOH–H2O
(MeOH–H2O 1:1) afforded compound 10 (1.7mg). D12 was
chromatographed by MPLC applying a gradient solvent system
with increasing EtOAc in n-hexane (5-100%) to get eight major
subfractions (D121–D128). From D123, the pure compound 3
(3.1mg) was isolated by using CPTLC with EtOAc in n-hexane
(5–100%). D124 was successively separated to 81 fractions by
CPTLC (same system), then subfractions 49–54 was subjected to
RP-HPLC with MeOH–H2O (15–50% H2O in MeOH) yielding
compound 9 (2.56mg).
D13 was separated by MPLC with increasing ratio of EtOAc
in n-hexane (5–100%) to get seven fractions (D131–D137). D133
was subjected to MPLC with the same solvent system to gain 19
subfractions. Finally, subfractions 1–2 were purified by using
CPTLC with toluene–EtOAc (90:10, 80:20, 70:30, 60:40, 50:50) as
eluents to gain compound 2 (100.4mg). Subfraction 3 from D133
was subjected to CPTLC by eluting with toluene–EtOAc (90:10,
80:20, 70:30, 60:40, 50:50) to yield 32 subfractions. Subfractions
18–19 of D133 were separated by PTLC with toluene–EtOAc
(1:1) to get compound 8 (35.3mg). Besides, subfractions 23–32
were chromatographed by RP-HPLC (MeOH–H2O 1:1) and then
by PTLC with toluene–EtOAc (1:1) to yield compounds 12
(1.02mg) and 1 (1.78mg). By using CPTLC with increasing con-
centration of EtOAc in toluene (5–100%) as eluents, subfraction
6 from D133 was chromatographed to get 43 subfractions.
Subfractions 24–28 and 36–40 were separated by PTLC with
CHCl3–MeOH–n-hexane (5:1:5) to retrieve compounds 4
(2.5mg) and 7 (21.7mg), respectively.
D3 was separated to five major fractions (D31–D35) by MPLC
with a solvent system containing increasing ratio of MeOH in
CHCl3 (0–100%). D33 was chromatographed by CPTLC with
raising the concentration of MeOH (0–20%) in the mixture of
cyclohexane–EtOAc (1:1) to afford 70 subfractions. Subfractions
21–23 contained the pure compound 11 (1.0mg). The main frac-
tion D4 was separated by MPLC to seven subfractions (D41–D47)
by raising the ratio of MeOH (0–100%) in acetone–toluene (1:1).
Subfraction D42 was subsequently chromatographed by PTLC
with eluting cyclohexane–EtOAc–MeOH (4.75:4.75:0.5) and com-
pound 5 (2.7mg) was isolated. Furthermore, D46 was purified
with CPTLC by increasing ratio of MeOH (0–100%) in acetone–
toluene (1:1); then compound 13 (2.9mg) was purified by using
RP-PTLC [MeOH–H2O (1:1)] from subfractions 35–37
(Figure 1).
Cell lines
L5178Y mouse T-cell lymphoma cells: parent, PAR cells
(ECACC cat. no. 87111908, obtained from FDA, Silver Spring,
MD) were transfected with pHa MDR1/A retrovirus. The
ABCB1-expressing L5178Y cell line (MDR) was selected by cul-
turing the infected cells in 60 ng/mL colchicine containing
medium. L5178Y PAR mouse T-cell lymphoma cells and the
L5178Y human ABCB1-transfected subline (MDR) were cultured
in McCoy’s 5A medium supplemented with 10% heat-inactivated
horse serum, 200mM L-glutamine, and penicillin–streptomycin
mixture in 100U/L and 10mg/L concentration, respectively, at
37 C and in a 5% CO2 atmosphere.
NIH/3T3 mouse embryonic fibroblast cell line (ATCC CRL-
1658) was purchased from LGC Promochem (Teddington, UK).
The cell line was cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma-Aldrich, St. Louis, MO), containing
4.5 g/L glucose, supplemented with 10% heat-inactivated foetal
bovine serum (FBS). The cells were incubated at 37 C, in a 5%
CO2, 95% air atmosphere.
Assay for antiproliferative effect
The effects of increasing concentrations of the analysed com-
pounds on cell proliferation were tested in 96-well flat-bottomed
microtiter plates (Poljarevic et al. 2018). The compounds were
diluted in 100lL of McCoy’s 5A medium. 6 103 mouse T-cell
lymphoma cells (PAR or MDR) in medium (100lL) were added
to each well, with the exception of the medium control wells.
The culture plates were further incubated at 37 C for 72 h; at
the end of the incubation period, 20lL of MTT solution
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Figure 1. Secondary metabolites isolated from Ducrosia anethifolia.
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(thiazolyl blue tetrazolium bromide, Sigma, St. Louis, MO) (from
a 5mg/mL stock) was added to each well. After incubation at
37 C for 4 h, 100lL of sodium dodecyl sulphate (SDS, Sigma,
St. Louis, MO) solution (10% in 0.01 M HCl) was added to each
well and the plates were further incubated at 37 C overnight.
The cell growth was determined by measuring the OD at 540 nm
(ref. 630 nm) with a Multiscan EX ELISA reader (Thermo
Labsystems, Waltham, MA). IC50 values were calculated via the
following equation:
IC50 ¼ 100
ODsampleODmediumcontrol
ODcellcontrol ODmediumcontrol
 
 100
Assay for cytotoxic effect
The effects of increasing concentrations of compounds on cell
growth were tested in 96-well flat-bottomed microtiter plates
(Poljarevic et al. 2018). The compounds were diluted in a volume
of 100 lL medium. Then, 1 104 cells in 100lL of medium
were added to each well, with the exception of the medium con-
trol wells. In case of NIH/3T3 cells, the compounds were added
after seeding the cells at 37 C overnight. The culture plates were
incubated at 37 C for 24 h; at the end of the incubation period,
20 lL of MTT solution (from a 5mg/mL stock) was added to
each well. After incubation at 37 C for 4 h, 100lL of SDS solu-
tion (10% in 0.01 M HCl) was added to each well and the plates
were further incubated at 37 C overnight. Cell growth was
determined by measuring the optical density (OD) at 540 nm
(ref. 630 nm) with a Multiscan EX ELISA reader. Inhibition of
the cell growth was determined according to the formula:
IC50 ¼ 100
ODsampleODmediumcontrol
ODcellcontrol ODmediumcontrol
 
 100
Results are expressed in terms of IC50, defined as the inhibi-
tory dose that reduces by a 50% the growth of the cells exposed
to the tested compound.
Assay for multidrug resistance reversing activity
The inhibition of the cancer MDR efflux pump ABCB1 by the
tested compounds was evaluated using flow cytometry measuring
the retention of rhodamine 123 by ABCB1 (P-glycoprotein) in
MDR mouse T-lymphoma cells, as the L5178Y human ABCB1-
gene transfected mouse T-lymphoma cell line (MDR) overex-
presses P-glycoprotein (Domınguez-Alvarez et al. 2016). This
method is a fluorescence-based detection system which uses ver-
apamil as reference inhibitor. Briefly, cell number of L5178Y
MDR and PAR cell lines was adjusted to 2 106 cells/mL,
re-suspended in serum-free McCoy’s 5A medium and distributed
in 0.5mL aliquots into Eppendorf centrifuge tubes. The tested
compounds were added at different concentrations and the sam-
ples were incubated for 10min at room temperature. Verapamil
(Sigma, St. Louis, MO) and tariquidar (Sigma, St. Louis, MO)
were applied as positive controls. Next, 10 mL (5.2 mM final con-
centration) of the fluorochrome and ABCB1 substrate rhodamine
123 (Sigma, St. Louis, MO) were added to the samples and the
cells were incubated for 20min at 37 C, washed twice and re-
suspended in 0.5mL PBS for analysis. The fluorescence of the
cell population was measured with a Partec CyFlowVR flow
cytometer (Partec, G€orlitz, Germany). The percentage of mean
fluorescence intensity was calculated for the treated MDR cells as
compared with the untreated cells. A fluorescence activity ratio
(FAR) was calculated based on the following equation which
relates the measured fluorescence values:
FAR ¼ MDRtreated=MDRcontrol
parentaltreated=parentalcontrol
The results obtained from a representative flow cytometry
experiment in which 20,000 individual cells of the population
were evaluated for amount of rhodamine 123 retained with the
aid of the Partec CyFlowVR flow cytometer, are first presented by
the histograms and these data converted to FAR units that define
fluorescence intensity, standard deviation, peak channel in the
total- and in the gated-populations. Parameters calculated are:
forward scatter (FSC, forward scatter count of cells in the sam-
ples or cell size ratio); side scatter (SSC, side scatter count of
cells in the samples); FL-1 (mean fluorescence intensity of the
cells) and FAR, whose values were calculated using the equation
given above.
Checkerboard combination assay
A checkerboard microplate method was applied to study the
effect of drug interactions between furocoumarins and the che-
motherapeutic drug doxorubicin (Takacs et al. 2015). This assay
was carried out using multidrug resistant mouse T-lymphoma
cells overexpressing the ABCB1 transporter. Doxorubicin is in
the class of anthracycline antitumor agents, and it exerts anti-
cancer activity as a topoisomerase-II (TI-2) inhibitor. The dilu-
tions of doxorubicin (Teva, Debrecen, Hungary, stock solution:
2mg/mL) were made in a horizontal direction in 100lL (final
concentration: 17.242 lM), and the dilutions of the test com-
pounds vertically in the microtiter plate in 50 lL volume. The
cells were re-suspended in McCoy’s 5A culture medium and dis-
tributed into each well in 50 lL containing 6 103 cells each.
The plates were incubated for 72 h at 37 C in 5% CO2 atmos-
phere. The cell growth rate was determined after MTT staining.
At the end of the incubation period, 20 lL of MTT solution
(from a stock solution of 5mg/mL) was added to each well.
After incubation at 37 C for 4 h, 100lL of SDS solution (10% in
0.01 M HCl) was added to each well and the plates were further
incubated at 37 C overnight. Optical density was measured at
540/630 nm with Multiscan EX ELISA reader (Thermo
Labsystems, Waltham, MA) as described elsewhere (Takacs et al.
2015). Combination index (CI) values at 50% of the growth
inhibition dose (ED50) were determined using CompuSyn soft-
ware (ComboSyn, Inc., Paramus, NJ) to plot four to five data
points to each ratio. CI values were calculated by means of the
median-effect equation, where CI <1, CI ¼ 1 and CI >1 repre-
sent synergism, additive effect (or no interaction) and antagon-
ism, respectively (Chou and Martin 2005; Chou 2010).
Results
Isolated compounds
Repeated column chromatography of the bioactive fractions
resulted in the isolation of 13 compounds. The compounds were
identified by careful interpretation of NMR data and comparison
of 1H and 13C chemical shifts with those reported in literature.
Nine linear furocoumarin derivatives, namely pabulenol (1) (Sbai
et al. 2016), (þ)-oxypeucedanin hydrate (aviprin) (2) (Sbai et al.
2016), oxypeucedanin (3) (Sbai et al. 2016), oxypeucedanin
methanolate (4) (Fujioka et al. 1999), (–)-oxypeucedanin hydrate
(prangol) (5) (Rahimifard et al. 2018), imperatorin (6) (Lv et al.
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2013), isogospherol (7) (Macias et al. 1990), heraclenin (8)
(Poonkodi 2016), heraclenol (9) (Harkar et al. 1984); along with
vanillic aldehyde (10) (Chung et al. 2011), harmine (11),
3-hydroxy-a-ionone (12) and 2-C-methyl-erythrytol (13) were
identified (1H NMR spectra see in Supporting Information). The
diastereomers (þ)-oxypeucedanin hydrate and ()-oxypeuceda-
nin hydrate were distinguished by determining their optical rota-
tions and comparing with literature (Atkinson et al. 1974).
The 1H and 13C NMR spectral data of 11, 12 and 13 in
CD3OD are reported here for the first time. Compound 11 (har-
mine): 1H NMR (500MHz, CD3OD) d ¼ 8.11 (H-3, d,
J¼ 5.5Hz), 8.02 (H-5, d, J¼ 8.7Hz), 7.86 (H-4, d, J¼ 5.5Hz),
7.06 (H-8, d, J¼ 1.9Hz), 6.89 (H-6, dd, J¼ 8.7Hz, 1.9Hz), 3.92
(s, 7-OCH3), 2.80 (s, 1-CH3);
13C NMR (125MHz, CD3OD)
d ¼ 162.9, 144.6, 141.6, 137.0, 136.2, 130.7, 123.7, 116.3, 113.5,
111.4, 95.4, 56.0, 19.1. Compound 12 (3-hydroxy-a-ionone): 1H
NMR (500MHz, CD3OD) d ¼ 6.67 (H-7, dd, J¼ 15.8Hz,
10.3Hz), 6.13 (H-8, d, J¼ 15.8Hz), 5.60 (H-4, br s), 4.22 (H-3,
br s), 2.58 (H-6, d, J¼ 10.3Hz), 2.27 (H3-10, s), 1.80 (H-2b, dd,
J¼ 13.2Hz, 5.9Hz), 1.63 (H3-13, s), 1.38 (H-2a, dd,
J¼ 13.2Hz, 7.2Hz), 1.01 (H3-11, s), 0.90 (H3-12, s); 13C NMR
(125MHz, CD3OD) d ¼ 200.8, 149.8, 135.9, 134.7, 127.3, 65.9,
55.6, 45.0, 35.0, 29.8, 27.1, 24.5, 22.8. Compound 13 (2-C-
methyl-erythrytol): 1H NMR (500MHz, CD3OD) d ¼ 3.80 (H-4a,
dd, J¼ 10.4Hz, 2.5Hz), 3.61 (H-3, m), 3.59 (H-4b, m), 3.52 (H-
1a, d, J¼ 11.1Hz), 3.44 (H-1b, d, J¼ 11.1Hz), 1.11 (2-CH3, s);
13C NMR (125MHz, CD3OD) d ¼ 76.2, 75.0, 68.5, 63.8, 19.7.
Antiproliferative and cytotoxic activities on cancer cell lines
Furocoumarins isolated from D. anethifolia were subjected to
bioassay for cytotoxic and antiproliferative activity against cancer
cell lines. All compounds exerted potent antiproliferative effect
on sensitive and resistant mouse T-lymphoma cells (Table 1).
However, they did not show any selectivity towards the resistant
cell line. The most potent compound was oxypeucedanin on
both cell lines. Some compounds had no toxic effects ((þ)-oxy-
peucedanin hydrate (2), heraclenol (9), isogospherol (7)); fur-
thermore, pabulenol (1), oxypeucedanin methanolate (4) and
imperatorin (6) were more toxic on the sensitive PAR cell line
(IC50 between 52 and 57 mM) without any toxicity on MDR cells
(Table 1). Oxypeucedanin (3) and heraclenin (8) exhibited cyto-
toxic activity; however, they were more potent on the sensitive
PAR cell line (Table 1). The cytotoxic activity of furocoumarins
was assessed using NIH/3T3 normal murine fibroblast cells.
Some compounds showed slight toxic effect on normal fibro-
blasts, namely (þ)-oxypeucedanin hydrate (2), heraclenol (4) and
isogospherol (8) with IC50 values of 83.55, 65.78 and 54.82 mM,
respectively. Pabulenol (1) possessed similar activity on fibroblast
and parental mouse lymphoma cells. In addition, oxypeucedanin
(3), oxypeucedin methanolate (5) and heraclenin (9) exhibited
mild toxicity on fibroblasts and parental lymphoma cells.
Imperatorin (7) had no toxic activity on fibroblasts.
Multidrug resistance reversing activity
Regarding the efflux pump inhibiting activity of the compounds
on ABCB1 overexpressing MDR mouse T-lymphoma cells, only
oxypeucedanin (3) showed moderate ABCB1 inhibiting effect
(FAR: 2.22); however, this inhibition was lower than in case of
the positive controls tariquidar (FAR: 100) and verapamil (FAR:
8.2) (Table 2, figures see in Supporting Information).
Combination assay results on MDR cells
The two most promising compounds in the previous assays were
investigated in combination with the standard chemotherapeutic
drug doxorubicin. The compounds oxypeucedanin (3) and hera-
clenin (8) showed slight synergistic effect with doxorubicin, for
this reason, they might be potential adjuvants in combined
chemotherapy applying standard anticancer drugs with com-
pounds that can act synergistically (Table 3).
Table 1. Antiproliferative (AA) and cytotoxic activities (CA) of the furocoumarins against PAR, MDR and NIH/3T3 cells presented as IC50 values.
Compounds AA on PAR cells (mM) AA on MDR cells (mM) CA on PAR cells (mM) CA on MDR cells (mM) CA on NIH/3T3cells (mM)
Pabulenol (1) 30.47 ± 0.47 29.28 ± 0.45 51.32 ± 3.32 >100 54.09 ± 3.83
(þ)-Oxypeucedanin hydrate (2) 41.96 ± 0.88 60.58 ± 2.74 >100 >100 83.55 ± 0.57
Oxypeucedanin (3) 25.98 ± 1.27 28.89 ± 0.73 40.33 ± 0.63 66.68 ± 0.00 57.18 ± 3.91
Oxypeucedanin methanolate (4) 35.88 ± 0.96 33.23 ± 0.51 56.42 ± 5.23 >100 47.16 ± 1.28
Imperatorin (6) 36.12 ± 0.91 42.24 ± 0.88 52.56 ± 4.19 >100 92.41 ± 2.80
Isogospherol (7) 46.53 ± 0.47 48.75 ± 0.28 >100 >100 54.82 ± 1.99
Heraclenin (8) 32.73 ± 2.40 46.54 ± 1.22 65.81 ± 1.00 83.94 ± 1.68 70.91 ± 4.26
Heraclenol (9) 52.31 ± 2.12 46.57 ± 0.47 >100 >100 65.78 ± 0.46
Doxorubicin 0.054 ± 0.005 0.468 ± 0.065 0.377 ± 0.02 7.152 ± 0.358 5.71 ± 0.50
Data were expressed as mean ± standard deviation (n¼ 3). Different letters represent significant differences (p< 0.05).
Table 2. Efflux pump inhibiting activities of furocoumarins.
Samples Conc. lM FSC SSC FL-1 FAR
PAR – 2069 658 98.20 –
MDR – 2152 725 1.79 –
MDR mean 1.182 –
Tariquidar 0.02 2156 719 119 100.68
Verapamil 20 2143 740 9.69 8.20
Pabulenol (1) 2 2324 728 0.596 0.82
20 2323 750 0.544 0.75
(þ)-Oxypeucedanin hydrate (2) 2 2325 725 0.715 0.98
20 2305 769 0.583 0.80
Oxypeucedanin (3) 2 2190 749 0.9 0.76
20 2164 763 2.62 2.22
Oxypeucedanin methanolate (4) 2 2310 737 0.58 0.80
20 2290 766 0.499 0.68
Imperatorin (6) 2 2165 749 0.727 0.62
20 2161 750 0.783 0.66
Isogospherol (7) 2 2305 741 0.531 0.73
20 2326 741 0.548 0.75
Heraclenin (8) 2 2318 723 0.942 1.29
20 2294 764 0.57 0.78
Heraclenol (9) 2 2300 742 0.995 1.37
20 2317 740 0.348 1.30
DMSO 2% (V/V) 2308 762 0.497 0.68
MDR – 2301 746 0.535 –
Table 3. Checkerboard combination assay of selected compounds with
doxorubicin.
Compound Best ratio CI at ED50 Interaction SD (±)
Oxypeucedanin 1:50 0.85537 Slight synergism 0.07800
Heraclenin 4:100 0.88955 Slight synergism 0.06334
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Discussion
Chromatographic separation of the extract of D. anethifolia herbs
resulted in the isolation of 13 compounds, among them were
nine furocoumarins. Compounds 2, 3, 5, 7, 10–13 were identi-
fied for the first time from Ducrosia genus.
The tested furocoumarins exerted antiproliferative effects on
sensitive and resistant mouse T-lymphoma cells with no selectiv-
ity towards the resistant cell line. This is the first comprehensive
analysis of this plant and its furocoumarins on these cells.
Oxypeucedanin (3) had the most remarkable activity on both cell
lines. The most effective furocoumarins, oxypeucedanin (3) and
heraclenin (9) exhibited marginal toxicity on normal fibroblast
cells and sensitive parental mouse lymphoma cells; furthermore,
they were less toxic on multidrug resistant lymphoma cells.
From the tested compounds, only oxypeucedanin showed moder-
ate MDR reversing activity. In the checkerboard assay, oxypeuce-
danin and heraclenin showed slight synergistic effect with
doxorubicin. These compounds might improve the cytotoxic
effect of the standard chemotherapeutic drug doxorubicin.
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Abstract: Matricaria chamomilla L. is a popular medicinal herb that is used for healing various diseases
and is widely distributed worldwide in temperate climate zones, and even in the subtropical climate
of Southern and Western Iran. This study was aimed at comparing the volatile oil constituents, along
with antiradical potential and HPLC analysis of methanolic extracts from twelve plant samples
growing in Iran. The present research was carried out for the first time on these populations. Among
seventeen identified volatile chemicals evaluated by GC/MS and GC/FID, representing 92.73–97.71%
of the total oils, α-bisabolone oxide A (45.64–65.41%) was the major constituent, except in case of
“Sarableh” as a new chemotype, where (E)- and (Z)-γ-bisabolene (42.76 and 40.08%, respectively) were
the predominant components. Oxygenated sesquiterpenes (53.31–74.52%) were the most abundant
compounds in the samples excluding “Sarableh” with 91.3% sesquiterpene hydrocarbons. “Sarableh”
also exerted the most potent antioxidant capacity with EC50 = 7.76± 0.3 µg/mL and 6.51 ± 0.63 mmol
TE (Trolox® equivalents)/g. In addition, populations “Lali” and “Bagh Malek” contained the highest
amounts of apigenin and luteolin with 1.19 ± 0.01 mg/g and 2.20 ± 0.0 mg/g of plant material,
respectively. Our findings depict a clear correlation between phytochemical profiles and antiradical
potential of M. chamomilla and geographical factors.
Keywords: Matricaria chamomilla L.; Iranian populations; ecological effects; volatile compounds;
antiradical capacity
1. Introduction
Matricaria chamomilla L. (syn. Chamomilla recutita L. Rauschert, German chamomile), belonging to
the Asteraceae family, is one of the well-known medicinal plant species which has been widely used
for centuries. The herb is currently consumed around the world as herbal tea, with more than 1 million
cups daily [1,2]. M. chamomilla is used in the treatment of many ailments and disorders; internally
to facilitate digestion and as antispasmodic, externally to treat minor wounds. In folk medicine, its
use spreads from the relief of various pains such as headaches and toothaches to the facilitation of
menstruation [3]. Chamomile essential oil (EO) has been commonly applied in Iranian folk medicine
as an anti-inflammatory, antispasmodic, anti-peptic ulcer, antibacterial and antifungal agent [4,5].
Several papers report sesquiterpenes as the most dominant constituent of M. chamomilla EO.
Spathulenol (12.50%) [6], α-bisabolol oxide A (7.9–62.1%) [7–10], α-bisabolol oxide B (25.56%) [10],
Molecules 2019, 24, 1315; doi:10.3390/molecules24071315 www.mdpi.com/journal/molecules
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β-farnesene (52.73%) [11], (E)-β-farnesene (42.59%) [12], β-cubebene (27.8%) [13], trans-β-farnesene [14,15],
chamazulene (27.8–31.2%) [16], and α-bisabolol (56.9%) [17] were recently reported as the main
EO compounds.
Non-volatile compounds of M. chamomilla have also been investigated. The major phytochemicals
comprise polyphenols, particularly the flavonoids apigenin, patuletin, quercetin, luteolin and their
glucosides [18–20]; among them apigenin is reported as one of the most bioactive phenolics [19,21].
In the present study, EO compositions of twelve Iranian M. chamomilla populations collected from
diverse regions were qualitatively and quantitatively assessed. Since the main radical scavengers are
phenolics, flavonoids being the major group within phenolics [22], our study was also designed to
determine apigenin and luteolin contents, as its main flavonoid aglycons [19,23], by utilizing analytical
HPLC. Antiradical capacities of the extracts with DPPH and ORAC assays were also compared.
In order to make comparison, the plants were harvested at the same flourishing period. To the best of
our knowledge, this is the first report of these populations.
2. Results
2.1. Essential Oil Contents
As shown in Table 1, the studied plant samples were characterized mostly with similar EO yields.
Populations “B” (1.03 ± 0.003%) and “BM” (0.78 ± 0.017%) contained the highest and lowest amount
of EO, respectively (Table 1). As the plant sample “B” was cultivated in the university’s garden and it
was regularly irrigated, the highest EO content can be predicted.
2.2. Chemical Profiles of Volatile Oils
Seventeen compounds were detected in these twelve populations. The sesquiterpene α-bisabolone
oxide A (45.64–65.41%) was the major EO constituent in the samples except “B” and “S”, whereas its
concentration was the highest in population “Mu” (Table 1).
The cultivated sample “B” was rich in α-bisabolol oxide B (21.88%) and chamazulene (19.22%),
while the percentages of these compounds were lower under the wild growth conditions. The blue
colour of EOs in all samples except “S” represented their chamazulene contents, whereas, “S” due
to lack of this compound showed a yellowish green colour. Accordingly, oxygenated sesquiterpenes
(53.31–74.52%) were the predominant chemical group of EO constituents in all studied samples,
excluding “S”, which was rich in sesquiterpene hydrocarbons (Figure 1).
Figure 1. Volatile oil components from Matricaria chamomilla populations as a percentage of total
identified compounds.
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Table 1. Essential oil constituents and yields of twelve harvested Matricaria chamomilla populations.
No. RI A RT B
Compounds C
Populations B I BM L MS Mo G SS Mu A DS S
Amount (%)
1 1063 7.79 Artemisia ketone nd 0.65 nd nd nd nd nd nd nd nd nd nd
2 1423 17.75 Trans-caryophyllene nd nd nd nd nd nd nd nd nd nd nd 0.5
3 1454 18.75 (E)-β-Farnesene 8.51 b 16.68 a 9.58 a,b 10.60 a,b 13.92 a,b 13.91 a,b 9.82 a,b 6.61 b 10.33 a,b 15.29 a 12.37 a,b 5.25 b
4 1484 19.45 Germacrene D 1.31 nd nd nd nd nd nd nd nd 0.55 nd 2.21
5 1500 20 Bicyclo-germacrene 2.01 nd nd nd nd nd nd nd nd nd nd nd
6 1506 20.21 (Z)-α-Bisabolene nd nd nd nd nd 0.81 nd nd nd nd nd nd
7 1514 20.3 (Z)-γ-Bisabolene nd nd nd nd nd nd nd nd nd nd nd 40.08
8 1529 20.7 (E)-γ-Bisabolene nd nd nd nd nd nd nd nd nd nd nd 42.76
9 1561 21.65 (E)-Nerolidol 1.76 nd nd nd nd nd nd nd nd nd nd nd
10 1577 22.1 (+)-Spathulenol 1.53 nd nd nd nd nd nd nd nd nd nd nd
11 1630 23.18 (γ)-Eudesmol nd nd nd nd nd nd nd nd nd nd nd 1.78
12 1656 24.16 α-Bisabolol oxide-B 21.88 a 1.55 b,c 1.52 b,c 1.59 b,c 1.39 c 1.65 b,c 1.68 b,c 1.80 b 1.58 b,c 1.64 b,c 1.37 c nd
13 1685 24.56 α-Bisabolol nd nd nd nd 1.32 2.86 2.07 nd nd nd nd nd
14 1693 24.9 α-Bisabolone oxide A 11.36 d 47.91 b,c 53.28 b 52.14 b,c 46.98 c 46.74 c 45.64 c 51.87 b,c 65.41 a 47.7 b,c 49.18 b,c nd
15 1730 25.76 Chamazulene 19.22 a 8.29 b,c 9.74 b 4.74 e 8.44 b,c 6.14 d 8.02 c 9.3 b,c 4.18 e 2.58 f 6.06 d nd
16 1748 26.18 α-Bisabolol oxide A 16.78 b,c 14.03 c 13.93 c 19.35 b 16.75 b,c 19.41 b 24.02 a 22.26 a,b 7.53 d 20.25 b 17.22 b,c nd
17 1890 26.31 (E)-Spiroether 8.37 a 7.51 b 4.70 c 5.75 b,c 7.12 a,b 6.41 b 6.49 b 3.73 c 5.31 b,c 5.96 b 7.26 a,b nd
Total identified compounds % 92.73 96.64 92.76 94.2 95.27 96.51 97.71 95.59 94.35 94.53 93.47 93.08
EOs yield % 1.03 ±0.003
0.84 ±
0.006
0.78 ±
0.17
0.88 ±
0.012
0.94 ±
0.035
0.79 ±
0.006
0.88 ±
0.021
0.91 ±
0.009
0.9 ±
0.023
0.89 ±
0.006
0.83 ±
0.009
0.98 ±
0.021
A Relative retention index to C8–C24 n-alkanes on HP-5MS column; B Retention times; C Compounds listed in order of elution from HP-5MS column; nd: not detected; the means were
compared using Duncan’s comparisons test (p < 0.05); small letters (a, b, c) in each row show the significant difference of related component among various populations.
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2.3. Apigenin and Luteolin Quantification of Methanolic Extracts
Methanolic extracts of samples “L” and “A” contained the highest amounts of apigenin, with
1.19 ± 0.01 mg/g and 1.02 ± 0.01 mg/g, respectively. Luteolin was present in higher concentrations in
“BM” (2.20 ± 0.0 mg/g) and “A” (1.01 ± 0.02 mg/g) extracts (Figure 2).
Figure 2. Apigenin and luteolin contents of twelve plant samples (mg/g of dry weight) analysed
by HPLC.
2.4. Classification of M. Chamomilla Populations
To characterize and identify the different chemotypes of Iranian M. chamomilla populations, their EO
compositions and main flavonoids (apigenin and luteolin) were submitted to cluster analysis (CA) and
principal component analysis (PCA). As shown in Figures 3 and 4, the dendrograms allowed separating
the M. chamomilla populations into three main groups, each representing a distinct chemotype.
Figure 3. Dendrogram of the Matricaria chamomilla populations resulting from the cluster analysis
(based on Euclidean distances) of the volatile oil components. chemotype I (α-bisabolone oxide A and
α-bisabolol oxide A), chemotype II (chamazulene and α-bisabolol oxide B), chemotype III ((Z) and
(E)-γ-bisabolene).
Figure 4. Principal component analysis (PCA) of the Matricaria chamomilla populations. ABOA:
α-bisabolol oxide A, ABOB: α-bisabolol oxide B, PEO: percentage of essential oil, CH: chamazulene,
SP: (E)-spiroether, ABNOA: α-bisabolone oxide A, BEF: (E)-β-farnesene, BZY: (Z)-γ-bisabolene, BEY:
(E)-γ-bisabolene, LUT: luteolin, API: apigenin.
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PCA is a mathematical procedure that transforms several correlated variables into various
uncorrelated variables called principal components (PC). PC1, PC2, and PC3 showed the highest
variation of phytochemicals among the studied populations. PC1 explained 41.57% of total variation
and had a positive correlation with α-bisabolol oxide A, (E)-β-farnesene, α-bisabolone oxide A and
(E)-spiroether, and negative correlation with (Z)-γ-bisabolene and (E)-γ-bisabolene. The second PC
(PC2), with 24.98% of variance, demonstrated positive correlation with chamazulene, α-bisabolol oxide
B, α-bisabolone oxide A and the EO content. Furthermore, PC3 represented positive correlation in the
case of apigenin and luteolin, which accounted for 12.02% of the total variance (Table 2).
Table 2. Eigenvalues, variance and cumulative variance for three principal components.
Major Phytochemicals Principal Components
PC1 PC2 PC3
Chamazulene 0.377 0.881 0.023
α-Bisabolol oxide A 0.760 0.126 0.114
(E)-β-Farnesene 0.679 −0.293 −0.004
α-Bisabolol oxide B 0.044 0.961 0.011
α-Bisabolone oxide A 0.742 0.525 0.104
(E)-Spiroether 0.849 0.377 −0.032
(Z)-γ-Bisabolene −0.965 −0.119 −0.130
(E)-γ-Bisabolene −0.965 −0.119 −0.130
Essential oil content −0.480 0.600 −0.348
Apigenin 0.002 −0.295 0.638
Luteolin 0.160 0.235 0.857
Eigen values 4.57 2.74 1.32
Variance (%) 41.57 24.98 12.02
Cumulative variance (%) 41.57 66.55 78.57
Regarding a significant contribution of phytochemical variation in PC1 and PC2, the scatter plot
of PC1 and PC2 was used to specify phytochemical distance. The studied populations were classified
in three groups, which confirmed the CA results.
In accordance with the CA, the populations “I”, “DS”, “Mo”, “MS”, “Mu”, “G”, “SS”, “L”,
“A” and “BM” were classified into the same category, while, “B” and “S” were grouped into the
individual subclasses. The first group possessed α-bisabolone oxide A and α-bisabolol oxide A as the
major constituents as well as apigenin and luteolin (chemotype I). The second chemotype (II), was
characterized by high amounts of chamazulene and α-bisabolol oxide B. The chemotype (III) was the
richest in (Z) and (E)-γ-bisabolene.
2.5. Effect of Environmental Factors on Phytochemicals
In order to assess the effect of environmental factors on EO components, along with apigenin
and luteolin contents, canonical correspondence analysis (CCA) was applied based on a matrix of
three environmental factors including altitude, mean annual temperature (MAT), and mean annual
precipitation (MAP) [24] and major EO compounds, along with apigenin and luteolin contents
(Figure 5).
According to the CCA, phytochemicals of populations in first group were significantly affected
by ecological parameters (altitude, temperature and precipitation) while the main oil composition and
flavonoids of “Sarableh” and “Boldgold” were changed by genetic factors. Therefore, the “Sarableh”
population can be introduced as a new chemotype.
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Figure 5. Canonical correspondence analysis (CCA) biplot of Matricaria chamomilla populations, linking
percentages of the major constituents, collected from different environmental conditions. Populations
B: Bodgold, I: Izeh, BM: Bagh Malek, L: Lali, MS: Masjed Soleyman, Mo: Mollasani, SS: Saleh Shahr,
Mu: Murmuri, A: Abdanan, DS: Darreh Shahr, and S: Sarableh, MAT: mean annual temperature; MAP:
mean annual precipitation; ABOA: α-bisabolol oxide A, ABOB: α-bisabolol oxide B, PEO: essential oil
percentage, CH: chamazulene, SP: (E)-spiroether, ABNOA: α-bisabolone oxide A, BEF: (E)-β-farnesene,
BZY: (Z)-γ-bisabolene, BEY: (E)-γ-bisabolene, LUT: luteolin, API: apigenin.
2.6. Antiradical Activity of the Extracts
In the evaluation of the antioxidant potential of the twelve selected populations, “S” showed
the most significant antiradical capacity, with EC50 = 7.76 ± 0.3 µg/mL and 6.51 ± 0.63 mmol TE/g
measured by DPPH and ORAC assays, respectively. However, the extracts showed lower activity
compared to ascorbic acid (EC50 = 0.3 ± 0.02 µg/mL) in the DPPH and rutin (20.22 ± 0.63 mmol TE/g)
and EGCG (11.97 ± 0.02 mmol TE/g) in the ORAC assay (Figures 6 and 7).
Figure 6. Antiradical scavenging activity of twelve plant samples of Matricaria chamomilla in the DPPH assay.
Figure 7. Antiradical capacity of selected Matricaria chamomilla populations in the ORAC assay.
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3. Discussion
The results of the present study confirm the variability of EO composition, flavonoid profile and
antiradical activity, which are significantly affected by a diversity of ecological conditions.
The abiotic factors (e.g., moisture, topography, temperature, and edaphic factors) highly impact
the phytoconstituents variation, and/or biotic factors remarkably influenced the terpene biosynthesis
pathways and chemotype profiles [25]. However, the role of other ecological effects such as climatic
factors (e.g., humidity, wind, atmospheric gases, and light), physiographic factors (e.g., steepness and
sunlight on vegetation and direction of slopes), edaphic factors (the soil attributes), and biotic factors
(e.g., the existence of lianas, epiphytes, parasites etc.) may also be considerable in chemotype variations.
In accordance with our findings, oxygenated sesquiterpenes (53.31–74.52%) are the most dominant
EO compounds of the selected Matricaria chamomilla L. samples, which corroborates previous reports.
The wild populations were significantly different compared with the cultivated sample (Bodgold) in
EO composition. α-Bisabolone oxide A was mostly the major EO constituent in the populations.
In the literature, α-bisabolone oxide A was previously identified from M. chamomilla by different
groups; for instance, the EO, diethyl ether and dichloromethane fractions of EO contained α-bisabolone
oxide A, with 47.7, 57.7 and 50.5%, respectively [8]; whereas the EO of an Estonian M. chamomilla sample
was characterized by high bisabolone oxide A content (13.9%) [2]. This compound was the major EO
constituent of M. chamomilla grown in Italy (9.2–11.2%) [26], Iran (53.45%) [27], India (20.4 and 8.9%) [28]
and Turkey (47.7%) [7]. The evaluation of the daily α-bisabolol oxide A content in M. chamomilla EO
revealed that the highest amount can be between 16:00–18:00 (55.41%) [29]. Moreover, this aromatic
phytoconstituent was isolated with three extraction methods (7.9, 42.3 and 50.5%) in EO of the species [9].
It is noteworthy, that the sample “Sarableh” (with the highest altitude and least minimum and
maximum annual temperatures) as a new chemotype was the richest in two geometric isomers of
γ-bisabolene (82.84%), whilst these sesquiterpenes were not markedly detected in the other plant
populations. This population also demonstrated the most potent antiradical capacity compared with
those samples.
γ-Bisabolene was previously specified as the major characteristic constituent of Pimpinella pruatjan
Molk. [30]. EO of Ocimum africanum Lour. was also rich in (E)-γ-bisabolene (2.6–9.5%) [31]. This
sesquiterpene was isolated from seeds of Ziziphus jujuba var. inermis. [32]. The main EO compounds of
M. chamomilla harvested in Iran were identified as α-bisabolol (7.27%), (Z,Z)-farnesol (39.70–66.00%) [33],
(E)-β-farnesene (24.19%) [34] and α-bisabolol oxide A (17.14%) [35]. EOs containing remarkable
amounts of γ-bisabolene exhibited anti-inflammatory properties and anti-proliferative activities in
human prostate cancer, glioblastoma, lung carcinoma, breast carcinoma, colon adenocarcinoma and
human oral squamous cell lines [36–39].
According to the results, the abundance of luteolin was much higher than the apigenin content.
The lack of luteolin and apigenin as the selected flavones was reported in populations “MS” and “Mo”.
These samples are most probably rich in other phenolic natural products.
The total phenolic and flavonoid contents of a M. chamomilla extract were 37.51 and 21.72 mg/g of
dry weight, respectively; this report was formerly accomplished by using HPLC-DAD [40]. Moreover,
chlorogenic acid, apigenin-7-glucoside, rutin, cynaroside, luteolin, apigenin and apigenin-7-glucoside
derivatives were previously qualified as the significant phytochemical composition of M. chamomilla
extract [23].
As apigenin and luteolin were present in “Sarableh” in low concentrations, the high free radical
scavenging capacity of this sample is obviously related to other polyphenolic compounds.
In a similar study, methanol extracts of M. chamomilla yielded from different samples indicated
more potent antiradical activity than EOs analysed by the DPPH test, due to polyphenols present in
extracts; although, they possessed a moderate effect in comparison with the standards [6].
Furthermore, in vitro antioxidant activities of M. chamomilla extracts, along with its apigenin
and apigenin-7-glycoside contents were previously characterized, with IC50 of 18.19 ± 0.96 µg/mL,
2.0 ± 0.1 mg/g and 20.1 ± 0.9 mg/g, respectively [41], confirming the primary importance of apigenin
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in the antioxidant capacity of M. chamomilla. Moreover, free radical scavenging activity (DPPH assay)
of M. chamomilla volatile oil and its major components were formerly recorded in the following order:
chamazulene > α-bisabolol oxide A > chamomile EO > (E)-β-farnesene > α-bisabolol [7].
4. Materials and Methods
4.1. Plant Material
M. chamomilla flowers (300 g/sample) were individually collected from different regions of Iran in
the flowering period, in spring (April) 2017. The harvested populations “Izeh”, “Bagh Malek”, “Lali”,
“Masjed Soleyman”, “Mollasani”, “Gotvand” and “Saleh Shahr” from Khuzestan and “Murmuri”,
“Abdanan”, “Darreh Shahr” and “Sarableh” from Ilam province were compared with “Bodgold”,
which was cultivated at the botanical garden of Department of Horticultural Sciences, Shahid Chamran
University of Ahvaz, Ahvaz, Iran.
The plants were identified by Dr. Mehrangiz Chehrazi affiliated with the same department, and a
voucher specimen of each sample was deposited in the herbarium of the department. The voucher’s
codes and geographic coordinates including the latitude, longitude, altitude using the Global Positioning
System (GPS), along with mean annual temperatures of the studied populations are given in Table 3.
The meteorological data (MAP, MAT, MMaxAT, and MMinAT) were collected from September until May
2017 [24]. The flowers were shade dried and finely ground. Each powdered sample was individually
well-mixed and subjected to analysis.
4.2. Chemicals and Spectrophotometric Measurements
Analytical grade 1,1-diphenyl-2-picrylhydrazyl (DPPH), 2,2′-azobis-2-methylpropionamidine
dihydrochloride (AAPH) and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox®)
(Sigma-Aldrich, Steinheim, Germany), fluorescein (Fluka Analytical, Buchs, Germany); ascorbic acid,
rutin and Na2SO4 (Merck, Darmstadt, Germany); epigallocatechin gallate (EGCG), apigenin (≥99%)
and luteolin (≥97%) (Sigma-Aldrich, Germany) were purchased. Furthermore, all solvents of analytical
grade were provided by the Merck company (Germany). Spectrophotometric measurements were
carried out by a UV-VIS spectrophotometer (FLUOstar Optima, BMG Labtech, Ortenberg, Germany).
4.3. Extraction of Volatile Oils
To extract the EOs, 60 g of each powdered sample was individually subjected to Clevenger apparatus
(hydro-distillation method) for 3 h. The obtained EOs were dried over anhydrous sodium sulphate and
stored in refrigerator at 4 ◦C until analysis. Yields of extracted EOs were calculated by Equation (1):
EO% = (EOs weight)/(dried plants weight) × 100 (1)
Diethyl ether was used to elute the whole amount of EOs from the apparatus, and the weighing
process was performed after evaporating the solvent.
4.4. Gas Chromatographic Analysis (GC-FID)
In the case of GC-FID analysis, the EOs were analyzed by Shimadzu GC-17A (Kyoto, Japan)
equipped with an FID detector and SGE™ BP5 capillary column (Trajan Scientific and Medical, Victoria,
Australia) (30 m × 0.25 mm column with a 0.25 µm film thickness). The split mode in GC was a ratio
of 1:100. Injector and FID detector temperatures were set at 280 and 300 ◦C, respectively. The oven
temperature was kept at 60 ◦C for 1 min and then raised to 250 ◦C at 5.0 ◦C/min and held for 2 min,
while the ambient oven temperature range was +4 to +450 ◦C. Helium gas was used at a flow rate of
1 mL/min as a carrier gas.
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Table 3. Geographic locations and climatic conditions of the studied Matricaria chamomilla populations from Iran.
Population Name Voucher’s Code Abbreviated Name Altitude (m) Latitude Longitude MAP (mm/year) MAT (◦C) MMaxAT (◦C) MMinAT (◦C)
Bodold (Ahvaz) KHAU_236 B 16 31◦18′ N 48◦39′ E 98.20 22.62 35.77 9.47
Izeh KHAU_237 I 428 31◦57′ N 48◦49′ E 472.80 18.35 31.28 5.42
Bagh Malek KHAU_238 BM 907 31◦19′ N 50◦05′ E 285.90 20.28 32.17 8.4
Lali KHAU_239 L 373 32◦20′ N 49◦05′ E 280.60 21.26 33.57 8.95
Masjed Soleyman KHAU_240 MS 250 32◦02′ N 49◦11′ E 241.30 22.67 34.27 11.07
Mollasani KHAU_241 Mo 51 31◦39′ N 48◦57′ E 100.80 22.26 36.35 8.17
Gotvand KHAU_242 G 70 32◦14′ N 48◦48′ E 159.70 21.08 34.96 7.21
Saleh Shahr KHAU_243 SS 65 32◦04′ N 48◦40′ E 164.30 20.69 34.07 7.32
Murmuri KHAU_244 Mu 530 32◦46′ N 47◦37′ E 213.90 23.35 35.17 11.53
Abdanan KHAU_245 A 740 32◦55′ N 47◦31′ E 363.60 19.62 30.44 8.8
Darreh Shahr KHAU_246 DS 629 33◦05′ N 47◦28′ E 463.00 17.85 30.9 4.8
Sarableh KHAU_247 S 1037 33◦47′ N 46◦35′ E 345.80 15.01 27.31 2.71
MAP: mean annual precipitation; MAT: mean annual temperature; MMaxAT: mean maximum anuual temperature; MMinAT: mean minimum anuual temperature.
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4.5. Gas Chromatography-Mass Spectrometric (GC-MS) Analysis
Analysis of the samples was carried out using an Agilent 7890B gas chromatograph (Agilent
Technologies, Inc., Santa Clara, CA, USA) equipped with a 5977B mass spectrometry detector. The GC
instrument was equipped with a split inlet, working in a split ratio of 100:1 mode with a 30 m × 0.25 mm
HP-5MS capillary column with a 0.25 µm film thickness and 0.25 µm particle size (temperature range:
−60 to +320/340 ◦C). The injection port temperature was 250 ◦C. The oven temperature was kept at
60 ◦C for 1 min and then programmed from 60 ◦C to 250 ◦C at 5 ◦C/min; then, the temperature was
kept at 250 ◦C for 2 min. Helium (99.999%) was used as a carrier gas with a flow rate of 1 mL/min and
inlet pressure 35.3 kPa. The mass spectrometer was operated in the electron impact mode at 70 eV, and
the inert ion source (HES EI) temperature was set to 350 ◦C; the temperature of the quadrupole was set
at 150 ◦C, while the MS interface was set to 250 ◦C. A scan rate of 0.6 s (cycle time: 0.2 s) was applied,
covering a mass range from 35 to 600 amu.
4.6. Identification of Essential Oil Components
Most of the compounds were identified using two different analytical approaches: (a) comparison
of Kovats indices of n-alkanes (C8–C24) [42] and (b) comparison of mass spectra (using authentic
chemicals and Wiley spectral library collection). Identification was considered tentative when based
on mass spectral data alone. In GC-FID and GC-MS, data acquisition and analysis were performed
using Chrom-cardTM (Scientific Analytical Solutions, Zurich, Switzerland, version DS) and XcaliburTM
software (Thermo Fisher Scientific, Waltham, MA, USA, 4.0 Quick Start), respectively.
4.7. Preparation of Solvent Extracts
Five g of each sample was individually extracted with MeOH (3 × 75 mL) in an ultrasonic bath
(VWR-USC300D) for 10 min, at 40 ◦C under power grade 9.
After removing the solvent under reduced pressure at 50 ◦C (Rotavapor R-114, Büchi), the
concentrated extracts were subjected to evaluate the antiradical assays and HPLC analysis.
4.8. HPLC Analysis of Apigenin And Luteolin
Twenty µL of each extract (1 mg/mL) was separately injected into an analytical high-performance
liquid chromatography system (HPLC) (Knauer, Berlin, Germany) by using an end capped Eurospher II
100-5 C18, Vertex Plus Column (Knauer, Berlin, Germany) (250 × 4.6 mm with precolumn) with particle
size: 5 µm, pore size: 100 Å and temperature 30 ◦C; coupled to UV detector (Knauer GmbH-Smartline
2600, Berlin, Germany) at a wavelength range 190 to 500 nm (quantification at 330 nm), while
MeOH/H2O was applied as the mobile phase with a gradient system, increasing MeOH from 30% to
70% within 40 min, with a flow rate of 1 mL/min, at ambient temperature. Analysis was performed
using SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA).
4.9. Antiradical Capacity
4.9.1. DPPH Assay
Free radical scavenging activity of the plant extracts was assessed by DPPH assay [43].
The measurement was carried out on 96-well microtiter plates. In brief, Microdilution series of samples
(1 mg/mL, dissolved in MeOH) were prepared starting with 150 µL. To gain 200 µL of sample, 50 µL
of DPPH reagent (100 µM) was added to each sample. The microplate was stored at room temperature
under dark conditions. The absorbance was measured after 30 min at 550 nm using the microplate
reader. MeOH (HPLC grade) and ascorbic acid (0.01 mg/mL) were used as a blank control and
standard, respectively. Antiradical activity was calculated using the following Equation (2):
I% = [(A0 − A1/A0) × 100] (2)
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where A0 is the absorbance of the control and A1 is the absorbance of the standard sample. Anti-radical
activity of the samples was expressed as EC50 (concentration of the compounds that caused 50%
inhibition). EC50 (µg/mL) values were calculated using GraphPad Prism software version 6.05
(GraphPad Software, San Diego, CA, USA). Each sample was measured in triplicate.
4.9.2. ORAC Assay
Twelve extracts were subjected to ORAC assay [44] with slight modifications. Microtiter plates
(96-well) were used for measurement of the samples. Briefly, 20 µL of extracts (0.01 mg/mL) was
mixed with 60 µL of AAPH (peroxyl free radical generator) (12 mM) and 120 µL of fluorescein solution
(70 mM). Then, the fluorescence was measured for 3 h at 1.5-min cycle intervals with the microplate
reader. The standard Trolox® was used. Activity of all samples was compared with rutin and EGCG
as positive controls. Antioxidant capacities were reported as µmol TE (Trolox® equivalents)/g of
dry matter.
4.10. Statistical Analysis
All the experiments were done in triplicate, and the results are expressed as means± SD. The data
were assessed with one-way analysis of variance (ANOVA) using SAS software (version 9.2, SAS
Institute Inc., Cary, NC, USA) and GraphPad Prism version 6.05. The means were compared using
Duncan’s comparisons test (p < 0.05).
5. Conclusions
According to our preliminary study, the chemo-diversity and antiradical potential of twelve
studied Matricaria chamomilla populations were highly affected by a variety of ecological conditions.
To acquire the best yield with a good profile of active principles, it is crucial to combine a good
genotype with optimal environmental circumstances.
In accordance with our findings, oxygenated sesquiterpenes are the most dominant EO compounds
of the selected Matricaria chamomilla samples. Almost all plant populations contained apigenin and
luteolin. Since the plant sample “Sarableh” indicated the most potent capacity to scavenge free radicals
and its apigenin and luteolin contents were insignificant, its activity undoubtedly refers to the presence
of other polyphenolic compounds. Due to high amounts of apigenin and luteolin, populations “Lali”
and “Bagh Malek” can be considered as a rich source of these compounds. Our results confirm the effects
of growth conditions on the quantity and quality of aromatic phytochemicals. More investigations
are required to study the amounts of other polyphenolic compounds in diverse populations and the
correlations between secondary metabolite contents, bioactivities and ecological effects.
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a  b  s  t  r  a  c  t
Saffron  crocus  (Crocus  sativus  L.)  has  been  widely  grown  in  Iran.  Its stigma  is  considered  as  the most
valuable  spice  for which  several  pharmacological  activities  have  been  reported  in preclinical  and  clinical
studies,  the  antidepressant  effect  being  the  most  thoroughly  studied  and  confirmed.  This  plant  part
contains  several  characteristic  secondary  metabolites,  including  the  carotenoids  crocetin  and  crocin,  and
the  monoterpenoid  glucoside  picrocrocin,  and  safranal.  Since  only  the  stigma  is  utilized  industrially,  huge
amount  of saffron  crocus  by-product  remains  unused.  Recently,  the number  of  papers  dealing  with  the
chemical  and  pharmacological  analysis  of  saffron  is increasing;  however,  there  are  no  systematic  studies
on the chemical  variability  of  the  major  by-products.
In  the present  study,  we  harvested  saffron  crocus  flowers  from  40 different  locations  of  Iran.  The
tepals  and  stamens  were  separated  and  subjected  to  qualitative  and  quantitative  analysis  by HPLC-
DAD.  The  presence  and  amount  of seven  marker  compounds,  including  crocin,  crocetin,  picrocrocin,
safranal,  kaempferol-3-O-sophoroside,  kaempferol-3-O-glucoside, and  quercetin-3-O-sophoroside  were
determined.
The  analytical  method  was  validated  for filter  compatibility,  stability,  suitability,  accuracy,  precision,
intermediate  precision,  and  repeatability.  Tepal  and  stamen  samples  contained  three  flavonol  glycosides.
The main  constituent  of the  tepals  was  kaempferol-3-O-sophoroside  (62.19–99.48  mg/g).  In the stamen,
the  amount  of  flavonoids  was  lower  than  in  the  tepal.  The  amount  of  kaempferol-3-O-glucoside, as  the
most abundant  compound,  ranged  between  1.72–7.44  mg/g.  Crocin,  crocetin,  picrocrocin,  and  safranal
were  not detected  in  any  of the  analysed  samples.
Our  results  point  out  that saffron  crocus  by-products,  particularly  tepals  might  be  considered  as  rich
sources  of  flavonol  glucosides.  The  data  presented  here  can  be useful  in  setting  quality  standards  for  plant
parts of  C.  sativus  that  are  currently  considered  as  by-products  of  saffron  production.
©  2020  The  Author.  Published  by  Elsevier  B.V. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Saffron crocus (Crocus sativus L., Iridaceae) is cultivated in some
sian and European countries, in highest extent in Iran. The stigma
f this plant (known as saffron) is a popular spice and has also
een applied in the traditional Arabic and Islamic medicine for
everal purposes, especially as cardiac and liver tonic and hep-
∗ Corresponding author.
E-mail address: csupor.dezso@pharmacognosy.hu (D. Csupor).
ttps://doi.org/10.1016/j.jpba.2020.113183
731-7085/© 2020 The Author. Published by Elsevier B.V. This is an open access article un
.license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
atic deobstruent, to facilitate difficult labour and for the treatment
of female genito-urinary disorders and male impotence. Its effects
on the central nervous system have also been recorded; however,
old texts have to be reinterpreted according to the current concep-
tions of medicine and pharmacology. According to Sayyed Esma’il
Jorjani (1042–1136 A.D.) s¨affron is astringent and resolvent and
its fragrance can strengthen these two  effects. Hence, its action
on enlivening the essence of the spirit and inducing happiness is
great.T¨his supposed activity might be translated as a positive effect
on mood or as an antidepressant effect [1].
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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There is an overlap between the traditional uses and the
vidence-based applications of saffron. The clinical efficacy of
affron has been studied in diabetes [2], age-related macular
egeneration [3,4], cognitive impairment [5–8], glaucoma [9], sex-
al dysfunction in women [10] and men  [11], and premenstrual
yndrome [12]. However, most of the studies assessed its antide-
ressant activity and the efficacy in mild to moderate depression
as been confirmed by a recent meta-analysis as well [13].
Crocin, crocetin, picrocrocin and safranal are the main charac-
eristic compounds of saffron stigma. The colour of saffron is due
o the carotenoids crocin and crocetin, the specific bitterish taste
s attributed to the monoterpene glycoside picrocrocin, whereas
afranal, an aromatic aldehyde of the volatile oil contributes to the
roma [1].
Saffron is known as the most expensive spice in the world,
00 000 flowers are approximately required to obtain 1 kg of dried
tigma [14]. Considering its price and the increasing scientific
nterest for the bioactivities of saffron, the analysis of alternative
lant parts (the industrial by-products tepal and stamen), that
re available in larger amounts and hence are cheaper, seems to
e promising approach. Several papers have reported the con-
tituents of major saffron crocus by-products. It has to be noted,
hat several papers report the chemical composition of sepal and
etal samples, however, botanically these plant parts should be
efined as tepal. Therefore, in case of previous papers we refer
o the plant parts used by the authors. The petals of the plant
ere characterized by a high total phenolic and flavonoid content
ompared to stamens and styles [14,15]. Both sepals and sta-
ens of samples from different regions of Italy were characterized
ith kaempferol-3-O-sophoroside as main flavonoid constituent
16]. From the flower material of saffron crocus (except stigma)
aempferol-3-O-sophoroside was isolated as the major compo-
ent [17]. Beside flavonols, anthocyanins are also present in the
oral bioresidues of saffron crocus as major constituents, delphini-
in 3,5-di-O-glucoside being the predominant compound [18].
rom a methanolic extract of tepals, kaempferol glycosides com-
rising kaempferol 3-O-sophoroside, kaempferol 3-glucoside, and
aempferol 3-O--D-(2-O--D-6-acetylglucosyl)glucopyranoside-
-O--D-glucopyranoside were isolated as the major compounds
19]. Kaempferol 3-O-sophoroside was identified as main compo-
ent by utilizing HR-MAS NMR  spectroscopy as well [20]. Other
tudies have also reported flavonoids from tepals. Kaempferol-
-O-sophoroside, kaempferol-3-O-glucoside, and quercetin-3-O-
ophoroside were reported in these studies [21,22].
The antidepressant activities of tepals have been studied in ani-
al  experiments. Both the aqueous and ethanolic extracts of stigma
nd tepal decreased immobility time in comparison with normal
aline in the forced swimming test in mice [23]. Kaempferol, a
avonoid of the tepals was reported to have antidepressant activity
n mice and rats in the same test [24].
The efficacy of tepals has been confirmed in two clinical trials. In
 randomized, double-blind trial, 40 patients with mild to moderate
epression were treated either with 30 mg  saffron crocus tepal or
0 mg fluoxetine for 8 weeks. The herbal preparation was similarly
ffective as fluoxetine with remission rates of 25 % in both groups
25]. In a similar trial with 40 patients, the efficacy of the tepals
30 mg)  was compared to placebo. After 6 weeks of treatment, the
epal was more effective than placebo in improving the severity of
epression using the Hamilton Depression Rating Scale [26].
Considering the increasing scientific and industrial interest
or saffron crocus by-products, the aim of our study was to
ystematically analyse the composition of tepal and stamen
amples. We  developed and validated an HPLC/DAD method
or the analysis of seven marker compounds previously iden-
ified as the major constituents of saffron crocus stigma,
epal and stamen. Crocin, crocetin, picrocrocin, safranal and Pharmaceutical and Biomedical Analysis 184 (2020) 113183
flavonoids [kaempferol-3-O-sophoroside (K.S.), kaempferol-3-O-
glucoside (K.G.), quercetin-3-O-sophoroside (Q.S.)] were assessed
qualitatively and quantitatively in 40 tepal and stamen samples
collected from different regions of Iran.
2. Materials and methods
2.1. Plant materials
Saffron crocus (Crocus sativus L.) tepal and stamen samples were
collected from 40 different locations of Iran at the same harvest-
ing period in November 2018. All were dried under shade, then
the tepals were accurately separated from stamens. The plant sam-
ples were individually packed in the sealed plastic bags and stored
at room temperature. The growth locations, altitudes, and coor-
dinates of the harvested plant materials are shown in Table 1. For
comparison, a commercial saffron stigma sample was also analyzed
(Bahraman Co., Mashhad, Iran).
2.2. Chemicals and reagents
All solvents were of analytical grade. Kaempferol-3-O-glucoside
(K.G.) (Santa Cruz Biotech. California, USA), quercetin-3-O-
sophoroside (Q.S.), crocetin (trans-crocetin, 98 %), and picrocrocin
(Carbosynth, Berkshire, UK), safranal, and crocin (crocetin digentio-
biose ester, Sigma-Aldrich, St. Louis, Missouri, USA) were purchased
in analytical grade. Kaempferol-3-O-sophoroside (K.S.) was  iso-
lated in our laboratory, its structure and purity was determined
by NMR.
2.3. Extract preparation
20 mg  of tepal, 10 mg  of stigma, and 50 mg  of stamen samples
were extracted with the solvent mixture EtOH-H2O 1:1, using an
ultrasonic bath for 15 min, then diluted with the above solvents
to 10.0 mL  (tepal) and 5.0 mL  (stigma and stamen) in volumetric
flasks, respectively.
In case of filtered samples, the extracts were filtered via a filter
membrane (PTFE-L syringe filter, hydrophilic, FilterBio®, diameter:
13 mm,  pore size: 0.45 m),  the first 1 mL  was unused, and the rest
1.5 mL  was  analysed by HPLC-DAD. In case of centrifuged samples,
centrifugation was performed by using DLAB D1008 instrument
(7000 rpm) for 1 min. For all samples, three extracts were prepared
and analysed in triplicate.
2.4. HPLC apparatus and measurement conditions
HPLC-DAD analysis was  carried out on a Shimadzu SPD-M20A
HPLC (Shimadzu Corporation, Kyoto, Japan), equipped with a Shi-
madzu SPD-M20A photodiode array detector, an on-line degasser
unit (Shimadzu DGU-20A5R), a column oven (Shimadzu CTO-20AC
column oven) and autosampler (Shimadzu SIL-20ACHT) using a
RP Kinetex® C8 column (5 m,  100 Å, 150 × 4.6 mm,  Phenomenex,
Torrance, USA) at 30 ◦C. Chromatographic elution of the samples
was accomplished with a gradient solvent system by changing the
ratio of MeOH in H2O (containing 0.066 % of H3PO4) as follows:
30 % (0−1  min), 30–57% (1−7  min), 57–76% (7−12 min), 76–100%
(12−13 min), keeping at 100 % for 1 min, 100 to 30 % (14−15 min)
and keeping at 30 % for 3 min  at a flow rate of 1.5 mL/min. The sam-
ples were monitored in the UV-VIS range (190–800 nm) and at the
UVmax of the standards (picrocrocin: 247 nm,  Q.S.: 360 nm,  K.S.:
354 nm,  K.G.: 348 nm,  crocin: 441 nm,  safranal: 316 nm,  and cro-
cetin: 427 nm). Data assessment and acquisition were performed
with the LabSolutions (Version 5.82) software (Shimadzu, Kyoto,
J. Mottaghipisheh, M. Mahmoodi Sourestani, T. Kiss et al. / Journal of Pharmaceutical and Biomedical Analysis 184 (2020) 113183 3
Table  1
Provenances of saffron samples.
Code Location Altitude (m)  Latitude Longitude
1T, 1S Dehouye, Meshkan, Neyriz, Fars 1567 29◦ 15’ N 53◦ 56’ E
2T,  2S Dehouye, Meshkan, Neyriz, Fars 1567 29◦ 15’ N 53◦ 56’ E
3T,  3S Dehouye, Meshkan, Neyriz, Fars 1567 29◦ 15’ N 53◦ 56’ E
4T,  4S Dehouye, Meshkan, Neyriz, Fars 1567 29◦ 15’ N 53◦ 56’ E
5T,  5S Dehouye, Meshkan, Neyriz, Fars 1567 29◦ 15’ N 53◦ 56’ E
6T,  6S Meshkan, Neyriz, Fars 2167 29◦ 28’ N 54◦ 20’ E
7T,  7S Meshkan, Neyriz, Fars 2167 29◦ 28’ N 54◦ 20’ E
8T,  8S Meshkan, Neyriz, Fars 2167 29◦ 28’ N 54◦ 20’ E
9T,  9S Meshkan, Neyriz, Fars 2167 29◦ 28’ N 54◦ 20’ E
10  T, 10S Meshkan, Neyriz, Fars 2167 29◦ 28’ N 54◦ 20’ E
11  T, 11S Meshkan, Neyriz, Fars 2167 29◦ 28’ N 54◦ 20’ E
12  T, 12S Meshkan, Neyriz, Fars 2167 29◦ 28’ N 54◦ 20’ E
13  T, 13S Meshkan, Neyriz, Fars 2167 29◦ 28’ N 54◦ 20’ E
14T,  14S Meshkan, Neyriz, Fars 2167 29◦ 28’ N 54◦ 20’ E
15T,  15S Meshkan, Neyriz, Fars 2167 29◦ 28’ N 54◦ 20’ E
16T,  16S Dehchah, Neyriz, Fars 2188 29◦ 13’ N 54◦ 26’ E
17T,  17S Dehchah, Neyriz, Fars 2188 29◦ 13’ N 54◦ 26’ E
18  T, 18S Dehchah, Neyriz, Fars 2188 29◦ 13’ N 54◦ 26’ E
19T,  19S Dehchah, Neyriz, Fars 2188 29◦ 13’ N 54◦ 26’ E
20T,  20S Dehchah, Neyriz, Fars 2188 29◦ 13’ N 54◦ 26’ E
21  T, 21S Abadeh Tashk, Neyriz, Fars 1608 29◦ 48’ N 53◦ 43’ E
22  T, 22S Abadeh Tashk, Neyriz, Fars 1608 29◦ 48’ N 53◦ 43’ E
23  T, 23S Neyriz, Fars 1606 29◦ 11’ N 54◦ 19’ E
24  T, 24S MahmoudAbad, Neyriz, Fars 1579 29◦ 14’ N 54◦ 17’ E
25  T, 25S MahmoudAbad, Neyriz, Fars 1579 29◦ 14’ N 54◦ 17’ E
26  T, 26S MahmoudAbad, Neyriz, Fars 1579 29◦ 14’ N 54◦ 17’ E
27  T, 27S Roniz, Estahban, Fars 1593 29◦ 11’ N 53◦ 46’ E
28  T, 28S Roniz, Estahban, Fars 1593 29◦ 11’ N 53◦ 46’ E
29  T, 29S HasanAbad, Neyriz, Fars 1579 29◦ 44’ N 53◦ 54’ E
30  T, 30S Estahban, Fars 1797 29◦ 7’ N 54◦ 2’ E
31  T, 31S Estahban, Fars 1797 29◦ 7’ N 54◦ 2’ E
32  T, 32S Estahban, Fars 1797 29◦ 7’ N 54◦ 2’ E
33  T, 33S Estahban, Fars 1797 29◦ 7’ N 54◦ 2’ E
34  T, 34S Estahban, Fars 1797 29◦ 7’ N 54◦ 2’ E
35  T, 35S Estahban, Fars 1797 29◦ 7’ N 54◦ 2’ E
36  T, 36S Estahban, Fars 1797 29◦ 7’ N 54◦ 2’ E
37  T, 37S Ghaen, Khorasan e Jonoubi 1445 33◦ 43’ N 59◦ 11’ E
38  T, 38S Torbatejam, Khorasan e Razavi 894 35◦ 14’ N 60◦ 37’ E
39  T, 39S Dehdez, Khoozestan 1439 31◦ 42’ N 50◦ 17’ E
T
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apan). 10 and 20 L of tepal and stamen extracts were injected,
espectively.
.5. System validation
Validation of our analytical method was carried out according
o the ICH Harmonised Guideline [27] and completed with further
xperiments. Validation was performed by establishing the calibra-
ion curves of seven reference compounds, determining the limit
f detection and quantification values, assessing system suitability,
ccuracy, precision, repeatability, stability and filter compatibility
f the extracts or pure compounds.
. Results and discussion
.1. Validation
Our goal was to develop and validate an analytical method that
s suitable for the analysis of saffron stigma samples and saffron cro-
us by-products. Marker compounds that were used as reference
tandards during our experiments were chosen based on literature
ata as follows: crocin, crocetin, picrocrocin, safranal, K.S., K.G., and
.S. During validation, tepal samples and the mixture of the refer-
nce compounds were used, and where it was possible, validation
as carried out for all the analytes. However, since saffron cro-
us tepal did not contain crocin, crocetin, picrocrocin, and safranal,
alidation was  partial for these compounds.1439 31◦ 42’ N 50◦ 17’ E
3.1.1. Calibration curve and linearity
Seven major components of saffron crocus, K.S., K.G., Q.S., cro-
cetin, picrocrocin, safranal, and crocin were used to establish
calibration curves and limit of detection (LoD) and limit of quan-
titation (LoQ) values (Table 2). Calibration curves are based on
8–11 calibration points. The correlation coefficient of the calibra-
tion curves was  at least 0.998. Calibration curves covered 2 orders
of magnitude of analyte concentration.
3.1.2. Filter compatibility
To select the best method for sample preparation, one tepal
specimen was extracted by ultrasonic bath, then filtered or cen-
trifuged. Except for crocetin, sample preparation by filtration or
centrifugation had no major impact on quantitative results; how-
ever, in case of this compound, the amount of the analyte decreased
with 17.3 % as the result of filtration. For the other analytes, slight
higher values were measured in filtered samples (picrocrocin:
100.86 ± 0.35 %; Q.S.: 101.14 ± 0.31 %; K.S.: 100.89 ± 0.29 %; K.G.:
100.20 ± 1.4 %; crocin: 101.21 ± 0.38 %; safranal: 100.27 ± 1.37 %).
3.1.3. Stability
To evaluate the stability of the solutions of reference com-
pounds, the standard mixtures were prepared by filtration or
centrifugation, stored at 4 ◦C and room temperature (23 ◦C), then
injected at day 0, 1, 3, 5, and 7 (Table 3). In case of picrocrocin
and the flavonoids, storage time and temperature did not affect
the concentration of the analytes, whereas in case of crocin and
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Table 2
Calibration curve characteristics and limit of detection and quantification values.
Standard LoD (g/inj) LoQ (g/inj) Calibration points Range covered (g/inj) Regression equations R2
Picrocrocin 0.00245 0.00741 8 0.03-0.9 y = (1.10320 × 109)x -10690.0 0.9997394
Q.S.  0.02554 0.07739 10 0.082-6.15 y = (6.55841 × 108)x -5275.02 0.9996089
K.S.  0.02277 0.06901 9 0.076-3.04 y = (5.96019 × 108)x -20062.4 0.9996702
K.G.  0.06763 0.20495 9 0.1075-4.3 y = (1.36039 × 108)x -4682.70 0.9984738
Crocin 0.00128 0.00386 10 0.0145-0.58 y = (2.92163 × 109)x -13570.0 0.9994265
Safranal 0.00177 0.00536 8 0.08-2.4 y = (2.06147 × 109)x +37991.1 0.9982921
Crocetin 0.00032 0.00097 11 0.00172-0.129 y = (9.35271 × 109)x -5778.24 0.9999475
Table 3
Stability of the dissolved reference compounds after 1, 3, 5 and 7 days (values compared to 100 % day 0 values).
Sample Days Picrocrocin Q.S. K.S. K.G. Crocin Safranal Crocetin
23 ◦C
1 100.97 101.08 100.92 101.77 101.18 99.84 86.28
3  104.06 100.59 100.69 101.80 95.93 87.89 76.71
5  100.37 99.97 100.53 102.74 91.29 85.89 76.47
7  100.59 99.70 101.12 105.00 90.65 83.71 78.94
4
◦C
1 100.51 100.66 100.56 101.05 100.84 100.29 86.52
3  104.09 100.66 100.56 101.82 100.57 99.74 85.92
5  100.69 100.41 100.67 102.30 100.30 96.44 84.48
7  100.77 100.89 101.27 104.98 100.50 94.64 85.44
Table 4
Results of the system suitability tests.
Picrocrocin Q.S. K.S. K.G. Crocin Safranal Crocetin
RSD% of AUC 0.47 0.18 0.43 2.53 0.38 0.41 1.11
Tailing factor 1.139–1.145 1.043–1.067 1.113–1.127 1.356–1.408 1.177–1.910 1.171–1.184 1.310–1.334
RSD% of RT 0.66 0.62 0.36 0.22 0.19 0.14 0.10
RT: retention time.
Table 5
Recovery values (%) of the controls.
Level Picrocrocin (stigma) Q.S. K.S. K.G. Crocin (stigma) Safranal (stigma) Crocetin (stigma)
% RSD% % RSD% % RSD% % RSD% % RSD% % RSD% % RSD%
96,
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a50 % 111.92 0.27 106.54 0.12 100.95 0.29 
100  % 101.80 0.07 112.25 0.10 99.60 0.06 
150  % 110.32 1.32 116.26 0.30 101.54 0.12 
afranal, decomposition was observed especially at room tem-
erature. Interestingly, the concentration of crocetin decreased
emarkably after one day, and the temperature had no major influ-
nce on this process.
.1.4. System suitability
The mixture of the reference standards was injected 5 times
o assess suitability of the analytical system. The low RSD% values
f the AUCs and retention times, together with the tailing factors
elow confirm that the system is suitable for the measurement of
hese compounds (Table 4).
.1.5. Accuracy
The accuracy of the method was assessed by the determination
f recoveries (Table 5). Recoveries of the marker compounds was
ssessed by adding known amounts of the standards to a tepal (or in
ase of crocin, picrocrocin, crocetin, and safranal: stigma) sample at
hree different concentrations (50, 100, and 150 % of the previously
etermined amounts). Three independent samples were prepared
or each concentration levels and injected in triplicates. The recov-
ry values ranged between 96.09–111.92 %, 83.69–112.25 %, and
9.40–116.26 % in case of 50 %, 100 %, and 150 % amounts of added
nalytes, respectively.09 0.62 – – – – 99.54 1.33
,36 2.03 97.89 0.27 – – 83.69 1.73
57 2.77 108.10 0.06 – – 89.40 0.42
3.1.6. Precision
In order to determine the precision of the analytical method,
one tepal and one stigma sample was  extracted individually and
injected 10 times. Precision was  determined by calculating RSD%
values of the AUCs (Table 6). The RSD% values below 1% confirm
the precision of the method.
3.1.7. Repeatability
The repeatability of the experiment was performed by analy-
sis of six tepal sample extracts within 24 h (intra-assay precision).
Repeatability was characterized by RSD% values of the whole
datasets for Q.S., K.S., and K.G., RSD% values were 3.38 %, 3.71 %
and 3.44 %, respectively.
3.1.8. Intermediate precision
The same tepal sample was analysed by two analysts and inter-
mediate precision was determined as RSD% of the means. For Q.S.,
K.S., and K.G. the RSD% values were 3.81 %, 2.29 %, and 6.85 %,
respectively.
3.2. HPLC/DAD analysis of tepal and stamen samplesHPLC/DAD analysis of 40 different tepal and stamen samples
was carried out to qualitatively and quantitatively analyse their
selected marker compounds. Our newly developed HPLC method
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Table  6
Precision of the analytical method as determined by RSD%.
Samples Picrocrocin Q.S. K.S. K.G. Crocin Crocetin
Tepal – 1.72 0.07 0.53 – –
Stigma 1.86 0.30 2.26 2.68 0,58 1.86
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tFig. 1. HPLC chromatogram of the mixture of refer
llowed good separation and hence reliable analysis of these com-
ounds in saffron crocus samples (Fig. 1).
In stamen and tepal samples, three flavonols glycosides, namely
.S., K.S., and K.G. were detected as major components. For com-
arison, we analysed a saffron stigma sample as well. From this
ample picrocrocin, crocin, and crocetin were identified, which
s in line with the previous data. There is only one report on
he presence of crocin in saffron crocus tepal; however, very low
mount (0.6 %) was reported in the hydrolysed extracts compared
o kaempferol (12.6 %) [28]. A comparative study of the stamen
nd stigma revealed that crocin, picrocrocin, and safranal are not
resent in stamen, whilst they are major components of the stigma
29].
In Table 7, the amounts of marker compounds in tepal and
tamen samples are presented as means (mg/g plant material)
ogether with the standard deviation values. The tepal samples con-
ained Q.S., K.S. and K.G., in the ranges of 6.20–10.82, 62.19–99.48,
nd 27.38–45.17 mg/g, respectively, whereas the amount of these
ompounds was lower in the stamen (1.72–6.07, 0.89–6.62 and
.72–7.44 mg/g, respectively). K.S., as the major constituent of saf-
ron crocus tepal was present in the highest amount in sample
 with an amount of 99.48 mg/g. Tepal sample 23 contained the
ighest amount of Q.S. (10.82 mg/g), while tepal sample 5 con-
ained the lowest amounts of Q.S. and K.S. with 6.21 and 62.19 mg/g,
espectively. The content of K.G. in tepal samples was remark-
bly different from 27.74 to 45.18 mg/g analysed in samples 40
nd 1, respectively. In general, the stamen samples contained less
avonoids than the tepals. The highest amount of Q.S. in stamens
as observed in sample 29 with 6.08 mg/g, whilst sample 3 con-
ained the lowest concentration (1.63 mg/g). The content of K.S.ompounds (A), and of a tepal sample (B) (354 nm).
ranged from 6.62 mg/g (sample 40) to 0.93 mg/g (sample 3) in the
stamen. The quantity of K.G. was also variable, the highest and low-
est amounts were determined in sample 31 and 8 with 7.44 and
1.72 mg/g, respectively.
Our results confirmed some former findings. K.S., K.G., and Q.S.
were described as major or characteristic flavonoid components of
flowers and tepals by several authors [16,17,19–,20,21,22,29–31].
Flavonol derivatives (6–10 mg/g) were characterized as the major
compounds of stamen and tepal samples harvested from two  dif-
ferent region of Italy. K.S. was  the major compound (6.41–8.30 mg/g
of fresh tepals and 0.37–1.70 mg/g of fresh stamen) [16].
The comparison of our results to those published previously
has some limitations. Crocus flowers, having monocot characteristic
structure, consist of stamens, stigmas and tepal. However, numer-
ous studies refer to perianth as “sepal” and “petal.” In some cases
the investigated flower part is not clearly named, however, the
description narrows it to tepals [21,22,32]. Some of the studies are
referring to the investigated sample as “petals” without any fur-
ther description [19,20,25,26], while some further studies refer to
saffron flower without stigma [17,28,30,31].
3.3. Classification of saffron crocus populations
Cluster analysis (CA) and principal component analysis (PCA)
were performed to characterize and classify saffron crocus tepal
and stamen samples harvested from different locations in Iran
according to their Q.S., K.S., and K.G. contents. According to the CA
analysis, the saffron crocus samples collected from various loca-
tions were classified in three major groups demonstrating three
distinct chemotypes based on their flavonoid contents. Chemotype
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Table 7
Levels of marker compounds in saffron samples.
Sample
Q.S. K.S. K.G.
T S T S T S
1 10.24 ± 0.23 4.23 ± 0.14 99.48 ± 0.07 1.82 ± 0.1 45.18 ± 0.24 3.65 ± 0.21
2  6.29 ± 0.04 3.49 ± 0.14 76.40 ± 1.37 1.47 ± 0.06 37.31 ± 0.77 2.47 ± 0.12
3  6.23 ± 0.15 1.63 ± 0.18 62.41 ± 1.41 0.93 ± 0.02 33.71 ± 0.98 2.42 ± 0.46
4  9.19 ± 0.32 5.60 ± 0.2 74.82 ± 3.32 1.53 ± 0.26 36.01 ± 1.6 3.69 ± 0.15
5  6.21 ± 0.2 4.56 ± 0.2 62.19 ± 2.06 2.21 ± 0.09 35.73 ± 1.23 4.88 ± 0.29
6  7.92 ± 0.34 2.11 ± 0.12 71.81 ± 3.67 1.03 ± 0.03 39.25 ± 2.27 2.05 ± 0.01
7  7.61 ± 0.30 1.72 ± 0.02 77.35 ± 3.96 1.03 ± 0.06 37.38 ± 1.73 2.01 ± 0.11
8  9.43 ± 0.23 1.98 ± 0.06 75.00 ± 0.55 0.90 ± 0.03 37.30 ± 0.46 1.72 ± 0.12
9  8.68 ± 0.29 1.80 ± 0.06 74.88 ± 2.84 1.20 ± 0.03 34.09 ± 1.09 2.72 ± 0.24
10  8.26 ± 0.10 1.79 ± 0.04 71.45 ± 1.51 1.03 ± 0.0 32.08 ± 0.07 2.17 ± 0.09
11  8.51 ± 0.38 2.02 ± 0.08 68.55 ± 1.88 1.20 ± 0.04 32.08 ± 0.82 2.33 ± 0.05
12  10.26 ± 0.03 2.15 ± 0.1 82.91 ± 2.41 1.07 ± 0.07 38.75 ± 0.44 2.76 ± 0.09
13  8.24 ± 0.04 4.43 ± 0.15 72.94 ± 2.02 2.49 ± 0.13 32.58 ± 0.61 4.00 ± 0.08
14  8.37 ± 0.34 5.16 ± 0.06 79.83 ± 0.13 1.78 ± 0.04 35.34 ± 0.56 4.30 ± 0.06
15  7.10 ± 0.08 4.65 ± 0.2 77.79 ± 0.33 2.24 ± 0.25 38.77 ± 0.47 3.72 ± 0.22
16  9.14 ± 0.48 4.45 ± 0.11 86.50 ± 0.85 1.64 ± 0.06 34.83 ± 0.06 3.45 ± 0.09
17  8.34 ± 0.41 4.77 ± 0.11 72.03 ± 3.65 1.68 ± 0.06 30.28 ± 1.62 4.39 ± 0.23
18  7.47 ± 0.28 5.95 ± 0.6 72.28 ± 3.47 1.51 ± 0.01 34.49 ± 1.82 3.55 ± 0.1
19  7.56 ± 0.07 3.54 ± 0.11 83.01 ± 0.74 4.63 ± 0.26 38.17 ± 0.3 5.94 ± 0.01
20  7.91 ± 0.02 5.32 ± 0.14 86.22 ± 2.77 3.08 ± 0.12 37.44 ± 1.21 5.00 ± 0.14
21  9.25 ± 0.17 5.08 ± 0.19 85.59 ± 2.04 3.40 ± 0.02 37.59 ± 0.82 4.16 ± 0.14
22  7.45 ± 0.21 4.10 ± 0.23 79.01 ± 2.93 2.09 ± 0.13 33.23 ± 1.12 4.67 ± 0.22
23  10.82 ± 0.38 4.53 ± 0.19 98.99 ± 2.85 5.21 ± 0.22 36.44 ± 0.88 7.31 ± 0.05
24  7.24 ± 0.04 4.82 ± 0.03 67.80 ± 2.72 2.07 ± 0.0 37.28 ± 0.19 5.34 ± 0.53
25  8.25 ± 0.22 4.55 ± 0.24 79.30 ± 1.54 1.99 ± 0.09 40.96 ± 1.4 3.11 ± 0.09
26  7.58 ± 0.17 5.52 ± 0.13 71.07 ± 0.07 2.04 ± 0.07 33.31 ± 0.43 5.19 ± 0.1
27  8.63 ± 0.07 4.43 ± 0.08 75.66 ± 2.47 2.06 ± 0.06 33.22 ± 1.11 5.15 ± 0.24
28  7.83 ± 0.3 3.95 ± 0.22 76.59 ± 1.52 2.02 ± 0.03 34.77 ± 0.66 4.03 ± 0.17
29  7.44 ± 0.2 6.08 ± 0.36 75.61 ± 1.07 2.20 ± 0.05 36.73 ± 0.73 5.23 ± 0.41
30  7.39 ± 0.23 5.28 ± 0.28 80.46 ± 4.01 2.01 ± 0.02 34.76 ± 1.79 5.96 ± 0.43
31  7.16 ± 0.06 4.29 ± 0.21 87.52 ± 1.5 3.09 ± 0.19 42.51 ± 1.15 7.44 ± 0.31
32  8.37 ± 0.26 5.14 ± 0.3 74.16 ± 1.03 2.33 ± 0.13 33.61 ± 1.3 4.83 ± 0.01
33  7.83 ± 0.06 4.43 ± 0.08 75.77 ± 1.56 2.24 ± 0.13 36.99 ± 0.63 4.71 ± 0.15
34  8.35 ± 0.1 4.49 ± 0.3 74.16 ± 1.12 2.45 ± 0.17 34.69 ± 0.42 4.80 ± 0.25
35  7.83 ± 0.33 5.74 ± 0.09 75.86 ± 0.83 2.19 ± 0.08 41.03 ± 0.47 5.13 ± 0.05
36  9.43 ± 0.36 4.77 ± 0.13 88.63 ± 3.41 3.34 ± 0.19 43.68 ± 1.13 5.10 ± 0.11
37  6.75 ± 0.04 5.40 ± 0.31 76.00 ± 1.31 1.83 ± 0.1 34.32 ± 0.39 5.70 ± 0.05
38  8.96 ± 0.12 5.13 ± 0.15 81.03 ± 3.35 1.96 ± 0.1 36.87 ± 1.0 6.78 ± 0.04
39  6.87 ± 0.11 2.87 ± 0.06 74.44 ± 1.2 2.59 ± 0.15 29.04 ± 1.19 4.30 ± 0.22
40  6.42 ± 0.21 2.86 ± 0.12 73.91 ± 2.85 6.62 ± 2.06 27.74 ± 1.22 5.26 ± 1.03
T .: kaempferol-3-O-sophoroside; K.G.: kaempferol-3-O-glucoside; T: tepal; S: stamen.
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Table 8
Eigenvalues, variance and cumulative variance for four principal components.
Flavonoids
Principal components
PC1 PC2 PC3 PC4
PQS −0.02 −0.06 0.80 0.13
PKS  0.13 0.52 0.78 0.32
PKG  0.07 0.05 0.25 0.96
SQS  0.96 0.02 0.06 0.09
SKS  0.12 0.92 0.07 0.48
SKG  0.75 0.57 −0.05 −0.01
Eigenvalue 1.51 1.45 1.33 1.06
Variance (%) 25.17 24.22 22.09 17.69
Cumulative variance (%) 25.17 49.39 71.49 89.17
PQS: Quercetin-3-O-sophoroside in tepal; PKS: Kaempferol-3-O-sophoroside inhe amounts are presented as mg  of samples; Q.S.: quercetin-3-O-sophoroside; K.S
 was characterized with the highest Q.S. content of tepal samples,
ncluding the populations 2, 3, 6–12, and 39, samples belonging to
hemotype II contained high quantity of K.G. in tepal samples (pop-
lations 4, 5, 13, 14, 16–18, 22, 24, 26–30, 32–34, and 37), whereas
hemotype III was the richest in Q.S., K.S., and K.G. in the stamens,
nd K.S. in the tepals (populations 1, 15, 16, 19–21, 23, 25, 31, 35,
6, 38, 40). The results of the PCA are presented on a dendrogram
Fig. 2).
Eigenvalues, variances and cumulative variances of the four PCs
re listed in Table 8. In accordance with PCA analysis, four principal
omponents (PC): PC1, PC2, PC3, and PC4 explained 89.17 % of total
ariation. As demonstrated in Table 8, PC1 described 25.17 % of total
ariation which had positive correlation with SQS (0.96 %) and SKG
0.75 %). Interestingly, a positive correlation between PC2 with SKS
0.92 %), SKG (0.57 %) and PKS (0.52 %) was recorded by 24.22 % of
ariance. Furthermore, PC3 and PC4 explained 22.09 % and 17.69 %
f total variance, respectively, while the most positive correlations
n PC3 and PC4 were observed with PQS (0.80 %) and PKG (0.96 %),
espectively.
Biosynthesis of secondary metabolites may  be influenced by dif-
erent environmental factors (e.g. UV irradiation, temperature) at
ifferent altitudes. The impact of altitude on the composition of
ertain plant species has previously been studied. For example, we
ave confirmed that the apigenin and luteolin content of Matri-tepal; PKG: Kaempferol-3-O-glucoside in tepal; SQS: Quercetin-3-O-sophoroside
in stamen; SKS: Kaempferol-3-O-sophoroside in stamen; SKG: Kaempferol-3-O-
glucoside in stamen.
caria chamomilla L. was  significantly higher at higher altitude [33].
The diversity of total phenolic and flavonoid contents of different
Iranian Ferulago angulata (Schltdl.) Boiss. populations also confirm
the influence of altitude on the chemodiversity of plants [34]. The
volatile oil composition may  also be affected by altitude [33–36].
In case of saffron crocus, this is the first report on chemodiversity
of samples from different geographical locations.
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Fig. 2. Dendrogram of cluster analysis (based on Euclidean distances) of the saffron samples: chemotype I (Q.S in tepal), chemotype II (K.G in tepal), chemotype III (Q.S in
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atamen,  K.S in stamen, K.G in stamen, K.S in tepal).
. Conclusion
The industrial and scientific interests for saffron crocus by-
roducts, including tepals and stamens have considerably been
ncreased, due to the high price of saffron stigma and the new
ata on bioactivities of tepals. Here we report the development and
alidation of an HPLC-DAD method that allows the assessment of
affron crocus samples based on the analysis of seven marker com-
ounds (K.S., K.G., Q.S., picrocrocin, crocin, crocetin, and safranal).
 recent study reports the metabolomic fingerprinting of saffron by
sing LC–MS, which can be the basis of the authentication of this
pice [37]. LC–MS was used also for the analysis of saffron crocus
y-products, ie. tepals [31], tepals, stamens and flowers [32], leaves,
epals, spaths, corm, and tunics [38], however, this is the first report
n the analysis of a series of samples of different geographic origin.
he flavonol glycosides K.S., K.G., and Q.S. can be utilized as qual-
tative and quantitative marker compounds, their total amount in
ry tepal and stamen samples ranged between 62.19–99.48 mg/g
nd 0.90–6.62 mg/g for K.S., 27.74–45.18 mg/g and 1.72–7.44 mg/g
or K.G., and 6.21–10.82 mg/g and 1.63–6.08 mg/g for Q.S., respec-
ively. These ranges were established based on the analysis of 40
ifferent Iranian tepal and stamen samples. K.S. was  the main com-
onent of tepals (62.19–99.48 mg/g), while K.G. (1.72–7.44 mg/g)
as the predominant constituent of the stamen samples. Char-
cteristic compounds of the stigma (picrocrocin, crocin, crocetin,and safranal) could not be detected in tepal and stamen samples;
however, our method allows their determination as well.
The biplot was prepared based on the two  PCs by 89.17 % of
variance. As it was  shown in Fig. 3, saffron crocus samples were
grouped in three classes that approved the CA analysis. Accord-
ing to the PCA and CA analyses, some of the samples from long
distances, for example samples 40 and 38 deriving from locations
with different climate, were classified in the same group (III), while
others from the same location, Meshkan (population 12 in class I,
Meshkan samples 13 and 14 in group II, Meshkan 15 in group III),
were classified in separate groups. Saffron crocus is propagated by
vegetative method which may  affect plant diversity. It seems that
the analyzed flavonoids were not affected by genotype and climate
condition, however, edaphic factors, water and nutrition manage-
ment might be responsible for the chemodiversity of the studied
samples.
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